WO2003085119A1 - Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia - Google Patents
Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia Download PDFInfo
- Publication number
- WO2003085119A1 WO2003085119A1 PCT/JP2003/004504 JP0304504W WO03085119A1 WO 2003085119 A1 WO2003085119 A1 WO 2003085119A1 JP 0304504 W JP0304504 W JP 0304504W WO 03085119 A1 WO03085119 A1 WO 03085119A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cells
- cell
- fucose
- sugar chain
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 538
- 239000000203 mixture Substances 0.000 title claims abstract description 193
- 230000027455 binding Effects 0.000 title claims abstract description 111
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 10
- 235000000346 sugar Nutrition 0.000 claims abstract description 320
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 290
- 230000000694 effects Effects 0.000 claims abstract description 171
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 130
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims abstract description 127
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 127
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims abstract description 123
- 108090001090 Lectins Proteins 0.000 claims abstract description 80
- 102000004856 Lectins Human genes 0.000 claims abstract description 80
- 239000002523 lectin Substances 0.000 claims abstract description 80
- 229930182474 N-glycoside Natural products 0.000 claims abstract description 54
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 20
- 230000001419 dependent effect Effects 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 653
- 241000282414 Homo sapiens Species 0.000 claims description 209
- LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 claims description 150
- LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 claims description 142
- 108090000790 Enzymes Proteins 0.000 claims description 134
- 102000004190 Enzymes Human genes 0.000 claims description 127
- 239000002773 nucleotide Substances 0.000 claims description 81
- 125000003729 nucleotide group Chemical group 0.000 claims description 81
- 238000004519 manufacturing process Methods 0.000 claims description 68
- 108091006020 Fc-tagged proteins Proteins 0.000 claims description 62
- 241000196324 Embryophyta Species 0.000 claims description 60
- 210000004102 animal cell Anatomy 0.000 claims description 57
- 239000000427 antigen Substances 0.000 claims description 54
- 108091007433 antigens Proteins 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 54
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 52
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 43
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 43
- 102000005962 receptors Human genes 0.000 claims description 41
- 108020003175 receptors Proteins 0.000 claims description 41
- 238000012258 culturing Methods 0.000 claims description 38
- 241000238631 Hexapoda Species 0.000 claims description 37
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 36
- 210000001519 tissue Anatomy 0.000 claims description 35
- 230000004048 modification Effects 0.000 claims description 29
- 238000012986 modification Methods 0.000 claims description 29
- 230000003834 intracellular effect Effects 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 23
- 210000004408 hybridoma Anatomy 0.000 claims description 22
- 230000002829 reductive effect Effects 0.000 claims description 20
- 238000003786 synthesis reaction Methods 0.000 claims description 19
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 16
- 238000011088 calibration curve Methods 0.000 claims description 14
- 108010034897 lentil lectin Proteins 0.000 claims description 13
- 241000699673 Mesocricetus auratus Species 0.000 claims description 12
- 241000699802 Cricetulus griseus Species 0.000 claims description 11
- 240000006677 Vicia faba Species 0.000 claims description 11
- 235000010749 Vicia faba Nutrition 0.000 claims description 11
- 108020001507 fusion proteins Proteins 0.000 claims description 11
- 102000037865 fusion proteins Human genes 0.000 claims description 11
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 9
- 235000002098 Vicia faba var. major Nutrition 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 8
- 210000001672 ovary Anatomy 0.000 claims description 8
- 210000005084 renal tissue Anatomy 0.000 claims description 8
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 claims description 7
- 108010073807 IgG Receptors Proteins 0.000 claims description 6
- 102000009490 IgG Receptors Human genes 0.000 claims description 6
- 210000002288 golgi apparatus Anatomy 0.000 claims description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 5
- 230000003013 cytotoxicity Effects 0.000 claims description 5
- 231100000135 cytotoxicity Toxicity 0.000 claims description 5
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 4
- 108010087819 Fc receptors Proteins 0.000 claims description 4
- 102000009109 Fc receptors Human genes 0.000 claims description 4
- 229960002442 glucosamine Drugs 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 3
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 abstract description 15
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 abstract description 15
- 235000021310 complex sugar Nutrition 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 abstract 2
- 229950006780 n-acetylglucosamine Drugs 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 description 143
- 235000018102 proteins Nutrition 0.000 description 107
- 239000002609 medium Substances 0.000 description 98
- 239000013604 expression vector Substances 0.000 description 96
- 150000001413 amino acids Chemical group 0.000 description 94
- 239000002299 complementary DNA Substances 0.000 description 76
- 239000013598 vector Substances 0.000 description 71
- 108010078791 Carrier Proteins Proteins 0.000 description 68
- 102000014914 Carrier Proteins Human genes 0.000 description 64
- 241000699666 Mus <mouse, genus> Species 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 38
- 239000012228 culture supernatant Substances 0.000 description 36
- 239000000243 solution Substances 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 33
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 32
- 238000004458 analytical method Methods 0.000 description 32
- 239000013612 plasmid Substances 0.000 description 29
- 108010062427 GDP-mannose 4,6-dehydratase Proteins 0.000 description 28
- 108091034117 Oligonucleotide Proteins 0.000 description 28
- 239000012636 effector Substances 0.000 description 28
- 108020004999 messenger RNA Proteins 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 26
- 238000010367 cloning Methods 0.000 description 25
- 239000000523 sample Substances 0.000 description 25
- 241000588724 Escherichia coli Species 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 22
- 241000700159 Rattus Species 0.000 description 22
- 238000005516 engineering process Methods 0.000 description 21
- 239000012091 fetal bovine serum Substances 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 21
- 230000009261 transgenic effect Effects 0.000 description 21
- 101710203794 GDP-fucose transporter Proteins 0.000 description 20
- 241000700605 Viruses Species 0.000 description 20
- 238000010586 diagram Methods 0.000 description 20
- 235000013601 eggs Nutrition 0.000 description 20
- 238000000746 purification Methods 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 19
- 230000006870 function Effects 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- 238000010276 construction Methods 0.000 description 17
- 230000035772 mutation Effects 0.000 description 16
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 14
- 102000040811 transporter activity Human genes 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 108090000288 Glycoproteins Proteins 0.000 description 13
- 102000003886 Glycoproteins Human genes 0.000 description 13
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 13
- 230000001900 immune effect Effects 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 238000010828 elution Methods 0.000 description 12
- 102100037047 Fucose-1-phosphate guanylyltransferase Human genes 0.000 description 11
- 101001029296 Homo sapiens Fucose-1-phosphate guanylyltransferase Proteins 0.000 description 11
- JMVSBFJBMXQNJW-GIXZANJISA-N all-trans-pentaprenyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O JMVSBFJBMXQNJW-GIXZANJISA-N 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 210000000170 cell membrane Anatomy 0.000 description 11
- 210000000349 chromosome Anatomy 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 238000003018 immunoassay Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 10
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000009368 gene silencing by RNA Effects 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000013615 primer Substances 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 230000003248 secreting effect Effects 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 238000002744 homologous recombination Methods 0.000 description 9
- 230000006801 homologous recombination Effects 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 238000010369 molecular cloning Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000012552 review Methods 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 8
- 230000004544 DNA amplification Effects 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 231100000350 mutagenesis Toxicity 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 108090000994 Catalytic RNA Proteins 0.000 description 7
- 102000053642 Catalytic RNA Human genes 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- 108091092562 ribozyme Proteins 0.000 description 7
- 241000701447 unidentified baculovirus Species 0.000 description 7
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 101710186708 Agglutinin Proteins 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 101150074155 DHFR gene Proteins 0.000 description 6
- 101710146024 Horcolin Proteins 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 102100040648 L-fucose kinase Human genes 0.000 description 6
- 101710189395 Lectin Proteins 0.000 description 6
- 101710179758 Mannose-specific lectin Proteins 0.000 description 6
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 6
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 238000012300 Sequence Analysis Methods 0.000 description 6
- 239000000910 agglutinin Substances 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 238000010804 cDNA synthesis Methods 0.000 description 6
- 239000005018 casein Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 108010083136 fucokinase Proteins 0.000 description 6
- 238000010363 gene targeting Methods 0.000 description 6
- 238000010353 genetic engineering Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 108010002645 sophora japonica agglutinin Proteins 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 5
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000010364 biochemical engineering Methods 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 description 5
- 235000011010 calcium phosphates Nutrition 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 4
- 108010041181 Aleuria aurantia lectin Proteins 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000701489 Cauliflower mosaic virus Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 240000004322 Lens culinaris Species 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 235000019764 Soybean Meal Nutrition 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000010805 cDNA synthesis kit Methods 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000003113 dilution method Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000010841 mRNA extraction Methods 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000004455 soybean meal Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- MVMSCBBUIHUTGJ-UHFFFAOYSA-N 10108-97-1 Natural products C1=2NC(N)=NC(=O)C=2N=CN1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OC1OC(CO)C(O)C(O)C1O MVMSCBBUIHUTGJ-UHFFFAOYSA-N 0.000 description 3
- 241000221688 Aleuria aurantia Species 0.000 description 3
- 108010005231 Amaranthus caudatus lectin Proteins 0.000 description 3
- 241000272875 Ardeidae Species 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 229930192334 Auxin Natural products 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 102000001690 Factor VIII Human genes 0.000 description 3
- 108010054218 Factor VIII Proteins 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- MVMSCBBUIHUTGJ-GDJBGNAASA-N GDP-alpha-D-mannose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=C(NC(=O)C=2N=C1)N)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O MVMSCBBUIHUTGJ-GDJBGNAASA-N 0.000 description 3
- 108010001498 Galectin 1 Proteins 0.000 description 3
- 102100021736 Galectin-1 Human genes 0.000 description 3
- 101150003028 Hprt1 gene Proteins 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical class OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 235000010666 Lens esculenta Nutrition 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- -1 N-acetyldarcosamine Chemical compound 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 239000002363 auxin Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- NFLRWRCXIJABMY-UHFFFAOYSA-M cesium diaminomethylideneazanium 2,2,2-trifluoroacetate thiocyanate Chemical compound [Cs+].[S-]C#N.NC(N)=N.OC(=O)C(F)(F)F NFLRWRCXIJABMY-UHFFFAOYSA-M 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002414 glycolytic effect Effects 0.000 description 3
- 150000002337 glycosamines Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 108091008042 inhibitory receptors Proteins 0.000 description 3
- 229940100602 interleukin-5 Drugs 0.000 description 3
- 210000001821 langerhans cell Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 108091000699 pea lectin Proteins 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000012521 purified sample Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- FPXCYGSFMNEBPA-UHFFFAOYSA-N 1h-indole;prop-2-enoic acid Chemical compound OC(=O)C=C.C1=CC=C2NC=CC2=C1 FPXCYGSFMNEBPA-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000589158 Agrobacterium Species 0.000 description 2
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 239000004254 Ammonium phosphate Substances 0.000 description 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108010040220 Datura stramonium lectin Proteins 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 241001481760 Erethizon dorsatum Species 0.000 description 2
- 241001131785 Escherichia coli HB101 Species 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 108010073757 Evonymous europa lectin Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 108010045674 Fucose-1-phosphate guanylyltransferase Proteins 0.000 description 2
- 102100024637 Galectin-10 Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 2
- 101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 2
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 101150102264 IE gene Proteins 0.000 description 2
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 2
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010048733 Lipozyme Proteins 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108010017507 Ricinus communis agglutinin-1 Proteins 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 241000235346 Schizosaccharomyces Species 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 108010020764 Transposases Proteins 0.000 description 2
- 102000008579 Transposases Human genes 0.000 description 2
- 241000223230 Trichosporon Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 101100068489 Vicia faba AGPC gene Proteins 0.000 description 2
- 108010038211 Vicia lectins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 101710087237 Whey acidic protein Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- AJTUNRJTNFESSC-DPBDWXOKSA-N [(3s)-1-[[(2s,3r,4r,5s,6r)-6-[[(2r,3r,4r,5s,6r)-3-[[(3s)-3-dodecanoyloxytetradecanoyl]amino]-6-(hydroxymethyl)-5-phosphonooxy-4-[(3s)-3-tetradecanoyloxytetradecanoyl]oxyoxan-2-yl]oxymethyl]-2,5-dihydroxy-4-[(3s)-3-hydroxytetradecanoyl]oxyoxan-3-yl]amino]- Chemical compound O[C@H]1[C@H](OC(=O)C[C@@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)O[C@@H]1CO[C@H]1[C@H](NC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@H](OP(O)(O)=O)[C@@H](CO)O1 AJTUNRJTNFESSC-DPBDWXOKSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 2
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 2
- 235000019289 ammonium phosphates Nutrition 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 230000000702 anti-platelet effect Effects 0.000 description 2
- 230000002137 anti-vascular effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000002769 b effector cell Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011098 chromatofocusing Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 2
- 239000004062 cytokinin Substances 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 108010039433 dolichos biflorus agglutinin Proteins 0.000 description 2
- 108010053791 erythrina lectin Proteins 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 108010015750 fucose-binding lectin Proteins 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 239000006451 grace's insect medium Substances 0.000 description 2
- 239000011544 gradient gel Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 150000002402 hexoses Chemical class 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 238000000111 isothermal titration calorimetry Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108010003491 maclurin Proteins 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 235000010994 magnesium phosphates Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 235000013379 molasses Nutrition 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- IBONACLSSOLHFU-KEWYIRBNSA-N n-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]acetamide Chemical compound CC(=O)NC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBONACLSSOLHFU-KEWYIRBNSA-N 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 108010014765 tomato lectin Proteins 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108010043166 wisteria lectin Proteins 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- UHEPSJJJMTWUCP-DHDYTCSHSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-DHDYTCSHSA-N 0.000 description 1
- SESQMDHICVIJCF-PCMWHEESSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1 Chemical compound C([C@@H](C(=O)N[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 SESQMDHICVIJCF-PCMWHEESSA-N 0.000 description 1
- AAQFSZFQCXLMNT-ACMTZBLWSA-N (3s)-3-amino-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid;hydrochloride Chemical compound Cl.OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 AAQFSZFQCXLMNT-ACMTZBLWSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- NTMOHEVWDBTSGK-UHFFFAOYSA-N 6-(propylamino)-1h-pyrimidin-2-one Chemical compound CCCNC1=CC=NC(=O)N1 NTMOHEVWDBTSGK-UHFFFAOYSA-N 0.000 description 1
- 101150044182 8 gene Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241001385733 Aesculus indica Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 108010006836 Bauhinia purpurea lectin Proteins 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101100084503 Caenorhabditis elegans pas-3 gene Proteins 0.000 description 1
- 244000045232 Canavalia ensiformis Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 241000243251 Hydra Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108010060231 Insect Proteins Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241001521394 Maackia amurensis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000087624 Monoclona Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- FOEDNHBYWRNQGE-UHFFFAOYSA-M NC(N)=N.N#CS.[F-].F.F.[Cs+] Chemical compound NC(N)=N.N#CS.[F-].F.F.[Cs+] FOEDNHBYWRNQGE-UHFFFAOYSA-M 0.000 description 1
- 241001532689 Narcissus pseudonarcissus Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 1
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 description 1
- 244000046095 Psophocarpus tetragonolobus Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 101100013703 Rattus norvegicus Fut8 gene Proteins 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- DRUQKRWRXOUEGS-NGERZBJRSA-N Samin Chemical group C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3O)=C1 DRUQKRWRXOUEGS-NGERZBJRSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- QQGWBRJQPRTJDA-UHFFFAOYSA-N [Li].CC(O)=O Chemical compound [Li].CC(O)=O QQGWBRJQPRTJDA-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- YJFXSWKKBWMMCM-UHFFFAOYSA-N azanium;3-ethyl-2h-1,3-benzothiazole-6-sulfonate Chemical compound [NH4+].[O-]S(=O)(=O)C1=CC=C2N(CC)CSC2=C1 YJFXSWKKBWMMCM-UHFFFAOYSA-N 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000029803 blastocyst development Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000000366 colloid method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 108010014507 erythroagglutinating phytohemagglutinin Proteins 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000003234 fluorescent labeling method Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 101150106565 gmd gene Proteins 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000006698 hydrazinolysis reaction Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 108010084553 jacalin Proteins 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229930195732 phytohormone Natural products 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 108091092194 transporter activity Proteins 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- the present invention is an elevated Fc y method of enhancing the binding activity to the receptor Ilia, a method of enhancing antibody-dependent cellular cytotoxicity of antibody compositions, binding activity to Fc 7 receptor Ilia antibody compositions of an antibody composition Of an N-dalicoside-linked complex type sugar chain that binds to the Fc region contained in the antibody composition, wherein fucose is bound to N-acetyldarcosamine at the reducing end of the sugar chain.
- a method for detecting the proportion of non-glycosylated N-glycoside-linked complex-type glycans is resistant to lectins that recognize a sugar chain structure in which the 6-position of N-acetyltilcosamine at the reducing end and the 1-position of fucose are linked.
- TECHNICAL FIELD The present invention relates to an Fc fusion protein composition produced using cells having the same, and a method for producing the same.
- a humanized antibody such as a human-type chimeric antibody or a human-type complementarity-determining region (hereinafter, referred to as CDR) transplanted antibody is prepared from an antibody of an animal other than human. Have been tried.
- a human chimeric antibody is an antibody in which the antibody V region (hereinafter, referred to as V region) is an antibody of a non-human animal and the constant region (hereinafter, referred to as C region) is a human antibody.
- the human CDR-grafted antibody is an antibody obtained by replacing the CDR of a human antibody with the CDR of an antibody of a non-human animal. It has been clarified that there are five classes of mammalian antibodies, IgM, IgD, IgG, IgA, and IgE.However, blood is used for diagnosis and prevention of various human diseases.
- Antibodies of the human IgG class are mainly used because of their long half-life and functional properties such as having various effector functions [Monoclonal Antibodies: Principles and Applications , Wiley—Liss, Inc., Chapter 1 (1995)]. Antibodies of the human IgG class are further divided into four subclasses: IgGl, IgG2, IgG3, and IgG4. IgG A number of antibody-dependent cytotoxic activities (hereinafter, referred to as ADCC activities) and complement-dependent cytotoxic activities (hereinafter, referred to as CDC activities), which are one of the effector functions of class antibodies, have been reported so far.
- ADCC activities antibody-dependent cytotoxic activities
- CDC activities complement-dependent cytotoxic activities
- ADCC activity and CDC activity of human IgGl subclass antibodies requires the expression of antibody Fc region and antibody receptors present on the surface of effector cells such as killer cells, natural killer cells, monocytes, macrophages, etc. FcyR) and binding to various capture components, and the binding is determined by the hinge domain of the antibody and the second domain of the C region (hereinafter referred to as CH2 domain). Importance of some amino acid residues in E. [Eur. J. Immunol., 23 »1098 (1993), Immunology, 86, 319 (1995) Chemical Immunology, 65, 88 (1997)], and the importance of sugar chains linked to CH2 domains [Chemical Immunology, 65, 88 (1997)] Is suggested.
- CAMPATH a human CDR-grafted antibody produced in Chinese hamster ovary cells (hereinafter referred to as CH0 cells) or mouse myeloma NS0 cells (hereinafter referred to as NS0 cells).
- CH0 cells Chinese hamster ovary cells
- NS0 cells mouse myeloma NS0 cells
- sugar chain structure is extremely important for the effector function of human IgGl subclass antibodies. It plays a role, indicating that it is possible to produce antibodies with higher effector functions by changing the sugar chain structure.
- structures of sugar chains are diverse and complex, and it is hard to say that a structure that is truly important for effector functions could be identified.
- the sugar chain linked to the CH2 domain of an IgG-class antibody has a significant effect on the expression of one effector function of the antibody.
- some of the effector functions of antibodies are exerted through their interaction with FCT / R present on the surface of effector cells [annual 'review' op 'immunology (Annu. Rev. Immunol.), 18, 709 (2000), Anyuanore 'Review' ob 'Immunology (Annu. Rev. Immunol.), 19, 275 (2001)].
- FcyRI CD64
- Fc ⁇ yRII CD32
- FcyRIII CD16
- FcyRII and FcyRIII are further classified into Fc ⁇ RIIa, FcyRllb, FcyRIIIa, and FcRlllb.
- FcyR is a membrane protein belonging to the immunoglobulin superfamily
- FcyRII and FcyRIII are composed of two immunoglobulin-like domains
- FcyRI is composed of an ⁇ - chain having an extracellular region consisting of three immunoglobulin-like domains. ⁇ -chain is responsible for IgG binding activity.
- FcyRI and FeyRIII have a chain or a chain having a signal transduction function in association with the ⁇ chain as a component [Annual Review of Immunology (Annu. Rev. Immunol.), 18] , 709 (2000), Anyuanore 'Review of Immunology' (Annu. Rev. Immunol.), 19, 275 (2001)] 0
- FcyRI is, 10 8 ⁇ ; 10 9 M- 1 binding constants (hereinafter, K A and hereinafter) is a high-affinity receptors with, have a high binding activity to monomeric IgG [Ann's Hematol., 76, 231 (1998)].
- FcyRII and Fey RIII ranges, for the monomeric IgG, low affinity receptors that indicates the 10 5 -10 7 low M- 1 K A, and multimerized binding such as antigen Efficiently binds IgG immunocomplexes [Anals hematol., Ann . Hematol., 76, 231 (1998)].
- FcyR is divided into activating and inhibitory receptors according to their functions [Annual Review of Immunology (Annu. Rev. Immunol.), 19, 275 (2001)].
- the activating receptor has a sequence of 19 amino acid residues called immunoreceptor tyrosine-based activation motif (hereinafter referred to as ITAM) in the intracellular region of the ⁇ chain, the associated y chain, and the ⁇ chain.
- ITAM immunoreceptor tyrosine-based activation motif
- the inhibitory receptor has a sequence of 13 amino acid residues called immunoreceptor tyrosine-based inhibitory motif (hereinafter referred to as ITIM) in the intracellular region of the ⁇ chain. Phosphorylation of ITIM through its association with the activated receptor induces various reactions, including the activation of a phosphatase called SHIP, and an activation signal from the activated receptor. Suppress.
- ITIM immunoreceptor tyrosine-based inhibitory motif
- FCT / RI has an ITAM sequence in the intracellular region of the associated gamma chain.
- Fco / RI is expressed on macrophages, monocytes, dendritic cells, neutrophils, and eosinophils.
- FcyRIIa consists of a single ⁇ -chain, and has an ITAM-like sequence in its intracellular region.
- FcyRIIa is expressed on macrophages, mast cells, monocytes, dendritic cells, Langerhans cells, neutrophils, eosinophils, platelets and some B cells.
- FcyRIIIa has an ITAM sequence in the intracellular region of the associated gamma or ⁇ chain, and is found in NK cells, macrophages, monocytes, mast cells, dendritic cells, Langerhans cells, eosinophils, etc. Expressed force Not expressed on neutrophils, B cells and T cells.
- the low-affinity receptor Fc7Rllb consists of a single a chain and has about 90% homology with FcyRIIa in the amino acid sequence of the extracellular region.
- the ITIM sequence exists in the intracellular region and functions as an inhibitory receptor.
- FcyRIIb is expressed on B cells, macrophages, mast cells, monocytes, dendritic cells, Langerhans cells, basophils, neutrophils, and eosinophils, but not on NK cells or T cells. Not expressed.
- Fc ⁇ RHIb consists of a single en chain and has about 95% homology with Fc ⁇ RHIa in the amino acid sequence of the extracellular region.
- GPI glycosylphosphatidylinositol
- Fcy RIIIb binds the IgG immune complex, but cannot activate cells by itself, and is thought to function through association with a receptor having an ITAM sequence such as Fco RIIa .
- ITAM sequence such as Fco RIIa
- ADCC activity one of the effector functions of IgG class antibodies, is thought to result from the activation of effector cells such as NK cells, neutrophils, monocytes, and macrophages.
- NK cells play a major role among them [Blood, 76, 2421 (1990), Trends in Immunol., 22, 633 (2001), International ' Reviews 'ob' Immunology (Int. Rev. Immunol.), 20, 503 (2001)].
- Fe y R expressed on NK cells is Fcy RIIIa. Therefore, it is thought that ADCC activity can be increased by enhancing the activity signal from FcyRIIIa expressed in NK cells.
- Fc fusion proteins include Etanercept (trade name: Enbrel, manufactured by Iwake unex) (USP 5, 605, 690) and Alef acept (trade name: Amevive, manufactured by Biogen) (USP 5, 914, 111). ing. Also, CH2 domain of the antibody is known to be no existing unless ADCC activity (J. Immunol., 152, 2753 (1994)) 0 Disclosure of the Invention
- the present invention relates to the following (1) to (48).
- a method for enhancing the binding activity of an antibody composition to Fc ⁇ receptor Ilia which comprises modifying a complex N-glycoside-linked sugar chain that binds to an Fc region of an antibody molecule.
- Modification of the N-glycoside-linked complex type sugar chain that binds to the Fc region of the antibody molecule is such that the first position of fucose is a at position 6 of N-acetyldarcosamine at the N-glycoside-linked complex type sugar chain reducing end.
- the following proteins (a), (b) and (c) are involved in the modification of the sugar chain that binds fucose to N-acetyldarcosamine at the reducing end of N-daricoside-linked complex type sugar chain.
- the method according to (3) which is a protein selected from the group consisting of:
- the cell is a cell selected from the group consisting of yeast, animal cells, insect cells, and plant cells.
- a method for producing an antibody composition having an enhanced binding activity to an Fcy receptor Ilia of an antibody composition comprising modifying an N-dalicoside-linked complex-type sugar chain that binds to an Fc region of an antibody molecule.
- Modification of the N-daricoside-linked complex-type sugar chain that binds to the Fc region of the antibody molecule has a 1-position of fucose at the 6-position of N-acetyldarcosamine at the reducing end of the N-daricoside-linked complex-type sugar chain.
- the cell is resistant to a lectin recognizing a sugar chain structure in which the position 1 of fucose is linked to the position 6 of Q-linked fucose at the position 6 of N-glycidyl-linked complex type sugar chain reducing terminal, 15) or the method according to (16).
- N-glycoside-linked complex type sugar chain manufactured by using lectin-resistant cells that recognize the sugar chain structure in which the 6-position of N-acetyldarcosamine at the reducing end and the 1-position of fucose are linked.
- Fc fusion protein composition
- a fibrous substance comprising an Fc fusion protein having an N-glycoside-linked complex type sugar chain in the Fc region of an antibody molecule, wherein all N-binding to the Fc region contained in the fibrous substance is performed.
- the sugar chain to which no fucose is bound is a sugar chain in which position 1 of the fucose is not linked to position 6 of N-acetyldarcosamine at the reducing end of the N-daricoside-linked complex type sugar chain.
- mouse myeloma cells are NS0 cells or SP2 / 0- A g 14 cells (45), wherein the cell.
- a method for producing an Fc fusion protein composition comprising the steps of:
- the present invention relates to a method for enhancing the binding activity of an antibody composition to the Fey receptor Ilia, which comprises modifying an N-dalicoside-linked complex-type sugar chain that binds to an Fc region of an antibody molecule.
- an antibody molecule includes any molecule as long as it contains the Fc region of an antibody. Specific examples include an antibody, an antibody fragment, a fusion protein having an Fc region, and the like.
- An antibody is a protein that is produced in a living body by an immune reaction as a result of stimulation with a foreign antigen and has an activity of specifically binding to an antigen.
- Antibodies can be obtained by immunizing an animal with an antigen and secreting the hybridoma cells produced from spleen cells of the immunized animal, as well as antibodies produced by genetic recombination techniques, that is, antibody expression vectors containing antibody genes. And an antibody obtained by introduction into a host cell. Specific examples include antibodies produced by hybridomas, humanized antibodies, human antibodies, and the like.
- the hybridoma has the desired antigen-specific 1 "life obtained by cell fusion of B cells obtained by immunizing a non-human mammal with an antigen and myeloma cells derived from a mouse or the like. A cell producing a monoclonal antibody is meant.
- humanized antibody examples include a human chimeric antibody and a human CDR-grafted antibody.
- Human chimeric antibodies are composed of antibody heavy chain V regions (hereinafter, heavy chains are also referred to as HV or VH as H chains) and antibody light chain V regions (hereinafter, light chains are referred to as L chains) of non-human animals.
- any animal can be used, such as mice, rats, hamsters, and egrets, as long as they can produce Neubridomas.
- the human chimeric antibody is obtained by obtaining cDNAs encoding VH and VL from a hybridoma producing a monoclonal antibody, and obtaining an expression vector for host cells having genes encoding human antibody CH and human antibody CL. Respectively, to construct a human chimeric antibody expression vector, and to introduce and produce the expression vector by introducing the expression vector into a host cell.
- the CH of the human chimeric antibody may be any as long as it belongs to human immunoglobulin (hereinafter, referred to as hlg), but is preferably of the hlgG class, and furthermore, hIgGl and hIgG2 belonging to the hlgG class. Any of the subclasses hIgG3, hIgG4 can be used.
- the CL of the human chimeric antibody may be any CL as long as it belongs to hlg, and a ⁇ class or L class can be used.
- the human-type CDR-grafted antibody means an antibody obtained by grafting the amino acid sequences of CDRs of VH and VL of an antibody of a non-human animal to an appropriate position of VH and VL of a human antibody.
- the human CDR-grafted antibody constructs a cDNA encoding the V region obtained by grafting the VH and VL CDR sequences of an antibody from a non-human animal to the VH and VL CDR sequences of a human antibody. Constructing a human-type CDR- grafted antibody expression vector by inserting each into a host cell expression vector having genes encoding the antibody CH and the human antibody CL, and introducing the expression vector into the host cell; And can be produced.
- any CH may be used as long as it belongs to hlg, but the hlgG class is preferable, and further, hIgGl, hIgG2, hIgG3, Any of the subclasses such as hIgG4 can be used.
- the CL of the human-type CDR-transplanted antibody may be any one belonging to hlg, and may be of the ⁇ class or the ⁇ class.
- human antibodies mean antibodies naturally occurring in the human body, but human antibody phage libraries created by recent advances in genetic engineering, cell engineering, and developmental engineering techniques are unlikely. Antibodies obtained from transgenic non-human animals producing human antibodies or transgenic plants producing human antibodies are also included.
- Antibodies that exist in the human body can be isolated, for example, by isolating human peripheral blood lymphocytes, infecting EB virus, etc., immortalizing them, and cloning them to culture human antibody-producing lymphocytes. More human antibodies can be purified.
- the human antibody phage library is a library in which antibody fragments such as Fab and single chain antibodies are expressed on the phage surface by introducing an antibody gene prepared from human B cells into the phage gene. From the library, phage expressing an antibody fragment having the desired antigen-binding activity can be recovered using the binding activity to the substrate on which the antigen is immobilized as an index. The antibody fragment can be further converted to a human antibody molecule consisting of two complete H chains and two complete L chains by genetic engineering techniques.
- a human antibody-producing transgenic non-human animal refers to an animal in which a human antibody gene has been integrated into cells.
- a human antibody-producing transgenic mouse can be produced by introducing a mouse ES cell hepatocyte antibody gene, transplanting the ES cell into an early embryo of another mouse, and then developing the embryo.
- a human antibody-producing transgenic non-human animal can be produced by introducing a human antibody gene into a fertilized egg of an animal and generating the fertilized egg.
- Human antibody-producing transgenic non-human animals can be prepared from human antibody-producing hybridomas by a conventional non-human mammal-producing hybridoma production method and cultured. Human antibodies can be produced and accumulated therein.
- transgenic non-human animals examples include porcupines, sheep, goats, pigs, porcupines, mice, rats, -birds, monkeys, and egrets.
- the antibody is an antibody that recognizes a tumor-associated antigen, an antibody that recognizes an antigen that is associated with allergy or inflammation, an antibody that recognizes an antigen that is associated with a cardiovascular disease, or an antibody that is associated with an autoimmune disease.
- It is preferably IgG.
- the antibody fragment refers to a fragment containing at least a part of the Fc region of the antibody.
- the Fc region refers to a region on the C-terminal side of the H chain of an antibody, a CH2 region and a CH3 region, and includes a natural type and a variant thereof. At least a part of the Fc region preferably refers to a fragment containing the CH2 region, more preferably a region containing the first aspartic acid present in the CH2 region.
- the Fc region of the IgG class is described in Kabat et al.'S EU Index [Sequences' Off, Sequences of Proteins of Immunological Interest, 0 " h Ed. Public Health Service , National Institutes of Health, Bethesda, MD. (1991)], meaning from Cys at position 226 to the C-terminus or from Pro at position 230 to the C-terminus. And dimers of H chains.
- a fusion protein having a part of the Fc region is a substance obtained by fusing an antibody or a fragment of an antibody containing a part of the Fc region of an antibody with a protein such as an enzyme or cytokin (hereinafter referred to as Fc Fusion protein).
- the N-glycoside-linked sugar chain that binds to the Fc region of the antibody molecule includes a branch of galactose-N-acetyldarcosamine (hereinafter referred to as Gal-GlcNAc) on the non-reducing terminal side of the core structure.
- Gal-GlcNAc galactose-N-acetyldarcosamine
- a complex type having one or more in parallel and having a structure such as sialic acid or pi-secting N-acetyldarcosamine on the non-reducing terminal side of Gal-GlcNAc can be given.
- the Fc region of the antibody molecule has a region to which each N-glycoside-linked sugar chain binds, two sugar chains are bound per antibody molecule. Since the two N-glycoside-linked sugar chains that bind to the antibody have a large number of sugar chains, determine the identity of the antibody molecule from the viewpoint of the sugar chain structure linked to the Fc region. Can be done.
- the antibody composition is a composition comprising an antibody molecule having an N-glycoside-linked complex type sugar chain in the Fc region, and the composition may be composed of an antibody molecule having a single sugar chain structure. However, it may be composed of a plurality of antibody molecules having different sugar chain structures.
- the modification of the N-glycoside-linked complex-type bran chain that binds to the Fc region of the antibody molecule involves the modification of the sugar chain in which fucose is not bound to N-acetyltilcosamine at the reducing end of the N-glycoside-linked complex-type sugar chain. It is preferable to bind to the Fc region.
- a sugar chain in which fucose is not bonded to N-acetinoledalcosamine at the reducing end of N-glycoside-linked complex type sugar chain is defined as having the N-glycoside-linked complex type sugar chain at position 1 of fucose.
- a sugar chain that is not ⁇ -linked to the 6-position of N-acetyltilcosamine at the reducing end is examined.
- the sugar chain is synthesized by a cell in which the activity of a protein involved in the modification of a sugar chain in which fucose is not bound to ⁇ ⁇ -acetyldarcosamine at the reducing end of ⁇ -glycoside-linked complex type sugar chain is reduced or deleted. .
- the enzyme protein involved in the modification of a sugar chain in which the 1-position of fucose is not ⁇ -linked to the 6-position of ⁇ ⁇ -glycidol-linked complex type sugar chain reducing terminal ⁇ -acetyldarcosamine includes:
- GDP-fucose synthase an enzyme protein involved in the synthesis of intracellular sugar nucleotide GDP-fucose (hereinafter referred to as "GDP-fucose synthase");
- N-glycoside-linked complex type sugar chain N-acetyldarcosamine at the reducing end has position 0 of fucose at position 6; an enzyme protein involved in the modification of the linked sugar chain (hereinafter referred to as “hi 1,6- Fucose-modifying enzyme ”);
- GDP-fucose transport protein a protein involved in the transport of GDP-fucose to the Golgi apparatus
- GDP-fucose synthase includes any enzyme that is involved in the synthesis of sugar nucleotide GDP-fucose, which is a source of fucose to sugar chains in a cell, and includes intracellular sugar nucleotide GDP. -Refers to enzymes that affect fucose synthesis.
- Intracellular sugar nucleotide GDP-fucose is supplied by the de novo synthesis pathway or the Salvage synthesis pathway. Therefore, all enzymes involved in these synthetic pathways are included in GDP-fucose synthase.
- GDP-fucose synthase involved in the de novo synthesis pathway examples include GDP-mannose 4-dehydratase (GDP-mannose 4-dehydratase; hereinafter referred to as GMD), GDP-keto-6 -aeoxymannose 3,5-epimerase, 4-reductase (GDP—keto-hydroxymannose 3,5-epimerase, 4-reductase; hereinafter, referred to as GMD), GDP-keto-6 -aeoxymannose 3,5-epimerase, 4-reductase (GDP—keto-hydroxymannose 3,5-epimerase, 4-reductase; hereinafter, referred to as Fx).
- GMD GDP-mannose 4-dehydratase
- Fx 4-reductase
- Fucokinase Fucokinase
- Examples of enzymes that affect the synthesis of intracellular sugar nucleotide GDP-fucose include those that affect the activity of the enzymes involved in the above-described intracellular sugar nucleotide GDP-fucose synthesis pathway and substances that serve as substrates for the enzyme. Enzymes that affect structure are also included.
- GMD examples include a protein encoded by DNA selected from the group consisting of the following (a) and (b), and a protein selected from the group consisting of the following (c), (d) and (e): .
- a protein comprising an amino acid sequence in which one or more amino acids are deleted, substituted, inserted or added in the amino acid sequence represented by SEQ ID NO: 71, and which has GMD activity;
- Fx examples include a protein encoded by DNA selected from the group consisting of the following (a) and (b), and a protein selected from the group consisting of the following (c), (d) and (e).
- a protein comprising an amino acid sequence represented by SEQ ID NO: 19 in which one or more amino acids are deleted, substituted, inserted and Z- or added, and having Fx activity;
- GFPP a protein comprising an amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO: 19 and having Fx activity.
- examples of the GFPP include a protein encoded by DNA selected from the group consisting of the following (a) and (b), and a protein selected from the group consisting of the following (c), (d) and (e).
- a protein comprising an amino acid sequence in which one or more amino acids have been deleted, substituted, inserted and / or added in the amino acid sequence represented by SEQ ID NO: 20, and having GFPP activity;
- the ⁇ , 1,6-fucose modifying enzyme is an enzyme involved in a reaction in which the 6-position of N-glycoside-linked complex type sugar chain reducing terminal N-acetyldarcosamine and the 1-position of fucose are ⁇ -linked. Any enzyme is included.
- ⁇ -Dalicoside-linked complex type sugar chain The enzyme involved in the reaction in which the 6-position of ⁇ ⁇ -acetyldarcosamine at the reducing end and 1-position of fucose are ⁇ -linked is ⁇ ⁇ -glycoside-linked complex type sugar chain at the reducing end.
- ⁇ , 6-fucose modifying enzyme include 1,6-fucosyltransferase ⁇ a-L-fucosidase.
- the ⁇ 1,6-fucosyltransferase includes a protein encoded by a DNA selected from the group consisting of the following (a), (b), (c) and (d), and the following (e), (f), ( and proteins selected from the group consisting of g), (h), (i) and (j).
- a protein comprising an amino acid sequence represented by SEQ ID NO: 23 in which one or more amino acids have been deleted, substituted, inserted, or added, and having 1,6-fucosyltransferase activity;
- amino acid sequence represented by SEQ ID NO: 24 one or more amino acids are composed of a deletion, substitution, insertion, Z or addition amino acid sequence, and a1,6-fucosyltransferase activity is A protein having;
- the GDP-fucose transport protein may be a protein involved in the transport of the intracellular sugar nucleotide GDP-fucose to the Golgi, or a protein that affects the reaction of transporting the intracellular sugar nucleotide GDP-fucose into the Golgi. Any protein is included.
- GDP-fucose transport protein examples include GDP-fucose transporter.
- proteins that affect the reaction of transporting the intracellular sugar nucleotide GDP-fucose into the Golgi include the proteins that affect the activity or expression of the above-mentioned GDP-fucose transport protein. .
- Examples of the GDP-fucose transporter of the present invention include proteins encoded by DNA selected from the group consisting of the following (a) to (! 1).
- DNA consisting of the nucleotide sequence represented by SEQ ID NO: 97 DNA that hybridizes with a DNA consisting of the nucleotide sequence represented by SEQ ID NO: 91 under stringent conditions and encodes a protein having GDP-fucose transporter activity;
- examples of the GDP-fucose transporter of the present invention include proteins selected from the group consisting of the following (i) to (t).
- (k) a protein consisting of the amino acid sequence represented by SEQ ID NO: 96;
- a protein comprising an amino acid sequence represented by SEQ ID NO: 94 in which one or more amino acids have been deleted, substituted, inserted, or Z-added, and having GDP-fucose transporter activity;
- a protein comprising an amino acid sequence represented by SEQ ID NO: 96 in which one or more amino acids have been deleted, substituted, inserted and / or added, and having GDP-fucose transporter activity;
- (P) a protein comprising an amino acid sequence represented by SEQ ID NO: 98 in which one or more amino acids have been deleted, substituted, inserted, or added, and having GDP-fucose transporter activity;
- SEQ ID consists amino acid sequence having the amino acid sequence and 80% or more homology, represented by 92, and GDP- fucose protein having a transporter activity I 1 production;
- a protein consisting of an amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO: 94 and having GDP-fucose transporter activity;
- (t) a protein consisting of an amino acid sequence having 80% or more homology with the amino acid sequence represented by SEQ ID NO: 98, and having GDP-fucose transporter activity;
- DNA that hybridizes under stringent conditions is, for example, DNA such as DNA having the nucleotide sequence represented by SEQ ID NO: 1, 2, 48, 51, 65, 91, 93, 95, or 97 or a fragment thereof.
- a probe is a DNA obtained by using the colony hybridization method, the plaque hybridization method, the Southern blot hybridization method, etc., specifically, derived from colonies or plaques. After performing hybridization at 65 ° C in the presence of 0.7 to 1.
- Omol / L sodium chloride using a filter on which DNA was immobilized 0.1 to 2 times the concentration of SSC solution (The composition of a 1-fold concentration SSC solution is composed of 150 ramol / L sodium chloride and 15 sodium / L sodium citrate), and can be identified by washing the filter at 65 ° C. DNA can be mentioned.
- soyable DNA include DNA having at least 60% or more homology with the nucleotide sequence represented by SEQ ID NO: 1, 2, 48, 51, 65, 91, 93, 95 or 97, preferably 70 % Or more, more preferably 80% or more, further preferably 90% or more, particularly preferably 95% or more, and most preferably 98% or more homologous DNA.
- SEQ ID NO: 1, 2, 48, 51 or 65 SEQ ID NO: 1, 2, 48, 51 or 65. It can be obtained by introducing a site-specific mutation into DNA encoding a protein having an amino acid sequence.
- the number of deletions, substitutions, insertions, Zs, or amino acids added is one or more, and the number is not particularly limited. The number is such that substitution or addition is possible, for example, 1 to several tens, preferably 1 to 20, more preferably 1 to 10; and still more preferably 1 to 5.
- the proteins In order for the protein to be used to have a 1,6-fucosyltransferase activity, GMD activity, Fx activity, GFPP activity or GDP-fucose transporter activity, the proteins must have SEQ ID NOs: 19, 20, 23, 24, 71, respectively. , 92, 94, 96 or 98 and BLAST [Journal 'Op' Molecular 'Biology (J. Mol. Biol.), 215, 403 (1990)] or FASTA [Methods in Enzymology (Methods in Enzymology), 183, 63 (1990)], and at least 80% or more, preferably 85% or more, more preferably 90% or more, and even more preferably 95% or more. %, More preferably 97% or more, most preferably 99% or more.
- any method can be used as long as the method can reduce or delete the target enzyme activity.
- Techniques for reducing or eliminating the above enzyme activity include:
- Another method is to select cells that are resistant to lectins that recognize an ⁇ - linked sugar chain structure at the 6-position of N-acetyldarcosamine and the 1-position of fucose at the reducing end of the N-dalicoside-linked complex type sugar chain. .
- Lectin-resistant cells are not inhibited from growing even if a certain effective concentration of lectin is present during cell culture.
- the effective concentration of lectin that does not inhibit the growth may be appropriately determined depending on the cell line, but is usually 10 / g / ml to 10.0 mg / ml, preferably 0.5 to 2.0 mg / ml. It is.
- the effective concentration of lectin when a mutation is introduced into the parent cell line is not less than the concentration at which the parent cell cannot grow normally, preferably the same concentration as that at which the parent cell cannot grow normally, more preferably 2 to 5 times. It is more preferably 10 times, most preferably 20 times or more.
- any lectin that can recognize the sugar chain structure may be used. Any lectin can be used. Specific examples include Lentil lectin LCA (Lentil Agglutinin from Lens Culinaris), Endo bean lectin PSA (Pe Lectin from Pi sum sativum), Broad bean lectin VFA (Agglutinin from Vicia faba), and Hilochawantake Lectin AAL (Lectin from Aleuria aurantia) and the like can be mentioned.
- Lentil lectin LCA Lientil Agglutinin from Lens Culinaris
- Endo bean lectin PSA Pe Lectin from Pi sum sativum
- Broad bean lectin VFA Adgglutinin from Vicia faba
- Hilochawantake Lectin AAL Lectin from Aleuria aurantia
- the parent cell is a cell before any treatment, that is, a cell before performing a step of selecting a cell having resistance to the lectin used in the present invention, and a genetic engineering to reduce or delete the above-mentioned enzyme activity. Before treatment.
- the parent cell is not particularly limited, but specific examples include the following cells.
- NS0 cells Parent cells of NS0 cells are described in the literature such as Bio / Technology, 10, 169 (1992), and Biotechnol. Bioeng., 73, 261 (2001). NS0 cells. Also, there are the NS0 cell line (RCB0213) registered with the RIKEN Cell Development Bank, or a substrain obtained by adapting these strains to a growth medium.
- the parental cells of SP2 / 0-Agl4 cells include, for example, Journal 'Ob' Immunol. (J. Immunol.), 126, 317, (1981), Nature, 276, 269, (1978), Huyman ' SP2 / 0-Agl4 cells described in the literature such as Anti-Ibodies' and Neubrids dormas (Human Antibodies and Hybridomas), 3, 129, (1992). Also, there are SP2 / 0-Agl4 cells (ATCC CRL-1581) registered with the ATCC, or a substrain (ATCC CRL-1581.1) obtained by adapting these strains to a growth medium.
- CH0 cells derived from Chinese hamster ovary tissue include Journal of Experimental Medicine, 108, 945 (1958), Proc. Natl. Acad. Sci. USA, 60, 1275 (1968), Genetics, 55, 513 (1968), Chromosoma, 41, 129 (1973), Methods in Cell Science, 18, 115 (1996), Radiation Research, 148, 260 (1997), Proc. Natl. Acad Sci. USA, 77, 4216 (1980), Pro Natl. Acad. Sci. 60, 1275 (1968), Cell, 6, 121 (1975), Molecular Cell Genetics, Appendix I, II (p. 883-900). And the like, and the like.
- CHO-K1 strains ATCC CCL-61
- DUXB11 strains ATCC CRL-9096
- Pro-5 strains ATCC CRL-1781
- commercially available CHO-S strains Lifetechnologies Cat. # 11619
- Parent cells of the rat myeloma cell line YB2 / 3HL. P2. Gil. 16Ag. 20 cells include cell lines established from Y3 / Agl. 2.3 cells (ATCC CRL-1631). Specific examples thereof include YB2 / 3HL. P2. Gil. 16Ag. 20 cells described in references such as J. Cell. Biol. 93, 576 (1982) and Methods Enzymol. 73B, 1 (1981). Is raised. Also, there are YB2 / 3HL. P2. Gil. 16Ag. 20 cells (ATCC CRL-1662) registered with the ATCC, or substrains obtained by adapting these strains to a medium in which they can grow.
- FcyR refers to an Fc receptor (hereinafter, also referred to as FcR) for an IgG class antibody.
- FcR means a receptor that binds to the Fc region of an antibody [Annual 'Review' Obb 'Immunology (Annu. Rev. Immunol.), 9, 457 (1991)].
- FcyR also includes the FcyRI, FcyRII, FcyRIII subclasses, their allelic variants, and isoforms resulting from alternative splicing.
- Fcy RII includes Fcy RIIa and Fc ⁇ yRIIb
- Fey RIII includes Fcy RIIIa and Fcy RIIIb
- the ratio of sugar chains in which fucose is not bound to N-acetyltylcolasamine at the reducing end of the sugar chain is preferably 20% or more, more preferably
- the binding activity to Fc RHIa can be increased.
- the ratio of the sugar chain in which fucose is not bonded to N-acetyltyldarcosamine at the reducing end of the sugar chain, of the total N-daricoside-linked complex type sugar chains binding to the Fc region, is defined as Fc contained in the composition.
- Fc contained in the composition For the total number of all N-glycoside-linked complex-type sugar chains that bind to the region, sugar chains in which fucose is not linked to N-acetyltylcolasamine at the reducing end of the sugar chain Means the percentage of the number.
- the ratio of the sugar chain preferably refers to the ratio of the sugar chain in which the 1-position of fucose is not CK-bonded to the 6-position of N-acetyldarcosamine at the reducing end of the sugar chain.
- a sugar chain in which fucose is not bonded to N-acetylglycosamine at the reducing end of an N-glycoside-linked complex type sugar chain is defined as fucose that is linked to N-acetylethyl glucosamine at the reducing end of an N-glycoside-linked complex type sugar chain.
- fucose that is linked to N-acetylethyl glucosamine at the reducing end of an N-glycoside-linked complex type sugar chain.
- unlinked sugar chains Preferably, a sugar chain in which the 1-position of fucose is not ⁇ - linked to the 6-position of N-acetyldarcosamine of the N-glycoside-linked complex type sugar chain is exemplified. .
- the ratio of sugar chains in which fucose is not bound to N-acetyltylcolasamine at the sugar chain reducing end contained in a composition comprising an antibody molecule having ⁇ -daricoside-linked complex sugar chains in the Fc region is determined by the ratio of the antibody Using known methods such as hydrazinolysis and enzymatic digestion from molecules [Biological Chemistry Experimental Method 23-Glycoprotein Sugar Chain Research Method (Society Press Center), edited by Reiko Takahashi (1989)], release sugar chains and release them. It can be determined by labeling the bran chains with a fluorescent label or an isotope and separating the labeled sugar chains by a chromatography method.
- An antibody composition having an increased binding activity to FcyRIIIa by the method of the present invention has high ADCC activity.
- ADCC activity refers to the activity of an antibody bound to a cell surface antigen such as a tumor cell in a living body to activate an effector cell through the binding between the antibody Fc region and FcR present on the surface of the effector cell.
- Monoclonal Antibodies Principles and Applications, Wiley-Liss, Inc., Capter 2.1 (1995) ].
- the effector cells include killer cells, natural killer cells, monocytes, macrophages, and the like.
- host cells used in the method of the present invention in which the activity of a protein involved in the modification of a sugar chain that binds fucose to N-acetyltilcosamine at the N-glycoside-linked complex type sugar chain reducing terminal is reduced or deleted.
- the method for manufacturing the will be described in detail.
- the host cell used in the method of the present invention can be prepared by the method described below.
- GDP-fucose synthase ase, alpha 1,6-fucose modifying enzyme or GDP-gene fucose transport protein targets
- GDP-fucose synthase include GMD, Fx, GFPP and Fucokinase.
- al, 6-fucose modifying enzymes include o! l, 6-fucosyltransferase, -L-fucosidase and the like.
- GDP-fucose transport proteins include GDP-fucose transporters.
- the gene referred to here includes DNA or RNA.
- the method for gene disruption includes any method capable of disrupting the gene of the target enzyme. Examples include the antisense method, the ribozyme method, the homologous recombination method, the RNA-DNA oligonucleotide (RD0) method, the RNA interference (RNAi) method, the method using retrowinores, and the method using a transposon. . Hereinafter, these will be described in detail.
- the host cells used in the method of the present invention target the GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or the GDP-fucose transport protein gene, and are described in Cell Engineering, 1-239 (1993), Biotechnology. (BI0 / TECHN0L0GY), 17, 1097 (1999), Hüman 'Molecular' Genetics. (Hum. Mol. Genet.), 5, 1083 (1995), Cell Engineering, 13 ⁇ 4 255 (1994), Proceedin's Using the antisense method or the ribozyme method described in, for example, Bu, The National Academi, Bu, Science (Proc. Natl. Acad. Sci. USA), 96, 1886 (1999). It can be made as follows.
- the DNA encoding the GDP-fucose synthase, the ⁇ 1,6-fucose modifying enzyme, or the GDP-fucose transport protein, the untranslated region, etc.
- an appropriate length antisense gene or ribozyme construct containing an intron portion is designed.
- a recombinant vector is prepared by inserting the prepared DNA fragment or full length downstream of the promoter of an appropriate expression vector.
- a transformant is obtained by introducing the recombinant vector into a host cell suitable for the expression vector.
- the host cell used in the method of the present invention can be obtained. Further, by selecting a transformant using the sugar chain structure of the glycoprotein on the cell membrane or the sugar chain structure of the produced antibody molecule as an index, a host cell used in the method of the present invention can also be obtained.
- the host cells used for producing the host cells used in the method of the present invention include yeast, animal cells, insect cells, plant cells, and other targeted GDP-fucose synthase, ⁇ 1,6-fucose modification Any enzyme can be used as long as it has the gene for the GDP-fucose transport protein. Specific examples include the host cells described in section 3 below.
- the expression vector those which can replicate autonomously in the above-mentioned host cells or can be integrated into the chromosome, and which contain a designed antisense gene or a promoter containing a promoter at a position where the ribozyme can be transcribed are used. Specific examples include the expression vectors described in section 3 below.
- the method for introducing a gene into various host cells As a method for introducing a gene into various host cells, the method for introducing a recombinant vector suitable for various host cells described in Section 3 below can be used.
- a method for selecting a transformant using the sugar chain structure of a glycoprotein on a cell membrane as an index for example, the method described in 1 (5) below can be mentioned.
- Examples of a method for selecting a transformant using the sugar chain structure of the produced antibody molecule as an index include the methods described in Section 6 or 7 described below.
- Methods for preparing cDNAs encoding GDP-fucose synthase, 1,6-fucose modifying enzyme, or GDP-fucose transport protein include the following methods.
- Total RNA or mRNA is prepared from tissues or cells of a human or non-human animal.
- the mRNA of a human or non-human animal tissue or cell may be a commercially available one (for example, manufactured by Clontech), or may be prepared from a human or non-human animal tissue or cell as follows. .
- Methods for preparing total RNA from human or non-human animal tissues or cells include the guanidine thiocyanate-cesium trifluoroacetate method [Methods in Enzymology, 154, 3 (1987)], Acid-produced guanidine thiocyanate 'phenol' black mouth form (AGPC) method [Analytical 'Analytical Biochemistry, 162, 156 (1987); Experimental Medicine, 9, 1937 (1991)].
- oligo (dT) -immobilized cellulose column method (Molecular 'Cloning 2nd Edition) and the like can be mentioned.
- mRNA can be prepared by using a kit such as Fast Track mRNA Isolation Kit (Invitrogen) or Quick Prep mRNA Purification Kit (Pharmacia).
- kit such as Fast Track mRNA Isolation Kit (Invitrogen) or Quick Prep mRNA Purification Kit (Pharmacia).
- a cDNA library is prepared from the prepared human or non-human animal tissue or cell total RNA or mRNA.
- Methods for preparing a cDNA library include the methods described in Molecular Cloning, 2nd Edition, Current Protocols, Molecular Biology, etc., or kits sold on the market, such as the Superscript Plasraid System for cDNA Synthesis and Plasmid. Cloning (manufactured by Life Technologies), and a method using ZAP-cDNA Synthesis Kit (manufactured by STRATAGENE).
- a closing vector for preparing a cDNA library any of a phage vector, a plasmid vector and the like can be used as long as it can replicate autonomously in E. coli K12 strain.
- Escherichia coli is preferably used. Specifically, Escherichia coli XL1-Blue MRF, [STRATAGENE, Strategies, 5, 81 (1992)], Escherichia coli C600 [Genetics, 39, 440 (1954)] ], Escherichia coli Y1088 [Science, 222, 778 (1983)], Escherichia coli Y1090 [Science, 222, 778 (1983)], Escherichia coli marauder 522 [Giananole-op-molecular pyrology] (J. Mol.
- This cDNA library may be used as is for subsequent analyses, but in order to reduce the proportion of incomplete-length cDNAs and obtain full-length cDNAs as efficiently as possible, the oligocap method developed by Sugano et al. ), 138, 171 (1994); Gene, 200, 149 (1997); protein nucleic acid enzyme, ⁇ , 603 (1996); experimental medicine,, 2491 (1993); cDNA cloning (Yodosha) (1996).
- a cDNA library prepared using the method for preparing a gene library (Yodosha) (1994)] may be used for the following analysis.
- the fact that the obtained gene fragment is a DNA encoding GDP-fucose synthase, a 1,6-fucose modifying enzyme, or a GDP-fucose transport protein can be determined by a commonly used nucleotide sequence analysis method, for example, Sanger et al.
- the Didoxy method [Procedures' Op-The 'National' Academy 'Ob' Science (Proc. Natl. Acad. Sci. USA), 74, 5463 (1977)], or ABI PRISM 377 DNA Sequencer (PE Biosystems, Inc.) Can be confirmed by analysis using a base sequence analyzer such as
- a cDNA or cDNA library synthesized from mRNA contained in human or non-human animal tissues or cells is used as a probe for colony hybridization and plaque hybridization (Molecular Cloning 2nd Edition). ), DNA of GDP-fucose synthase, 1,6-fucose modifying enzyme, or GDP-fucose transport protein can be obtained.
- primers used to obtain a gene fragment encoding GDP-fucose synthase can be used to treat human or non-human animal tissues or cells.
- a cDNA or a cDNA library synthesized from the contained mRNA as a type III protein screening is performed using the PCR method to obtain GDP-fucose synthase, 1,6-fucose modifying enzyme, or GDP-fucose transport protein. DNA can also be obtained.
- nucleotide sequence analysis method generally used, for example, Sanger (Sanger) et Jidokishi Method [Procedures of the National Academy of Sciences (Proc. Natl. Acad. Sci. USA), 74, 5463 (1977)], or ABI PRISM 377 DNA Sequencer (PE Biosystems)
- the nucleotide sequence of the DNA is determined by analysis using a nucleotide sequence analyzer such as that described above.
- nucleotide sequence of the cDNA Based on the determined nucleotide sequence of the cDNA, using a homology search program such as BLAST, Genbank, by carrying out a search of nucleotide sequence databases such as EMBL and DDBJ, GDp in genes in the database - fucose synthase , alpha 1, it is also possible to determine the gene encoding 6-fucose modifying enzyme, or GDP- fucose transport protein.
- the nucleotide sequence of the gene encoding GDP-fucose synthase obtained by the above method For example, the base sequence described in SEQ ID NO: 48, 51 or 65 can be mentioned.
- nucleotide sequence of the gene encoding the ⁇ 1,6-fucose modifying enzyme examples include the nucleotide sequence of SEQ ID NO: 1 or 2.
- the nucleotide sequence of the gene encoding the GDP-fucose transport protein includes, for example, the nucleotide sequence of SEQ ID NO: 91, 93, 95 or 97.
- GDP-fucose synthase can be synthesized by chemical synthesis using a DNA synthesizer such as the DNA synthesizer Model 392 manufactured by Pakinkin-Elma using the phosphoramidite method.
- 6-fucose modifying enzyme, or cDNA of GDP-fucose transport protein can also be obtained.
- Genomic DNA of GDP-fucose synthase, 1,6-fucose modifying enzyme, or GDP-fucose transport protein is described, for example, in Molecular 'Cloning 2nd Edition' or Current 'Protocols in Molecular Biology'. Publicly known methods. It can also be prepared by using a genomic DNA library screening system (Genome Systems) or Universal GenomeWalker TM Kits (CL0NTECH).
- the nucleotide sequence of the genomic DNA of GDP-fucose synthase obtained by the above method includes, for example, the nucleotide sequence of SEQ ID NO: 67 or 70.
- the nucleotide sequence of genomic DNA of GDP-fucose transport protein includes, for example, the nucleotide sequence of SEQ ID NO: 99 or 100.
- an antisense oligonucleotide or ribozyme designed based on the nucleotide sequence of GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or GDP-fucose transport protein can be directly transferred to host cells.
- host cells used in the method of the present invention can also be obtained.
- the antisense oligonucleotide or ribozyme can be prepared by a conventional method or by using a DNA synthesizer. More specifically, in the nucleotide sequence of cDNA or genomic DNA encoding GDP-fucose synthase, al, 6-fucose modifying enzyme, or GDP-fucose transport protein, contiguous 5 to: 150 bases, preferably Based on the sequence information of the oligonucleotide having a sequence corresponding to 5 to 60 bases, more preferably 5 to 40 bases, an oligonucleotide (antisense oligonucleotide) corresponding to a sequence complementary to the oligonucleotide or the oligonucleotide.
- Oligonucleotides include oligo RNAs and derivatives of the oligonucleotides (hereinafter referred to as oligonucleotide derivatives).
- Oligonucleotide derivatives include oligonucleotide derivatives in which the phosphodiester bond in the oligonucleotide is converted to a phosphorothioate bond, and phosphodiester bonds in the oligonucleotide to the N3, -P5 'phosphoramidate bond.
- oligonucleotide derivatives in which ribose and phosphoric acid diester bond in oligonucleotide are converted to peptide nucleic acid bond, Oligonucleotide derivative in which peracyl in oligonucleotide is substituted with C-5 propynylperacyl Derivative oligonucleotide in which peracyl in the oligonucleotide is substituted with C-5 thiazyl peroxyl, Oligonucleotide derivative in which cytosine in the oligonucleotide is substituted with C-5 propyl-cytosine, in oligonucletide Oligonucleotide derivatives in which cytosine is substituted with phenoxazine-modified cytosine, oligonucleotide derivatives in which the ribose in the oligonucleotide is substituted with 2'-0-propylribos
- the host cell used in the method of the present invention targets a gene for GDP-fucose synthase, a 1,6-fucose modifying enzyme, or a GDP-fucose transport protein, and homologous recombination of the target gene on the chromosome is performed. It can be prepared by modifying with
- Modification of the target gene on the chromosome can be performed using the Manipulating the Mouse Embryo A Laboratory Manual, Second Edition, and the old Spring Harbor Laboratory Press (1994) (hereinafter, ⁇ manipulating 'the' mouse 'embryo. Abbreviation), Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993), Bioma-Yuanore Series 8 Gene Targeting, Generation of Mutant Mice Using ES Cells, Yodosha (1995) (hereinafter For example, the method described in “Generation of mutant mice using ES cells” can be used as follows.
- Target genes to be modified based on the base sequence of genomic DNA eg, GDP-fuco A target vector for homologous recombination of DNA, synthase, al, 6-fucose modifying enzyme, or the structural gene or promoter gene of GDP-fucose transport protein.
- the host cell used in the method of the present invention can be prepared by introducing the prepared target vector into a host cell and selecting a cell in which homologous recombination has occurred between the target gene and the target vector.
- Host cells include yeast, animal cells, insect cells, plant cells, etc. that have the target GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or GDP-fucose transport protein gene. Any of them can be used. Specific examples include the host cells described in section 3 below.
- genomic DNA described in (1) (1) (a) above can be used as a method for preparing genomic DNA of GDP-fucose synthase, eel, 6-fucose modifying enzyme, or GDP-fucose transport protein.
- Preparation methods and the like can be mentioned.
- the nucleotide sequence of the genomic DNA of GDP-fucose synthase obtained by the above method includes, for example, the nucleotide sequence of SEQ ID NO: 67 or 70.
- the base sequence of genomic DNA of 1,6-fucose modifying enzyme is, for example, the base sequence of SEQ ID NO: 3.
- the nucleotide sequence of genomic DNA of GDP-fucose transport protein includes, for example, the nucleotide sequence of SEQ ID NO: 99 or 100.
- Target vectors for homologous recombination of the target gene can be prepared according to the methods described in Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993), Production of Mutant Mice Using ES Cells, etc. it can.
- the target vector may be either a replacement type or an insertion type.
- the method for introducing a recombinant vector suitable for various host cells described in Section 3 below can be used.
- Methods for efficiently selecting homologous recombinants include, for example, positive selection, promoter selection described in Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993), production of mutant mice using ES cells, etc. , Negative selection, poly A selection, and the like.
- Methods for selecting the desired homologous recombinant from the selected cell lines include the Southern hybridization method for genomic DNA (Molecular Clawing, 2nd ed.) And the PCR method [PCR Protocols ( PCR Protocols), Academic Press (1990)] And the like. '
- the host cell used in the method of the present invention targets the gene for GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or GDP-fucose transport protein, and uses the RD0 method, for example, as follows: Can be made.
- an appropriate length including a portion encoding GDP-fucose synthase, a 1,6-fucose-modifying enzyme, or a GDP-fucose transport protein, an untranslated region or an intron.
- RD0 construct is designed and synthesized. Introduce the synthesized RD0 into host cells and select the target enzyme, that is, a transformant in which the GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or GDP-fucose transport protein has a mutation.
- the target enzyme that is, a transformant in which the GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or GDP-fucose transport protein has a mutation.
- Host cells include yeast, animal cells, insect cells, plant cells, etc. that have the gene for the target GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or GDP-fucose transport protein. Any of them can be used. Specific examples include the host cells described in section 3 below.
- RD0 For the introduction of RD0 into various host cells, the method for introducing a recombinant vector suitable for various host cells described in Section 3 below can be used.
- Examples of a method for preparing cDNA of GDP-fucose synthase, al, 6-fucose modifying enzyme, or GDP-fucose transport protein include, for example, the method of preparing DNA described in (a) of item (1) above. And so on.
- Methods for preparing genomic DNA of GDP-fucose synthase, 1,6-fucose modifying enzyme, or GDP-fucose transport protein include, for example, the genomic DNA described in (1) (a) of (1) above. And the like.
- the DNA base sequence is digested with an appropriate restriction enzyme and the like, cloned into a plasmid such as pBluescript SK (-) (Stratagene), and subjected to a commonly used nucleotide sequence analysis method, for example, the dideoxy method of Sanger et al. [Procedinations' Op 'The National' Academy 'ob' Science (Proc. Natl. Acad. Sci. USA), 74, 5463 (1977)] or an ABI PRISM 377 DNA sequencer (manufactured by PE Biosystems) to determine the base sequence of the DNA.
- a plasmid such as pBluescript SK (-) (Stratagene)
- a commonly used nucleotide sequence analysis method for example, the dideoxy method of Sanger et al. [Procedinations' Op 'The National' Academy 'ob' Science (Proc. Natl. Acad. Sci. USA), 74, 5463 (1977)]
- RD0 can be prepared by a conventional method or by using a DNA synthesizer.
- a method for introducing RD0 into a host cell and selecting a transformant in which the gene for the targeted enzyme, GDP-fucose synthase, al, 6-fucose modifying enzyme, or GDP-fucose transport protein has a mutation is selected.
- Methods for directly detecting mutations in chromosomal genes such as those described in Molecular Cloning, Second Edition, Current Biochemistry, Molecular Biotechnology, and the like.
- a transformant is selected by using the activity of the introduced GDP-fucose synthase, the 1,6-fucose modifying enzyme, or the GDP-fucose transport protein described in (a) of the above item (1) as an index.
- a method for selecting a transformant using the sugar chain structure of a glycoprotein on a cell membrane as described in 1 (5) below as an index or a method for producing a transformant as described in 6 or 7 below.
- a method for selecting a transformant using the sugar chain structure of the antibody molecule as an index can also be used.
- RD0 The construction of RD0 is described in Science, 273, 1386 (1996); Nature Medicine, 4, 285 (1998); Hepatology, 25, 1462 (1997); Gene. 'Therapy (Gene Therapy), 5, 1960 (1999); Journal' Ob Molecular ', J. Mol. Med., 75, 829 (1997); Proceedings' Ob 'The' National 'Academy'. USAl, Proc. Natl. Acad. Sci. USA, 96, 8774 (1999); USA), 96, 8768 (1999); Nucleic Acids Res., 27, 1323 (1999); Investigation Off, Inc., Invest. Dematol. ), 111, 1172 (1998); Nature Biotech., 16, 1343 (1998); Nature, Biotechnology. -(Nature Biotech.), 18, 43 (2000); can be designed in accordance with the description in Nature Biotech., 18, 555 (2000).
- the host cell used in the method of the present invention targets a gene for GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or GDP-fucose transport protein, and uses the RNAi method,
- a gene for GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or GDP-fucose transport protein For example, it can be manufactured as follows.
- RNAi gene of appropriate length, including a portion encoding GDP-fucose synthase, al-, 6-fucose modifying enzyme, or GDP-fucose transport protein or a non-translated region.
- a recombinant vector is prepared by inserting the prepared DNA fragment or full length downstream of the promoter of an appropriate expression vector.
- a transformant is obtained by introducing the recombinant vector into a host cell suitable for the expression vector.
- Transformants are selected based on the activity of the introduced GDP-fucose synthase, 1,6-fucose modifying enzyme, or GDP-fucose transport protein, or the sugar chain structure of the produced antibody molecule or the glycoprotein on the cell surface. By doing so, a host cell used in the method of the present invention can be obtained.
- yeast As host cells, yeast, animal cells, insect cells, plant cells, etc., which have the target GDP-fucose synthase, al, 6-fucose modifying enzyme, or GDP-fucose transport protein gene Any of them can be used. Specific examples include the host cells described in section 3 below.
- RNAi gene As the expression vector, those which can replicate autonomously in the above host cells or can be integrated into the chromosome, and which contain a promoter at a position where the designed RNAi gene can be transcribed are used. Specific examples include the expression vectors described in section 3 below.
- Methods for selecting a transformant using the activity of GDP-fucose synthase, 1,6-fucose modifying enzyme, or GDP-fucose transport protein as an index include, for example, (a) of the above item (1) (1). And the method described in (1).
- Methods for selecting a transformant using the sugar chain structure of a glycoprotein on a cell membrane as an index for example, the method described in 1 (5) below can be mentioned.
- Methods for selecting a transformant using the bran chain structure of the produced antibody molecule as an index include, for example, the method described in Section 6 or Examples of the method include the methods described in Section 7 below.
- RNAi gene designed based on the nucleotide sequence of GDP-fucose synthase, a1,6-fucose modifying enzyme, or GDP-fucose transport protein can be directly introduced into host cells.
- the host cells used in the method of the present invention can also be obtained.
- the RNAi gene can be prepared by a conventional method or using a DNA synthesizer.
- RNAi gene construct is described in [Nature, 391, 806 (1998); Pseudo-Seedings 'ob' The National 'akademi-iob' Science (Proc. Natl. Acad. Sci. USA), 95 , 15502 (1998); Nature, 395, 854 (1998); Proc. Natl. Acad. Sci. USA, 96, 5049 (1999); Cell, 95, 1017 (1998); Proceedings 'ob' the 'national' academy 'op' science (Proc. Natl. Acad. Sci. USA), 96, 1451 (1999). ); Proceedings 'Ob the' Nashinanore 'Accademia ⁇ Oob' Science (Proc. Natl. Acad. Sci. USA), 95, 13959 (1998); Nature Cell Biol. ), 70 (2000)].
- the host cell used in the method of the present invention is a transposon system described in Nature Genet., 25, 35 (2000), etc., and is composed of GDP-fucose synthase, ⁇ 1,6-fucose.
- a mutant based on the activity of the modifying enzyme or GDP-fucose transport protein, or the sugar chain structure of the produced antibody molecule or the glycoprotein on the cell membrane, a host cell used in the method of the present invention is prepared. be able to.
- the transposon system is a system in which a foreign gene is randomly inserted into a chromosome to induce mutation.
- a foreign gene inserted in a transposon is used as a vector to induce mutation, and this gene is At the same time as a transposase expression vector Introduce into.
- transposase Any transposase can be used as long as it is suitable for the sequence of the transposon to be used.
- any gene can be used as long as it can induce mutation in the DNA of the host cell.
- yeast, animal cells, insect cells, plant cells and the like GDP targeting - fucose synthase, shed 6 fucose modifying enzyme, or GDP can also be used.
- Specific examples include the host cells described in section 3 below.
- the methods for introducing a recombinant vector suitable for various host cells described in Section 3 below can be used.
- GDP- fucose synthase, alpha 1 as a method for selecting a mutant based on the activity metrics 6 fucose modifying enzyme, or GDP- fucose transport ⁇ white matter, for example, of the 1
- a method for selecting a mutant using the sugar chain structure of a glycoprotein on a cell membrane as an index includes, for example, the method described in 1 (5) below.
- Methods for selecting mutants using the sugar chain structure of the produced antibody molecule as an index include, for example, the methods described in Section 6 or 7 below.
- the host cell used in the method of the present invention targets a gene of GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or GDP-fucose transport protein, and introduces a dominant negative body of the enzyme.
- GDP-fucose synthase include GMD, Fx, GFPP and Fucokinase.
- al, 6-fucose modifying enzymes include ⁇ ; 1,6-fucosyltransferase, o; -L-fucosidase and the like.
- Specific examples of the GDP-fucose transport protein include the GDP-fucose transporter.
- threonine at position 155, 157 A dominant negative body can be prepared by substituting the glutamic acid at position 179, the cysteine at position 179, and the lysine at position 183 with another amino acid.
- the production of such an amino acid substitution-introduced gene is performed using the site-directed mutagenesis method described in Molecular Cloning, 2nd edition, Current Protocols, In Molecular Molecular Biology, etc. It can be carried out.
- the host cells used in the method of the present invention are prepared by using the dominant negative gene of the target enzyme prepared as described above, using Molecular 'Cloning 2nd edition, current.protoconorez'in'molecular'biology, According to the method for gene transfer described in Ting, Mouse and Embrio, 2nd edition, for example, the following method can be used.
- a DNA fragment of an appropriate length containing a portion encoding the protein is prepared as necessary.
- a recombinant vector is prepared by inserting the DNA fragment or the full-length DNA downstream of an appropriate expression vector promoter.
- a transformant is obtained by introducing the recombinant vector into a host cell suitable for the expression vector.
- a host cell used in the method of the present invention can be prepared by selecting a transformant based on white matter activity or a sugar chain structure of a produced antibody molecule or a glycoprotein on a cell membrane.
- Host cells include yeast, animal cells, insect cells, plant cells, etc. that have the target GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or GDP-fucose transport protein gene. Any of them can be used. Specific examples include the host cells described in section 3 below.
- the expression vector those which can replicate autonomously in the above-mentioned host cells or can be integrated into the chromosome, and which contain a promoter at a position capable of transcribing the DNA encoding the desired dominant negative body are used. Specific examples include the expression vectors described in section 3 below.
- Methods for selecting a transformant using the activity of GDP-fucose synthase, ct1,6-fucose modifying enzyme, or GDP-fucose transport protein as an index include, for example, (a) of the above item (1) (1). And the method described in (1).
- a method for selecting a transformant using the sugar chain structure of a glycoprotein on a cell membrane as an index for example, the method described in 1 (5) below can be mentioned.
- Examples of a method for selecting a transformant using the sugar chain structure of the produced antibody molecule as an index include the methods described in Section 6 or 7 described below.
- Host cells used in the method of the present invention GDP-fucose synthase, alpha 1, by introducing a mutation for a gene of 6-fucose modifying enzyme or GDP-fucose transport protein, resulting in a mutation in the enzyme It can be prepared by using a technique for selecting a desired cell line.
- GDP-fucose synthase includes GMD, Fx, GFPP and Fucokinase.
- ⁇ 1,6-fucose modifying enzyme include 1,6-fucosyltransferase, ⁇ -L-fucosidase and the like.
- Specific examples of the GDP-fucose transport protein include the GDP-fucose transporter.
- Methods for introducing mutations into enzymes include: 1) GDP-fucose synthase from mutants obtained by treating the parent strain by mutagenesis treatment or spontaneously occurring mutants.
- a method for selecting a desired cell line based on the activity of an element, al, 6-fucose modifying enzyme, or GDP-fucose transport protein; 2) a mutant obtained by treating a parent strain by mutagenesis treatment or spontaneously A method of selecting a desired cell line from the resulting mutants using the sugar chain structure of the produced antibody molecule as an index.3) A mutant or a spontaneously generated mutant obtained by treating the parent strain by mutagenesis.
- a method of selecting a desired cell line using the sugar chain structure of a glycoprotein on the cell membrane of the cell as an index can be mentioned.
- any treatment that induces a point mutation, deletion or frame shift mutation in the DNA of the cell line of the parent strain can be used.
- Spontaneously occurring mutants include those spontaneously generated by continuing subculturing under normal cell culture conditions without special mutagenesis treatment. .
- the host cell used in the method of the present invention targets the gene for GDP-fucose synthase, 1,6-fucose modifying enzyme, or GDP-fucose transport protein, and is provided with antisense RNA / DNA technology.
- GDP-fucose synthase examples include GMD, Fx, GFPP, and Fucokinase.
- Specific examples of the CK 1,6-fucose modifying enzyme include 1,6-fucosyltransferase and ⁇ -L-fucosidase.
- GDP-fucose transport Proteins include, specifically, GDP-fucose transporters.
- Method for selecting a strain resistant to lectin recognizing a sugar chain structure in which the 6-position of N-acetyldarcosamine at the reducing end of the N-glycoside-linked sugar chain and the 1-position of fucose are ⁇ -linked The method of the present invention Select a strain that is resistant to a lectin recognizing a sugar chain structure in which the 6-position of ⁇ ⁇ -glycidyl-linked glycan and the 1-position of fucose are ⁇ -linked. It can be manufactured by using a technique.
- Methods for selecting strains that are resistant to lectins that recognize a sugar chain structure in which the 6-position of 1-fucose and the 6-position of fucose at the reducing end of ⁇ ⁇ -daricoside-linked sugar chain are ⁇ -linked include, for example, A method using a lectin described in Somatake 'Cell' and 'Molecular' Genetics (Somatic Cell Mol. Genet.), 12, 51 (1986).
- any lectin can be used as long as it recognizes a sugar chain structure in which the 6-position of ⁇ ⁇ -daricoside-linked sugar chain-reducing terminal ⁇ -acetyldarcosamine and the 1-position of fucose are ⁇ -linked.
- specific examples include lentil lectin LCA (Lentil Agglutinin from Lens Culinaris), endumamelectin PSA (Pea Lectin from Pi sum sativum), broad bean lectin VFA (Agglutinin from Vicia faba), and Hylochawanta lectin AAL (Lectin from Aleuria aurantia) and the like can be mentioned.
- the cells are cultured in a medium containing the above lectin at a concentration of 1 ⁇ g / mL to 1 mg / mL for 1 day to 2 weeks, preferably 1 day to 1 week, and surviving cells are subcultured.
- the colony is picked up, transferred to another incubator, and further cultured in a lectin-containing medium, whereby the N-acetyl-darcosamine at the reducing end of the N-dalicoside-linked sugar chain of the present invention is ranked 6th and 1st in fucose.
- Strain that is resistant to lectin recognizing the sugar chain structure linked to it can be selected.
- Methods for confirming lectin-resistant cells include methods for confirming the expression of GDP-fucose synthase, 1,6-fucose modifying enzyme or GDP-fucose transport protein, Examples include a method of culturing cells in a medium to which lectin is added directly. Specifically, the expression level of mRNA for the 1,6-fucosyltransferase, one of the ⁇ 1,6-fucose modifying enzymes in the cell, was measured. It can be said that the cells are resistant.
- the cells used in the method of the present invention have an activity of at least one protein selected from the group consisting of GDP-fucose synthase, al, 6-fucose modifying enzyme protein and GDP-fucose transport protein. It can be produced using a transgenic non-human animal or plant whose genomic gene has been modified so as to be reduced or deleted, or a progeny thereof.
- the transgenic non-human animal or plant or progeny thereof can be prepared using the same method as described in 1., targeting the gene of the protein described above.
- the target non-human animal for example, embryonic stem cells such as a horse, a sheep, a goat, a pig, a pig, a mouse, a rat, a chicken, a monkey, a rabbit, etc.
- the method used in the present invention in which the activity of the GDP-fucose synthase, the 1,6-fucose modifying enzyme, or the GDP-fucose transport protein is reduced or deleted is performed by using the same method as described in (1). To produce embryonic stem cells.
- a gene encoding GDP-fucose synthase, al, 6-fucose modifying enzyme or GDP-fucose transport protein on a chromosome can be obtained by a known homologous recombination technique [for example, Nature, 326, 6110 (1987), Cell, 51, 503 (1987), etc.] to produce a mutant clone inactivated or substituted with an arbitrary sequence.
- a mutant clone thus prepared chimeric individuals comprising embryonic stem cell clones and normal cells can be prepared by a technique such as injection chimera method or assembly chimera method of injecting animal fertilized eggs into blastocysts (Blastocyst). it can.
- transgenic non-genes with reduced or deleted activity of GDP-fucose synthase, ⁇ 1,6-fucose modifying enzyme, or GDP-fucose transport protein in whole body cells Human animals can be obtained.
- Target vectors for homologous recombination of the target gene can be prepared according to the methods described in Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993), Production of Mutant Mice Using ES Cells, etc. it can.
- Target vectors are replacement type, insertion type, Any type can be used.
- any method for introducing a target vector into lunar Pi stem cells any method can be used as long as it introduces DNA into animal cells.
- the electoporation method [Cytotechnology, 3, 133 (1990)] calcium phosphate method (Japanese Unexamined Patent Publication No. 2-227075), lipofection method [Procedures of the National Academy of Sciences (Proc. Natl. Acad. Sci. USA), 84, 7413 (1987)]
- the injection method manipulating 'mouse' embryo 2nd edition
- a method using a particle gun (gene gun) Japanese Patent No. 2517813
- DEAE -Dextran method Ray manual series 4.
- Gene transfer, expression and analysis Yamamoto Yokota, Kenichi Arai (1994)
- virus vector method manipulating 'mouse') Enprio, 2nd edition.
- Methods for efficiently selecting homologous recombinants include, for example, positive selection and promoter selection described in Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993), creation of mutant mice using ES cells, etc. , Negative selection, poly A selection, and the like.
- a target vector containing the hprt gene after introduction into the embryonic stem cells lacking the hprt gene, the embryonic stem cells are cultured in a medium containing aminopterin, hypoxanthine and thymidine, and the aminobuterin-resistant By selecting strains, positive selection for selecting homologous recombinants containing the hprt gene can be performed.
- a target vector containing the neomycin resistance gene embryo-derived stem cells into which the vector has been introduced are cultured in a G418-containing medium, and G418-resistant strains are selected to select homologous recombinants containing the neomycin resistance gene. Positive selection can be made.
- a target vector containing the DT gene embryonic stem cells into which the vector has been introduced are cultured, and the growing strain is selected. (Recombinants randomly inserted into the chromosome other than homologous recombination have the DT gene in the chromosome.
- Methods for selecting the desired homologous recombinant from the selected cell lines include the Southern hybridization method (molecular cloning, second edition) for genomic DNA and the PCR method [PCR Protocols ( PCR Protocols), Academic Press (1990)] and the like.
- embryonic stem cells When embryonic stem cells are incorporated into fertilized eggs using the enriched chimera method, generally It is preferred to use fertilized eggs at a developmental stage before the cell phase. When embryonic stem cells are incorporated into a fertilized egg using the injection chimera method, it is generally preferable to use a fertilized egg from the 8-cell stage to the stage of blastocyst development.
- pseudopregnant female mice When a fertilized egg is transplanted into a female mouse, the fertilized egg obtained in a pseudopregnant female mouse in which fertilization has been induced is artificially transplanted by mating with a vasectomized male non-human mammal. ⁇ Implantation is preferable, and pseudopregnant female mice can be obtained by natural mating. After administration of luteinizing hormone-releasing hormone (hereinafter abbreviated as LHRH) or an analog thereof, the mice are mated with male mice. Pseudopregnant female mice with induced fertility can also be obtained.
- LHRH luteinizing hormone-releasing hormone
- a method similar to the method described in the above item 1 is applied to a fertilized egg cell of a target non-human animal, for example, a horse, a sheep, a goat, a pig, a horse, a mouse, a rat, a chicken, a monkey, a rabbit, etc.
- a fertilized egg cell of the present invention in which the activity of GDP-fucose synthase, a 1,6-fucose modifying enzyme, or GDP-fucose transport protein has been reduced or deleted can be produced.
- the fertilized egg cells thus prepared are transplanted into the oviduct or uterus of a pseudopregnant female using the method of embryo transfer described in Manipulating 'Mouse' Embryo 2nd Ed.
- a transgenic non-human animal having reduced or deleted activity of 1,6-fucose modifying enzyme or GDP-fucose transport protein can be produced.
- the activity of GDP-fucose synthase or N-glycoside-linked complex-type sugar chain reduction is applied to the target plant virulent cells or cells by using the same method as described in the above item 1.
- the callus of the present invention can be produced in which the activity of an enzyme involved in sugar chain modification in which the 1-position of fucose is a-linked to the 6-position or 3-position of N-acetyldarcosamine at the terminal is reduced or deleted.
- the prepared callus was applied to a known method [tissue culture, 20 (1994); tissue culture, ⁇ 1 (1995); Trends, Biotechnology, Trends in Biotechnology, 15, 45 (1997)].
- Transgenes with reduced or deleted activity of GDP-fucose synthase, ctI, 6-fucose modifying enzyme, or GDP-fucos transport protein are regenerated by culturing in a medium containing auxin and cytokinin.nick plants can be produced. 3. Production method of antibody composition
- Antibody compositions are described in Molecular 'Cloning 2nd Edition, Current' Protocols' in Molecular Cube, Inc., Antibodies, A Laboratory manual, Cold Spring Harbor Laboratory, 1988 (hereinafter abbreviated as Antibodies), Monoclonal Antibodies: Principles and practice, Third Edition, Acad. Press, 1996 (hereafter abbreviated as Monoclona / Le 'Antibodies), Antibody Engineering, A Practical Approach, IRL Press at Oxford University Press, 1996 (hereafter, Antibody Engineering). Can be obtained by expressing in a host cell as follows, for example.
- a full-length cDNA of the antibody molecule is prepared, and a DNA fragment of an appropriate length containing a portion encoding the antibody molecule is prepared.
- a recombinant vector is prepared.
- a transformant producing an antibody molecule By introducing the recombinant vector into a host cell suitable for the expression vector, a transformant producing an antibody molecule can be obtained.
- any of yeast, animal cells, insect cells, plant cells, and the like can be used as long as it can express the gene of interest.
- yeast animal cells, insect cells, plant cells, and other cells as host cells into which an enzyme involved in the modification of the N-glycoside-linked sugar chain that binds to the Fc region of the antibody molecule has been introduced using genetic engineering techniques. You can also.
- those which can replicate autonomously in the above-mentioned host cells or can be integrated into the chromosome, and which contain a promoter at a position where the DNA encoding the antibody molecule of interest can be transcribed are used.
- the cDNA is obtained from a human or non-human animal tissue or cell according to the DNA preparation method described in the above (1) (1) (a), using a probe primer specific for the antibody molecule of interest or the like. It can be prepared using
- expression vectors When yeast is used as a host cell, examples of expression vectors include YEP13 (ATCC37115), YEp24 (ATCC37051), YCp50 (ATCC37419) and the like.
- YEP13 ATCC37115
- YEp24 ATCC37051
- YCp50 ATCC37419
- any promoter can be used as long as it can be expressed in yeast strains.
- promoters for glycolytic genes such as hexose kinase,
- Examples include the PH05 promoter, PGK promoter, GAP promoter, ADH promoter, gal 1 promoter, gal 10 promoter, heat shock protein promoter, MF a1 promoter, CUP 1 promoter and the like.
- yeast belonging to the genera Saccharomyces, Schizosaccharomyces, Krybetella genus, Trichosporon, Schuniomyces, and the like. I can give you S.
- any method can be used as long as it is a method for introducing DNA into yeast.
- an electoral port method [Methods. Enzymol., 194, 182] (1990)]
- Supoku Plast Method [Pec Seedings 'Ob' The 'National' Academy of Sciences (Proc. Natl. Acad. Sci. US A), 84, 1929 (1978)]
- Acetic Acid Lithium method [J. Bacteriology, 153, 163 (1983)], Proceedings' ob 'the' National Academy 'op' Science (Proc. Natl. Acad. Sci. US A), 75, 1929 (1978)].
- an expression vector for example, (manufactured by Funakoshi) P cDNAI, pcDM8, pAGE107 [JP-A 3-22979; site Technology (Cytotechnology), 3, 133 ( 1990)], pAS3 -3 (Japanese Patent Laid-Open No. 2-227075), pCDM8 [Nature, 329, 840 (1987)], pcDNAI / Amp (Invitrogen), pREP4 (Invitrogen), pAGE103 [Journal of Novo] J. Biochemistry, 101, 1307 (1987)], pAGE210 and the like.
- any promoter can be used as long as it can be expressed in animal cells.
- the promoter of the immediate early (IE) gene of cytomegalovirus (CMV) the early promoter of SV40, and the promoter of retrovirus , Meta mouth thionein promoter, heat shock promoter, SRa promoter and the like.
- the enhancer of the IE gene of human CMV may be used together with the promoter.
- Host cells include Namalwa cells, human cells, COS cells, monkey cells, CH0 cells, Chinese hamster cells, HBT5637 (Japanese 63-299), rat myeloma cells, mouse myeloma cells, Syrian hamsters, kidney-derived cells, embryonic stem cells, fertilized egg cells, and the like.
- any method for introducing DNA into animal cells can be used.
- electroporation [Cytotechnology, 3, 133 (1990)]
- Calcium phosphate method Japanese Unexamined Patent Publication No. 2-227075
- Lipofxion method [Procedures' Ob the National. Academy 'Ob' Science (Proc. Natl. Acad. Sci. USA), 84, 7413 (1987)]
- Injection method [Ma-Purating 'The Mouse' Embrio 'A' Laboratory 'Manual], Method using particle gun (gene gun) (Japanese Patent No. 2606856, Japanese Patent No. 2517813), DEAE-Dextran method Manual Series 4
- Gene Transfer and Expression Analysis (Yodosha) Takashi Yokota, Kenichi Arai (1994)]
- Winores Vector Method Manipulating Usu-Enburio the second edition
- the recombinant gene transfer vector and paculovirus are co-transfected into insect cells to obtain the recombinant virus in the culture supernatant of insect cells, and then the insect virus is further infected with the recombinant virus to express the protein. be able to.
- Examples of the gene transfer vector used in the method include pVL1392, pVL1393, pBlueBacIII (all manufactured by Invitorogen) and the like.
- the paculovirus for example, Autographa californica nuclear polyhedrosis virus, which is a virus that infects night roth moth insects, such as Autographa californica nucleus, can be used.
- Insect cells include Sf9 and Sf21, which are ovarian cells of Spodopterafrugiperda [current'protoconorezin • molecular • noology Baculovirus Expression Vectors, A Laboratory Manual, WH Freeman and Company, New York (1992)], Trichoplusia Ni 5 ovarian cells such as High 5 (manufactured by Invitrogen) can be used.
- Examples of a method for co-transferring the above-described recombinant gene introduction vector and the above baculovirus into insect cells for preparing a recombinant virus include a calcium phosphate method.
- examples of the expression vector include a Ti plasmid and a tobacco mosaic virus vector.
- Any promoter can be used as long as it can be expressed in plant cells, and examples thereof include the 35S promoter of cauliflower mosaic virus (CaMV) and the geneactin 1 promoter.
- CaMV cauliflower mosaic virus
- Examples of the host cell include plant cells such as tobacco, potato, tomato, carrot, soybean, abrana, alfa alfa, rice, wheat, and wheat.
- any method for introducing DNA into plant cells can be used.
- a method using Agrobacterium Japanese Patent Laid-Open No. 59-140885, 60-78080, W094 / 00977
- electoral-portion method JP-A-60-251887
- method using a particle gun Japanese Patent No. 2517813
- a method for expressing a gene in addition to direct expression, secretory production, fusion protein expression between the Fc region and another protein, and the like can be performed according to the method described in Molecular Cloning, 2nd edition.
- an antibody molecule having a sugar or a sugar chain attached to the introduced gene is obtained. be able to.
- the antibody composition can be produced by culturing the transformant obtained as described above in a medium, producing and accumulating antibody molecules in the culture, and collecting from the culture.
- the method for culturing the transformant in a medium can be performed according to a usual method used for culturing host cells.
- the medium for culturing the transformant obtained using yeast as a host is a medium containing a carbon source, a nitrogen source, inorganic salts, and the like, which can be used by the organism, and which can efficiently culture the transformant. If so, either a natural medium or a synthetic medium may be used.
- the carbon source may be any one that can be assimilated by the organism; glucose, fructose, sucrose, molasses containing these, carbohydrates such as starch or starch hydrolysate, organic acids such as acetic acid and propionic acid, Alcohols such as ethanol and propanol can be used.
- Nitrogen sources include ammonium salts of inorganic or organic acids such as ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate, etc., other nitrogen-containing compounds, peptone, meat extract, yeast extract, Corn chiple liquor, casein hydrolyzate, soybean meal and soybean meal hydrolyzate, various fermented bacterial cells and digests thereof can be used.
- inorganic or organic acids such as ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate, etc.
- other nitrogen-containing compounds such as peptone, meat extract, yeast extract, Corn chiple liquor, casein hydrolyzate, soybean meal and soybean meal hydrolyzate, various fermented bacterial cells and digests thereof can be used.
- potassium potassium phosphate potassium potassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, man sulfate, copper sulfate, calcium carbonate and the like can be used.
- the culture is usually performed under aerobic conditions such as shaking culture or deep aeration stirring culture.
- the cultivation temperature is preferably 15 to 40 ° C, and the cultivation time is usually 16 hours to 7 days.
- the pH during the culture is maintained between 3.0 and 9.0.
- the pH is prepared using an inorganic or organic acid, an alkaline solution, urea, calcium carbonate, ammonia, or the like.
- an antibiotic such as ampicillin or tetracycline may be added to the medium during the culture.
- an inducer may be added to the medium, if necessary.
- an inducer may be added to the medium, if necessary.
- culturing yeast transformed with a recombinant vector using a promoter culturing yeast transformed with a recombinant vector using a trp promoter, such as isopropyl-] 3-D-thiogalatatopyranoside, is used. When doing so, it may be possible to add indol acrylic acid or the like to the medium.
- a medium for culturing a transformant obtained using animal cells as a host As a medium for culturing a transformant obtained using animal cells as a host, a commonly used RPMI1640 medium [The journal of the American. Medical Association ;, 199, 519 (1967)], Eagle's MEM medium [Science, 122, 501 (1952)], Danolebecco's modified MEM medium [Virology, 8, 396 (1959)] ], 199 medium [Proceeding of the Society for the Biological Medicine], 73, 1 (1950)], Whitten medium [Development Engineering Experiment Manual- Transge How to make Enic's mouse (Kodansha) Motoya Katsuki (ed., 1987)] or a medium in which fetal bovine serum is added to these mediums can be used.
- Culturing is usually pH6. 0 ⁇ 8. 0, 30 ⁇ 40 ° C, 5% C0 2 1 ⁇ 7 days line under conditions such presence
- an antibiotic such as kanamycin or penicillin may be added to the medium during the culture.
- Culture media for transformants obtained using insect cells as hosts include commonly used TNM-FH medium (Pharmingen), Sf-900II SFM medium (Life Technologies), ExCell400, ExCell405 (All manufactured by JRH Biosciences), Grace's Insect Medium [Nature, 195, 788 (1962)] and the like can be used.
- the cultivation is usually performed under conditions of pH 6.0 to 7.0, 25 to 30 ° C, etc. for 1 to 5 days.
- an antibiotic such as gentamicin may be added to the medium during the culture.
- a transformant obtained using a plant cell as a host can be cultured as a cell or after being differentiated into a plant cell or organ.
- a medium for culturing the transformant include commonly used Murashige's and Sturg (MS) medium, white medium, or a medium to which plant hormons such as auxin and cytokinin are added. Can be used.
- Cultivation is usually performed at pH 5.0 to 9.0 and 20 to 40 ° C for 3 to 60 days.
- an antibiotic such as kanamycin or hygromycin may be added to the medium during the culture.
- a yeast, animal cell, insect cell or plant cell-derived transformant having a recombinant vector into which the DNA encoding the antibody molecule is incorporated is cultured according to a conventional culture method, and the antibody composition is obtained.
- the antibody composition can be produced by producing and accumulating, and collecting the antibody composition from the culture.
- Methods for producing an antibody composition include a method of producing the antibody composition in a host cell, a method of secreting the antibody out of the host cell, and a method of producing the antibody composition on the host cell outer membrane.
- the method can be selected by changing the structure of the main cell or the antibody molecule to be produced.
- the antibody composition is produced in the host cell or on the host cell outer membrane, the method of Paulson et al. [Journal of the 'Ob Biological' Chemistry Bioi.
- a DNA encoding an antibody molecule and a DNA encoding a signal peptide suitable for expression of the antibody molecule are introduced into an expression vector, and the expression vector is expressed.
- the desired antibody molecule can be actively secreted outside the host cell.
- the production amount can be increased by using a gene amplification system using a dihydrofolate reductase gene or the like.
- transgenic non-human animal or plant (transgenic plant) into which the gene has been introduced is created.
- An antibody composition can also be produced using an individual.
- the transformant is an animal or plant individual
- the animal is bred or cultivated according to a conventional method to produce and accumulate the antibody composition, and the antibody composition is collected from the animal or plant individual.
- the antibody composition can be produced.
- Examples of a method for producing an antibody composition using an animal individual include, for example, a known method [American 'Journal of Clinical Nutrition'-Utility (American Journal of Clinical Nutrition), 63, 639S (1996); American' Genes according to the Journal of Clinical Nutrition, 63, 627S (1996); Bio / Technology, 9, 830 (1991)]. And a method for producing a desired antibody composition in an animal created by introducing the antibody.
- an antibody composition In the case of an animal individual, for example, a transgenic non-human animal into which DNA encoding the antibody molecule has been introduced is bred, the antibody composition is produced and accumulated in the animal, and the antibody composition is collected from the animal. Thus, an antibody composition can be produced.
- the Examples of the production and accumulation site in an animal include milk (eg, JP-A-63-309192) and eggs of the animal.
- the promoter used in this case any promoter that can be expressed in animals can be used.Examples include a promoter specific to a mammary gland cell; o; a casein promoter,] 3 casein promoter, ⁇ ratatoglobulin promoter, A whey acidic protein promoter or the like is preferably used.
- a transgenic plant into which DNA encoding an antibody molecule has been introduced can be prepared by a known method [tissue culture, (1994); tissue culture, ⁇ 1 (1995). Cultivation according to Trends in Biotechnology, 15, 45 (1997)], producing and accumulating an antibody composition in the plant, and collecting the antibody composition from the plant.
- tissue culture (1994); tissue culture, ⁇ 1 (1995). Cultivation according to Trends in Biotechnology, 15, 45 (1997)
- producing and accumulating an antibody composition in the plant and collecting the antibody composition from the plant.
- a method for producing an antibody composition can be mentioned.
- An antibody composition produced by a transformant into which a gene encoding an antibody molecule has been introduced is, for example, when the antibody or the compound is expressed in a lysed state in the cell, after the culture is completed, the cell is centrifuged. After the cells are collected and suspended in an aqueous buffer, the cells are disrupted using an ultrasonic framing machine, French press, Mantongaulin homogenizer, Dynomill, etc., to obtain a cell-free extract.
- a normal enzyme isolation and purification method that is, a solvent extraction method, a salting out method using ammonium sulfate, a desalting method, a precipitation method using an organic solvent, Anion exchange chromatography using a resin such as DEAE-Sepharose and DIAION III-75 (manufactured by Mitsubishi Chemical Corporation), cation exchange chromatography using a resin such as S_Sepharose FF (manufactured by Pharmacia), Electrophoresis such as hydrophobic I chromatography using resins such as Lucefalose and Phenoresepharose, gel filtration using molecular sieve, affinity chromatography, chromatofocusing, isoelectric focusing, etc. Using a technique such as electrophoresis alone or in combination, a purified preparation of the antibody composition can be obtained.
- the cells When the antibody composition is expressed by forming an insoluble form in the cells, the cells are similarly collected, crushed, and centrifuged to collect the insoluble form of the antibody composition as a precipitate fraction.
- the recovered insoluble form of the antibody composition is solubilized with a protein denaturant. After diluting or dialyzing the solubilized solution to return the antibody composition to a normal three-dimensional structure, a purified sample of the antibody composition can be obtained by the same isolation and purification method as described above.
- the antibody composition or a derivative thereof can be collected in the culture supernatant. That is, the culture is centrifuged as described above.
- a soluble fraction is obtained by the treatment according to the above method, and a purified sample of the antibody composition can be obtained from the soluble fraction by using the same isolation and purification method as described above.
- Examples of the antibody composition thus obtained include an antibody, a fragment of the antibody, a fusion protein having a part of the Fc region of the antibody, and the like.
- an antibody composition a composition of a humanized antibody and a method for producing an Fc fusion protein will be described.
- Other antibody compositions are obtained in the same manner as the above method. You can also.
- the expression vector for humanized antibody is an expression vector for animal cells into which genes encoding human antibody CH and CL have been incorporated, and the gene encoding human antibody CH and CL has been cloned into the expression vector for animal cell. Can be constructed.
- the C region of the human antibody can be CH and CL of any human antibody.
- the C region of the IgGl subclass of the H chain of the human antibody hereinafter referred to as hCyl
- the L chain of the human antibody Roh / c class C region hereinafter referred to as hC K
- genes encoding CH and CL of the human antibody chromosomal DNA consisting of exons and introns can be used, and cDNA can also be used.
- Any expression vector for animal cells can be used as long as it can integrate and express the gene encoding the C region of the human antibody.
- PAGE107 [Cytotechnology, 3, 133 (1990)]
- pAGE103 [Journal of Biochemistry. Biochem.]
- PHSG274 [Gene, 27, 223 (1984)]
- pKCR Proceedings of the National Academy of Sciences (Pro Natl. Acad. Sci. USA), 78, 1527 (1981)]
- pSGl ⁇ d2-4 [sai Technology (Cytotechnology), 4, 173 (1990)].
- promoters and enhancers used in expression vectors for animal cells include the early promoter and enhancer of SV40 [Journal 'ob' Biochemistry (J. Biochem.), 101. 1307 (1987)], and Moroni murine leukemia virus. LTR Leo Chemical and Pie W Off-Ige Research Biocommunications (Biochems. Biophys. Res. Commun.), 149, 960 (1987)], immunoglobulin heavy chain promoter [Cell, 41, 479 (1985)] and Enhancer [Cell, 33. 717 (1983)] and the like.
- the humanized antibody working vector can be either a type in which the antibody H chain and L chain are present on separate vectors or a type in which the antibody H chain and L chain are present on the same vector (hereinafter, referred to as tandem type).
- tandem type a type in which the antibody H chain and L chain are present on the same vector.
- a tandem human in view of the ease of construction of a humanized antibody expression vector, ease of introduction into animal cells, and balanced expression of antibody H-chain and L-chain in animal cells.
- Preferred is a vector for expressing a conjugated antibody [Journal of Immunology.], J. Immunol. Methods, 167, 271 (1994).
- the constructed humanized antibody expression vector can be used for expression of a human chimeric antibody or a human CDR-transplanted antibody in animal cells.
- CDNAs encoding non-human animal antibodies for example, VH and VL of mouse antibodies, can be obtained as follows.
- MRNA is extracted from hybridoma cells producing the desired mouse antibody, and cDNA is synthesized. Cloning the synthesized cDNA into a vector such as a phage or a plasmid creates a cDNA library. From the library, a recombinant phage having a cDNA encoding VH or a recombinant phage having a recombinant plasmid and a cDNA encoding VL, using the C region or V region of an existing mouse antibody as a probe, Each recombinant plasmid is isolated.
- the entire nucleotide sequence of VH and VL of the target mouse antibody on the recombinant phage or recombinant plasmid is determined, and the entire amino acid sequence of VH and VL is deduced from the nucleotide sequence.
- kits for preparing whole thighs from hybridoma cells include: Fast Track mRNA Isolation Kit (Invitrogen), Quick Prep mRNA Purification Kit (Pharmacia) and the like.
- any vector can be used as a vector into which cDNA synthesized as a mirror form of mRNA extracted from hybridoma cells can be inserted, as long as the vector can incorporate the cDNA.
- ZAP Express [Strategies, 5, 58 (1992)], pBluescript II SK (+) [Nucleic Acids Research, 17, 9494 (1989)], ⁇ zap II (Stratagene), L gtl0, gtll [DNA Cloning: A Practical Approach, I, 49 (1985)], Lambda BlueMid (Clontech), X ExCell , pT7T3 18U (Pharmacia), pcD2 [Molecular 'and' Cellular 'biology (Mol. Cell. Biol.), 3, 280 (1983)] and pUC18 [Gene, 33> 103 (1985)] Are used.
- any Escherichia coli can be used as long as it can introduce, express and maintain the cDNA library.
- XL1-Blue MRF ' [Strategies, 5, 81 (1992)], C600 [Genetics, 39, 440 (1954)], Y1088, Y1090 [Science, 222, 778 (1983)], Satsu 522 [Journal 'Ob' Molecular 'Biology (J. Mol. Biol.), 166, 1 (1983)], K802 [Giannano Op.' Molecular Biology (J. Mol. Biol.), 16, 118 (1966)] and JM105 [Gene, 38, 275 (1985)].
- Methods for selecting cDNA clones encoding VH and VL of non-human animal antibodies from cDNA libraries include colony hybridization or plaque hybridization using isotope or fluorescently labeled probes. (Molecular 'Cloning 2nd Edition).
- primers are prepared, and cDNA or a cDNA library synthesized from mRNA is used as a mirror type, and the polymerase chain reaction [hereinafter, referred to as PCR method; CDNA encoding VH and VL can also be prepared according to Roning 2nd Edition; Current Protocols in Molecular Biology, Supplement 1-34].
- the cDNA selected by the above method is digested with an appropriate restriction enzyme and the like, and then cloned into a plasmid such as pBluescript SK (-) (manufactured by Stratagene), and a commonly used nucleotide sequence analysis method, for example, Sanger The dideoxy method [Procedures' Ob. The National 'Academy' off, Science (Proc. Natl. Acad. Sci. USA), 74, 5463 (1977)] or ABI PRISM 377 DNA sequencer.
- the base sequence of the DNA can be determined by analysis using a base sequence analyzer such as PE Biosystems.
- VH and VL The entire amino acid sequence of VH and VL was deduced from the determined nucleotide sequence, and the entire amino acid sequence of VH and VL of a known antibody [Sequences of Proteins of Immunological Interest (Sequences of Proteins of Proteins of Immunological Interest) ), US Dept. Health and Human Services (1991), hereafter abbreviated as Sequences 'op' Proteins 'ob immunological' Interest]. And that they encode the complete amino acid sequence of VL.
- a cDNA encoding VH and VL of a non-human animal antibody is cloned upstream of the gene encoding CH and CL of the human antibody in the humanized antibody expression vector described in the above item 3 (1),
- a human-type chimeric antibody expression vector can be constructed.
- cDNA encoding the VH and VL of a non-human animal Synthetic DNA consisting of the base sequence at the 3 'end of VH and VL of the antibody from the outside animal and the base sequence at the 5' end of the CH and CL of the human antibody at both ends.
- a chimeric antibody expression vector can be constructed.
- CDNA encoding VH and VL of the human CDR-grafted antibody can be constructed as follows. First, the amino acid sequence of the VH and VL framework (hereinafter referred to as FR) of the human antibody to which the VH and VL CDRs of the desired non-human animal antibody are transplanted is selected.
- FR the amino acid sequence of human antibody VH and VL
- any amino acid sequence can be used as long as it is derived from a human antibody.
- FR amino acid sequences of VH and VL of human antibodies registered in databases such as Protein Data Bank, and common amino acid sequences of each subgroup of FR of VH and VL of human antibodies (Sequences 'ob') Proteins 'ob' immunological 'interest').
- VH and VL it is desirable to select an amino acid sequence having the highest possible homology (at least 60% or more) with the amino acid sequence of FR.
- the amino acid sequences of the CDRs of the VH and VL of the antibody of the non-human animal of interest are transplanted into the amino acid sequences of the FRs of the selected human antibody VH and VL, and the VH and VL of the human CDR-grafted antibody are grafted.
- the amino acid sequence of is designed. Convert the designed amino acid sequence into a DNA sequence in consideration of the frequency of codons found in the nucleotide sequence of the antibody gene (sequences of proteins). Design the DNA sequence encoding the VH and VL amino acid sequences of the antibody. Based on the established DNA sequence, several synthetic DNAs having a length of about 100 bases are synthesized, and PCR is performed using them. In this case, it is preferable to design six synthetic DNAs for both the H chain and the L chain in view of the reaction efficiency in PCR and the length of the DNA that can be synthesized.
- an appropriate restriction enzyme recognition sequence is introduced into the 5 ′ end of the synthetic DNA located at both ends.
- the humanized CDR of the humanized antibody expression vector is cloned upstream of the genes encoding CH and CL of the human antibody so that they can be expressed in an appropriate form.
- a transplant antibody expression vector can be constructed.
- humanized chimeric antibody and human CDR-grafted antibody are introduced into the appropriate animal cells by introducing the humanized antibody expression vector described in (3) (4) above (6). (Referred to as an antibody) can be obtained stably.
- Examples of a method for introducing a humanized antibody expression vector into animal cells include an electroporation method [Japanese Unexamined Patent Publication (Kokai) No. 2-257891; Cytotechnology, 3, 133 (1990)] and the like.
- any animal cell that can produce a humanized antibody can be used.
- Examples include BHK cells, Namalva cells which are human myeloma cells, etc., preferably, CH0 / DG44 cells which are Chinese hamster monoovary cells, rat myeloma YB2 / 0 cells, and the method of the present invention according to the above item 1.
- the host cell to be used is exemplified.
- a transformant that stably produces the humanized antibody can be obtained using G418 sulfate (hereinafter referred to as G418) according to the method disclosed in JP-A-2-257891. (Available from SIGMA Co., Ltd.).
- Culture media for animal cells include RPMI1640 medium (Nissui Pharmaceutical), GIT medium (Nippon Pharmaceutical), EX-CELL302 medium (JRH), IMDM medium (GIBCO BRL), Hybridoma-SFM A medium (manufactured by GIBCO BRL) or a medium obtained by adding various additives such as fetal bovine serum (hereinafter also referred to as FBS) to these mediums can be used.
- a humanized antibody By culturing the obtained transformant in a medium, a humanized antibody can be produced and accumulated in the culture supernatant.
- the amount of humanized antibody produced in the culture supernatant and the antigen-binding activity can be measured by an enzyme-linked immunosorbent assay (hereinafter referred to as ELISA; Antibodies, Chapter 14, Monoclonal Antibody).
- ELISA enzyme-linked immunosorbent assay
- the transformed strain can increase the amount of humanized antibody produced using a dhfr gene amplification system or the like according to the method disclosed in JP-A-2-2577891.
- Humanized antibodies can be purified from the culture supernatant of the transformant using a protein A column (Antibodies, Chapter 8, Monoclonal Antibody).
- Antibodies Chapter 8, Monoclonal Antibody
- other purification methods usually used for protein purification can be used.
- purification can be performed by a combination of gel filtration, ion exchange chromatography, and ultrafiltration.
- the molecular weight of the purified humanized antibody H chain, L chain or whole antibody molecule can be determined by polyacrylamide gel electrophoresis [hereinafter referred to as SDS-PAGE; Nature, 227, 680 (1970)] or Western blotting. It can be measured by the following method (Antibodies, Chapter 12, Monoclonal Antipodes).
- An Fc fusion protein expression vector is an expression vector for animal cells into which a gene encoding a protein to be fused with the Fc region of a human antibody is integrated, and is fused to the expression vector for animal cells with the Fc region of a human antibody. It can be constructed by cloning a gene encoding a protein.
- the Fc region of a human antibody includes a region containing the CH2 and CH3 regions, as well as a region containing the hinge region and a part of CH1. Any compound may be used as long as at least one amino acid of CH2 or CH3 has been deleted, substituted, added or inserted, and has substantially the activity of binding to the Fey receptor.
- the gene encoding the protein to be fused with the Fc region of a human antibody chromosomal DNA consisting of exons and introns can be used, and cDNA can also be used.
- each gene sequence is used as a type II PCR method (Requra-I 'Cloning, 2nd edition; Current' Protocols.
- Any expression vector for animal cells can be used as long as it can integrate and express the gene encoding the C region of the human antibody.
- PAGE107 [Cytotechnology, 3, 133 (1990)]
- pAGE103 [Journal of Biop. Chem. (J. Biochem.), 101, 1307 (1987)]
- PHSG274 [Gene, 27, 223 (1984)]
- pKCR Procedin's 'ob' The Nashinanore Academy of Sciences (Proc. Natl. Acad. Sci. USA), 78, 1527 (1981)]
- pSGl ⁇ d2_4 Site technology (Cytotechnology), 4, 173 (1990)].
- promoters and enhancers used in expression vectors for animal cells include the early promoter and enhancer of SV40 [Journal of Biochemistry (J. Biochem.), 101, 1307 (1987)], Moro-I mouse leukemia virus. Biochem. Biophys. Res. Commun., 149, 960 (1987)], Immunoglobulin H chain promoter [Cell, 41, 479 (1985) )] And Enhanser [Cell, 33, 717 (1983)].
- DNA encoding a protein to be fused with the Fc region of a human antibody can be obtained as follows.
- MRNA is extracted from cells or tissues that express the protein to be fused with the desired Fc, and cDNA is synthesized.
- the synthesized cDNA is cloned into a vector such as a phage or plasmid to prepare a cDNA library.
- a recombinant phage or recombinant plasmid having a cDNA encoding the target protein is isolated using the gene sequence portion of the target protein as a probe.
- the entire nucleotide sequence of the target protein on the recombinant phage or recombinant plasmid is determined, and the entire amino acid sequence is estimated from the nucleotide sequence.
- any animal such as a mouse, a rat, a hamster, and a heron, can be used as long as cells and tissues can be removed therefrom.
- Methods for preparing total RA from cells and tissues include guanidine thiocyanate-trifluoride cesium method [Methods in Enzymol., 154, 3 (1987)], and total RNA Methods for preparing raRNA include the oligo (dT) immobilized lignocellulose column method (Molecular 'Cloning 2nd Edition) and the like.
- kits for preparing mRNA from cells and tissues include Fast Track mRNA Isolation Kit (Invitrogen), Quick PrepRNA Purification Kit (Pharmacia) and the like.
- Methods for cDNA synthesis and cDNA library preparation can be performed by a conventional method (Molecular 'Clothing 2nd Edition; Current' Protocols 'in Molecule Ira' Biology, Supplement 1-34), or a kit sold on the market.
- a method using a Super Script TM Plasmid System for cDNA Synthesis and Plasmid Cloning (GIBCO BRL) or a ZAP-cDNA Synthesis Kit (Stratagene) can be used.
- any vector can be used as a vector for incorporating a cDNA synthesized as a type II mRNA extracted from cells or tissues, as long as the vector can incorporate the cDNA.
- ZAP Express [Strategies, 5, 58 (1992)], pBluescript II SK (+) [Nucleic Acids Research, 17, 9494 (1989)], ⁇ zapll ( Stratagene), Lgtl0, Igtll [DNA Cloning: A Practical Approach], I, 49 (1985)], Lambda BlueMid (Clontech), ⁇ ExCell, pT7T3 18U (Pharmacia), pcD2 [Molecular 'and' cellular 'biology (Mol. Cell. Biol.), 3, 280 (1983)] and pUC18 [Gene, 33, 103 (1985)], etc. Is used.
- any Escherichia coli can be used as long as the cDNA library can be introduced, expressed and maintained.
- XL1-Blue MRF ' [Strategies, 5, 81 (1992)], C600 [Genetics, 39, 440 (1954)], Y1088, Y1090 [Science, 222, 778] (1983)]
- NM522 Journal of Molecular Biology (j. Mol . Biol.), 166, 1
- K802 [Journal 'ob''Molecular' Biology (J. Mol. BioL), 16, 118 (1966)] and JM105 [Gene, 38, 275 (1985)]
- Methods for selecting a cDNA clone encoding the desired protein from the cDNA library include colony hybridization and plaque hybridization using an isotope or fluorescently labeled probe (Molecularization. Version) can be selected.
- primers can be prepared, and a cDNA or cDNA library synthesized from mRNA can be used as a type III cDNA to prepare a cDNA encoding the target protein by PCR.
- a PCR method can be used as a method for fusing the target protein with the Fc region of a human antibody.
- an arbitrary synthetic oligo DNA (primer) is set on the 5 'and 3' sides of the gene sequence of the target protein, and PCR is performed to obtain a PCR product.
- an arbitrary primer is set for the gene sequence of the Fc region of the human antibody to be fused, and a PCR product is obtained.
- a primer is set so that the same restriction enzyme site or the same gene sequence exists on the 3 ′ side of the PCR product of the protein to be fused and the 5 ′ side of the PCR product of the Fc region.
- the mutation is introduced by using a primer into which the mutation has been introduced. Both genes are ligated by performing further PCR using the obtained two types of PCR fragments. Alternatively, ligation can be performed by performing ligation after treating with the same restriction enzyme.
- the gene sequence ligated by the above method is cut with an appropriate restriction enzyme or the like, and then cloned into a plasmid such as pBluescript SK (-) (manufactured by Stratagene), and a commonly used nucleotide sequence analysis method, for example, Sanger The dideoxy method [Procedures 'ob' The 'National' Academy 'ob' Science (Proc. Natl. Acad. Sci. USA), 74, 5463 (1977)], or ABI PRISM 377 DNA theta-encer (PE Biosystems
- the base sequence of the DNA can be determined by performing analysis using a base sequence analyzer such as that manufactured by the company.
- a transformant that stably produces the Fc fusion protein By introducing the Fc fusion protein expression vector described in the above (1) into an appropriate animal cell, a transformant that stably produces the Fc fusion protein can be obtained.
- Examples of a method for introducing an Fc fusion protein expression vector into animal cells include an electroporation method [Japanese Patent Laid-Open No. 2-257891; Cytotechnology, 3, 133 (1990)] and the like.
- any animal cell that can produce the Fc fusion protein can be used. Specifically, it is derived from mouse myeloma cells NS0 cells, SP2 / 0 cells, Chinese hamster ovary cells CHO / dhfr- cells, CH0 / DG44 cells, rat myeloma YB2 / 0 cells, IR983F cells, and Syrian hamster kidney.
- Examples include BHK cells, Namalva cells which are human myeloma cells, etc., preferably, CH0 / DG44 cells which are Chinese hamster monoovary cells, rat myeloma YB2 / 0 cells, and the method of the present invention according to the above item 1.
- the host cell to be used is exemplified.
- a transformant that stably produces the Fc fusion protein can be selected using a medium for culturing animal cells containing a drug such as G418 according to the method disclosed in Japanese Patent Application Laid-Open No. 2-257891.
- a medium for culturing animal cells containing a drug such as G418 As culture media for animal cells, RPMI1640 medium (Nissui Pharmaceutical), GIT medium (Nippon Pharmaceutical), EX-CELL302 medium (JRH), IMDM medium (GIBCO BRL), Hybridoma-SFM medium (Manufactured by GIBCO BRL) or a medium obtained by adding various additives such as fetal bovine serum to these media.
- the Fc It combined protein By culturing the obtained transformant in a medium, the Fc It combined protein can be produced and accumulated in the culture supernatant.
- the production amount and antigen-binding activity of the Fc fusion protein in the culture supernatant can be measured by ELISA or the like.
- the transformed strain can increase the production amount of the Fc fusion protein using a dhfr gene amplification system or the like according to the method disclosed in JP-A-2-2577891.
- the Fc fusion protein can be purified from the culture supernatant of the transformant using a protein A column or a protein G column (Antibodies, Chapter 8, Monoclonal Antibody).
- a protein A column or a protein G column Antibodies, Chapter 8, Monoclonal Antibody
- other purification methods usually used for protein purification can be used.
- purification can be performed by a combination of gel filtration, ion exchange chromatography, ultrafiltration, and the like.
- the molecular weight of the whole purified Fc fusion protein molecule can be determined by SDS-PAGE [Nature, 227, 680 (1970)] or Western plotting (Antibodies, Chapter 12, Monoclonal Anti-Podise). Can be measured.
- the method for producing an antibody composition using animal cells as a host has been described.
- yeast, insect cells, plant cells, or individual animals or individual plants can be prepared using the same method as that for animal cells. Can be manufactured.
- the antibody composition can be produced by purifying the antibody composition.
- the binding activity of the antibody composition to FcyRIIIa can be measured by the method described below.
- FcyRIIIa a gene encoding FcyRIIIa and Fc ⁇ Rllla present on the cell surface of peripheral blood lymphocytes of a human or non-human animal was obtained, and the gene was introduced into a host cell and expressed on the cell surface.
- FcyRIIIa or FcyRHIa secreted from the cells can be used.
- a method for obtaining a gene encoding FcyRIIIa below introducing the gene into a host cell to express FcT / RIIIa on the host cell, and a method for obtaining FcyRIIIa by secreting FcT / RIIIa from the cell State.
- Total RNA or mRNA is prepared from human or non-human animal tissue or cells.
- the mRNA of a tissue or cell of a human or non-human animal may be a commercially available one (for example, manufactured by Clontech), or may be prepared from human or non-human animal tissue or cells as follows.
- Methods for preparing total RNA from human or non-human animal tissues or cells include the guanidine thiocyanate-cesium trifluoroacetate method [Methods in Enzymology], 154, 3 (1987). And guanidine acid thiocyanate 'Phenol' black mouth form (AGPC) method [Analytical biochemistry (Analytical Biochemistry), 162, 156 (1987); Laboratory medicine, 1937 (1991)].
- Methods for preparing mRNA as poly (A) + RNA from total RNA include oligo (dT) -immobilized cellulose column method (Molecular 'Cloning 2nd Edition) and the like. Furthermore, mRNA can be prepared by using a kit such as Fast Track mRNA Isolation Kit (Invitrogen) or Quick Prep mRNA Purification Kit (Pharmacia).
- a cDNA library is prepared from the prepared human or non-human animal tissue or cell total RNA or mRNA.
- Methods for preparing cDNA libraries include those described in Molecular 'Clothing Second Edition, Current Protocols' Molecular Biology, etc., or commercially available kits such as the Superscript Plasmid System for cDNA Synthesis and Plasmid Cloning (manufactured by Life Technologies), and a method using ZAP-cDNA Synthesis Kit (manufactured by STRATAGENE).
- any phage vector, plasmid vector, or the like can be used as long as it can replicate autonomously in E. coli K12 strain.
- ZAP Express [STRATAGENE, Strategies, 5, 58 (1992)], pBluescript II SK (+) [Nucleic Acids Research], 17, 9494 (1989) )], Lambda ZAP II (Stratagene), Lgtl0, Lgtll [DNA cloning, A Practical Approach], 1, 49 (1985)], ⁇ TriplEx (Clontech) ExCell (Pharmacia), pT7T318U (Pharmacia), pcD2 [Molecular 'Cellular' Biology (Mol. Cell. Biol.), 3, 280 (1983)] and P UC18 [Gene, 33 , 103 (1985)].
- Escherichia coli is preferably used. Specifically, Escherichia coli XLl-Blue MRF '[STRATAGENE, Strategies, 5, 81 (1992)], Escherichia coli C600 [Genetics, 39, 440 (1954)], Escherichia coli Y1088 [Science, 222, 778 (1983)], Escherichia coli Y1090 [Science, 222, 778 (1983)], Escherichia coli NM522 [Journal of 'Molecular' biology (J.
- This cDNA library can be used as is for subsequent analyses, but in order to reduce the percentage of incomplete-length cDNAs and obtain full-length cDNAs as efficiently as possible, the oligocap method developed by Sugano et al.
- the nucleotide sequence of the gene encoding FcyRIIIa obtained by the above method includes, for example, the nucleotide sequence of FcRHIa described in SEQ ID NO: 27.
- Parkin using the phosphoramidite method Encodes Fc7Rllla by chemically synthesizing with a DNA synthesizer such as Elma's D dish synthesizer Model 392 Genes can also be obtained.
- a recombinant vector is prepared by inserting the obtained cDNA encoding FcyRIIIa downstream of the promoter of an appropriate expression vector.
- a transformant producing an antibody molecule By introducing the recombinant vector into a host cell suitable for the expression vector, a transformant producing an antibody molecule can be obtained.
- any of yeast, animal cells, insect cells, plant cells, and the like can be used as long as it can express the gene of interest.
- those which can replicate autonomously in the above-mentioned host cells or can be integrated into the chromosome, and which contain a promoter at a position where the DNA encoding the desired FcyRIIIa can be transcribed are used.
- yeast When yeast is used as a host cell, examples of expression vectors include YEP13 (ATCC37115), YEp24 (ATCC37051), YCp50 (ATCC37419) and the like. Any promoter can be used as long as it can be expressed in yeast strains. For example, promoters for glycolytic genes such as hexose kinase,
- Examples include the PH05 promoter, PGK promoter, GAP promoter, ADH promoter, gal 1 promoter, gal 10 promoter, heat shock protein promoter, MF a1 promoter, CUP 1 promoter and the like.
- Examples of the host cell include microorganisms belonging to the genera Saccharomyces, Schizosaccharomyces, Krybetella genus, Trichosporon, Schuniomyces, and the like. it can.
- any method can be used as long as it is a method for introducing DNA into yeast.
- an electoporation method [Methods. Enzymol., 194, 182 ( 1990)]
- Supachi Plast Method [Proc Seedings 'ob' The 'National' Academy 'ob' Science (Proc. Natl. Acad. Sci. US A), 84> 1929 (1978)]
- lithium acetate Law Journal of J. Bacteriology, 153, 163 (1983)]
- Proceedin Das' Ob 'The' National 'Academy' Op 'Science' Proc. Natl. Acad. Sci. US A), 75, 1929 (1978).
- examples of expression vectors include pcDNAI, pcDM8 (Funakoshi), pAGE107 [Japanese Patent Laid-Open No. 3-22979; Cytotechnology, 3, 133 (1990)], pAS3- 3 (Japanese Patent Laid-Open No. 2-227075), pCDM8 [Nature, 329, 840 (1987)], pcDNAI / Amp (Invitrogen), pREP4 (Invitrogen), pAGE103 [Journal of Biochemistry] (J. Biochemistry), 101, 1307 (1987)], pAGE210 and the like.
- any promoter can be used as long as it can be expressed in animal cells.
- the promoter of the immediate early (IE) gene of cytomegalovirus (CMV) the early promoter of SV40, the promoter of retro-inoles, Meta mouth thionein promoter, heat shock promoter, SR CK promoter and the like.
- the enhancer of the IE gene of human CMV may be used together with the promoter.
- host cells examples include Namalwa cells, human cells, COS cells, monkey cells, CH0 cells, Chinese hamster cells, and HBT5637 (Japanese 63-299), rat myeloma cells, mouse myeloma cells, Syrian hamsters, kidney-derived cells, embryonic stem cells, fertilized egg cells, and the like.
- any method for introducing DNA into animal cells can be used.
- electoporation method [Cytotechnology, 3, 133 (1990)] calcium phosphate Method (Japanese Unexamined Patent Publication No. 2-227075), revoxion method [Proceedings' ob 'the' national 'academy'ob' science (Proc. Natl. Acad. Sci. USA), 84-7413 (1987)], injection Method [Maepulatory 'The Mouse' Embrio 'A' Laboratory 'Manual], Method using particle gun (gene gun) [Japanese Patent No. 2606856, Japanese Patent No.
- the recombinant gene transfer vector and paculovirus are co-transfected into insect cells to obtain the recombinant virus in the culture supernatant of insect cells, and then the insect virus is further infected with the recombinant virus to express the protein. be able to.
- Examples of the gene transfer vector used in the method include pVL1392, pVL1393, pBlueBacIII (all manufactured by Invitorogen) and the like.
- baculovirus for example, a virus that infects night moth insects such as Atographa, Ariformi, Nuclea, Polyhedrosis, and virus (Autographa californica nuclear polyhedrosis virus) can be used.
- Insect cells include Sf9 and Sf21, which are ovarian cells of Spodopterafrugiperda [current protocoronous in 'molecular biology, Baculovirus Expression Vectors, A Laboratory Manual, WH Freeman and Company, New York (1992)], Trichoplusiani Ovarian cells such as High 5 (manufactured by Invitrogen) or the like can be used.
- Examples of a method for co-transferring the above-described recombinant gene introduction vector and the above baculovirus into insect cells for preparing a recombinant virus include a calcium phosphate method.
- examples of the expression vector include a Ti plasmid and a tobacco mosaic virus vector.
- Any promoter can be used as long as it can be expressed in plant cells, and examples thereof include the 35S promoter of cauliflower mosaic virus (CaMV) and the geneactin 1 promoter.
- CaMV cauliflower mosaic virus
- Examples of the host cell include plant cells such as octopus, potato, tomato, carrot, soybean, rape, alfalfa, rice, wheat, and wheat.
- any method for introducing DNA into a plant cell can be used.
- a method using Agrobacterium Japanese Patent Application Laid-Open No. 59-140885, 60-70080, W094 / 00977
- Electroporation method Japanese Patent Application Laid-Open No. 60-251887
- method using particle gun Japanese Patent No. 2606856, Japanese Patent No. 2517813
- it can.
- Fc ⁇ RIIIa can be produced by culturing the transformant obtained as described above in a medium, producing and accumulating FcyRIIIa in the culture, and collecting from the culture.
- the method for culturing the transformant in a medium can be performed according to a usual method used for culturing host cells.
- a medium for culturing a transformant obtained using yeast as a host a medium that contains a carbon source, a nitrogen source, inorganic salts, and the like that can be used by yeast and that can efficiently culture the transformant can be used as a natural medium. Either a medium or a synthetic medium may be used.
- Any carbon source can be used as long as it can be assimilated by yeast; glucose, fructose, sucrose, molasses containing these, carbohydrates such as starch or starch hydrolysate, organic acids such as acetic acid and propionic acid, and ethanol. And alcohols such as propanol and the like.
- Nitrogen sources include ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate and other ammonium salts of inorganic or organic acids, other nitrogen-containing compounds, peptone, meat extract, yeast extract, corn steep liquor, Casein hydrolyzate, soybean meal and soybean meal hydrolyzate, various fermented bacterial cells and digests thereof can be used.
- potassium potassium phosphate potassium potassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, man sulfate, copper sulfate, calcium carbonate and the like can be used.
- the culture is usually performed under aerobic conditions such as shaking culture or deep aeration stirring culture.
- the cultivation temperature is preferably 15 to 40 ° C, and the cultivation time is usually 16 hours to 7 days.
- the pH during the culture is maintained between 3.0 and 9.0.
- the pH is adjusted using inorganic or organic acids, alkaline solutions, urea, calcium carbonate, ammonia and the like.
- an antibiotic such as ampicillin or tetracycline may be added to the medium during the culture.
- an inducer may be added to the medium, if necessary.
- an inducer may be added to the medium, if necessary.
- isopropyl-] 3-D-thiogalactopyranoside or the like is transformed with a recombinant vector using the tr promoter.
- indol acrylic acid or the like may be added to the medium.
- a commonly used RPMI1640 medium [The Journal of the American. Medica Norelle 'Soc. Journal of the American Medical Association), 199, 519 (1967)], Eagle's MEM medium [Science, 122, 501 (1952)], Dulbecco's modified MEM medium [Virology], 8, 396 (1959) )], 199 medium [Proceeding of the Society for the Biological Medicine], 73, 1 (1950)], Whitten medium [Development Engineering Experiment Manual- How to Make Transjek's Mouse (Kodansha) Motoya Katsuki (ed., 1987)] or a medium in which fetal calf serum or the like is added to these mediums can be used.
- Culturing is usually pH6. 0 ⁇ 8. 0, 30 ⁇ 40 ° C, 5% C0 2 1 ⁇ 7 days line under conditions such presence If necessary, antibiotics such as kanamycin and penicillin may be added to the medium during the culture.
- Culture media for transformants obtained using insect cells as a host include commonly used TNM-FH media (Pharmingen), Sf-900II SFM medium (Life Technologies), ExCell400, ExCell405 (All manufactured by JRH Biosciences), Grace's Insect Medium [Nature, 195, 788 (1962)] and the like can be used.
- Cultivation is usually carried out under conditions of pH 6.0 to 7.0, 25 to 30 ° C, etc .; Do for ⁇ 5 days.
- an antibiotic such as gentamicin may be added to the medium during the culture.
- a transformant obtained using a plant cell as a host can be cultured as a cell or after being differentiated into a plant cell or organ.
- a medium for culturing the transformant commonly used Murashige's and Sturg (MS) medium, white (White) medium, or a phytohormone such as auxin, cytokine, etc. was added to these mediums.
- MS Murashige's and Sturg
- White white
- phytohormone such as auxin, cytokine, etc.
- Cultivation is usually performed at pH 5.0 to 9.0 and 20 to 40 ° C for 3 to 60 days.
- an antibiotic such as kanamycin or hygromycin may be added to the medium during the culture.
- a transformant derived from a microorganism, animal cell, insect cell, or plant cell that has a recombinant vector into which DNA encoding FcyRIIIa has been incorporated is cultured according to a conventional culture method. By producing and accumulating RIIIa and collecting FcyRllla from the culture, FcRHIa can be produced.
- FcyRIIIa can be produced in host cells, secreted outside the host cells, or produced on the host cell outer membrane.
- the host cells to be used and the Fc ⁇ / The method can be selected by changing the structure of RIIIa.
- a DNA encoding FcyRIIIa and a DNA encoding a signal peptide suitable for expression of FcyRIIIa are introduced into an expression vector, and the expression vector is expressed.
- the desired FcyRIIIa can be actively secreted outside the host cell.
- the production amount can be increased using a gene amplification system using a dihydrofolate reductase gene or the like.
- transgenic animal or plant cells are redifferentiated to create an animal (transgenic non-human animal) or plant (transgene plant) into which the gene has been introduced.
- Fey R can also be manufactured using.
- the Fc ⁇ RHIa is collected and cultivated according to a usual method to produce and accumulate FcyRIIIa, and the Fc ⁇ RHIa is collected from the animal or plant individual.
- ⁇ Rllla can be produced.
- FcyRIIIa is produced and accumulated in the animal
- FcRllla is collected from the animal.
- the production and accumulation site in the animal include milk of the animal (JP-A-63-309192), eggs, and the like.
- the promoter used in this case can be used, so long as it can function in an animal, for example, alpha casein promoter mammary gland cell-specific promoters, j3-casein promoter, beta Ratatoglobulin promoters, whey acidic protein promoters and the like are preferably used.
- transgenic plants into which DNA encoding FeyR has been introduced can be prepared by a known method [tissue culture, ⁇ (1994); tissue culture, 21 (1995); ⁇ FcyRIIIa is cultivated according to Trends in Biotechnology, 15, 45 (1997)], Fcy Rllla is produced and accumulated in the plant, and the FcyRIIIa is collected from the plant to produce FcyRIIIa. There is a production method.
- FcyRllla produced by a transformant into which a gene encoding FcyRIIIa has been introduced is expressed in a lysed state in FcT / RIIIa cells, after the culture is completed, the cells are collected by centrifugation, and the After suspension in the buffer, the cells are disrupted using an ultrasonic disrupter, French press, Mantongaulin homogenizer, Dynomill, etc. to obtain a cell-free extract.
- a normal enzyme isolation and purification method is used, that is, a solvent extraction method, a salting out method using ammonium sulfate, a desalting method, a precipitation method using an organic solvent, a DEAE method.
- Fc 7 RIIIa is when expressed as an inclusion body in cells, the cells were disrupted after collection as well, followed by centrifugation to recover the inclusion body of Fco / RIIIa as precipitated fraction.
- the recovered insoluble FcyRIIIa is solubilized with a protein denaturant. After diluting or dialyzing the solubilized solution to return the FcyRIIIa to a normal three-dimensional structure, a purified sample of the Fey Rllla can be obtained by the same isolation and purification method as described above.
- the FcyRIIIa or its derivative can be recovered in the culture supernatant. That is, a soluble fraction is obtained by treating the culture by a technique such as centrifugation as described above, and the FcRllla is purified from the soluble fraction by using the same isolation and purification method as described above. You can get a sample.
- the binding activity of the antibody composition to FcyRIIIa expressed on the cell membrane should be measured by a fluorescent antibody method [Cancer Immunol. Immunother., 36, 373 (1993)] or the like. Can be.
- the binding activity to purified Fc T / RIIIa prepared by the method described in the above item 4 (1) was determined according to the literature [Monoclonal Antibodies: Principles and Applications].
- Radioimmunoassay, VIA (Viroimmunoassay), EIA (Enzymoimmunoassay), FIA (Fluoroimmunoassay, MIA (Metalloimmunoassay)) can be performed as follows, for example, according to immunological quantification methods.
- Immobilize FcyRIIIa on a plastic plate for EIA A sample containing the antibody composition is reacted. Next, the amount of the antibody composition bound using an appropriate secondary antibody is measured.
- the binding activity to the purified FcyRIIIa was measured using a biosensor [eg, BIAcore (manufactured by BIAC0RE)] [J. Immunol. Methods, 200, 121 (1997) ] And the Isothermal Titration Calorimetry method [Procedures' ob '' Zanashinanore 'akademi ⁇ ⁇ ob' Science ( proc . Natl. Acad. Sci. USA), 97, 9026 (2000)], etc. Can be determined.
- the binding activity to an antigen, the binding activity to an antigen-positive cultured cell line, and the binding activity to FcyRIIIa are determined by ELISA or fluorescent antibody method.
- Cancer Immunol. Immunother., 36, 373 (1993) Measurement using a noisysensor [for example, BIAcore (manufactured by BIACORE)] [Journal of Immunological Methods] (J. Immunol. Methods), 200, 121 (1997)], Isothermal Titration Calorimetry method (Proc. Natl. Acad. Sci. USA), 97, 9026 (2000)].
- cytotoxic activity against antigen-positive cultured cell lines can be evaluated by measuring CDC activity, ADCC activity, etc. [Cancer Immunol. Iramunother (Cancer Immunol. Iramunother ), 36, 373 (1993)].
- the sugar chain structure of the antibody molecule expressed in various cells can be determined in accordance with the conventional method for analyzing the sugar chain structure of a glycoprotein.
- the sugar chains bound to IgG molecules are composed of neutral sugars such as galactose, mannose, and fucose, amino sugars such as N-acetyldarcosamine, and acidic sugars such as sialic acid.
- the analysis can be performed using techniques such as composition analysis and sugar chain structure analysis using a two-dimensional sugar chain mapping method or the like.
- composition analysis of a sugar chain of an antibody molecule neutral sugar or amino sugar is released by performing acid hydrolysis of the sugar chain with trifluoroacetic acid or the like, and the composition ratio thereof can be analyzed.
- BioLC sugar composition analyzer
- HPAEC-PAD high performance anion-exchange chromatography-pulsed amperometric detection
- composition ratio can also be analyzed by a fluorescent labeling method using 2-aminopyridine. More specifically, a sample obtained by acid hydrolysis according to a known method [Agrcultural and Biological Chemistry (Agruc. Biol. Chem.), 55, 283 (1991)] is fluorescently labeled with 2-aminopyridylamide. Then, the composition ratio can be calculated by HPLC analysis. (2) Sugar chain structure analysis
- Structural analysis of the sugar chains of antibody molecules can be performed by two-dimensional sugar chain mapping [Analytical Biochemistry., 171, 73 (1988), Biochemistry Experimental Method 23-glycoprotein sugar chain research method (Academic Publishing Center), edited by Reiko Takahashi (1989)].
- the two-dimensional glycan map method for example, plots the retention time or elution position of a reverse-phase chromatography monosaccharide on the X-axis, and the retention time or elution position of the sugar chain by normal-phase chromatography on the Y-axis. This is a method of estimating the sugar chain structure by comparing the results with those of known sugar chains.
- the antibody is hydrazinolyzed, the sugar chain is released from the antibody, and the sugar chain is fluorescently labeled with 2-aminopyridine (hereinafter abbreviated as PA) [Journal of Ob pie Chemistry (J, Biochem.), 95, 197 (1984)], the sugar chain is separated from excess PA reagent by gel filtration, and reversed-phase chromatography is performed. Next, normal phase chromatography is performed on each peak of the separated sugar chain. Based on these results, the results were plotted on a two-dimensional glycan map and compared with the glycan standard (TaKaRa) and the literature [Analytical Biochemistry (Anal. Biochem.), 171, 73 (1988)]. The sugar chain structure can be estimated from the comparison of the spots.
- PA 2-aminopyridine
- mass spectrometry such as MALDI-T0F-MS of each sugar chain can be performed to confirm the structure estimated by the two-dimensional sugar chain mapping method.
- the antibody composition is composed of antibody molecules having different sugar chain structures binding to the Fc region of the antibody.
- the antibody composition having a sugar chain in which fucose is not linked to N-acetyltyl dalcosamine at the sugar chain reducing terminal among all the N-glycoside-linked complex-type sugar chains binding to the Fc region, as described in the above item 6. It can be identified by using the method for analyzing the sugar chain structure of the antibody molecule. In addition, it can be identified by using an immunological quantification method using lectin.
- a lectin that recognizes the sugar chain structure of the antibody molecule constituting the antibody composition is labeled, and the labeled lectin is allowed to react with the sample antibody composition. Next, the amount of the complex of the labeled lectin and the antibody molecule is measured.
- Lectins used to identify the sugar chain structure of the antibody molecule include, for example, WGA (wheat-germ agglutinin from T. vulgaris; ConA (concanavalin A from C. ensiformis), RIC (toxin from R. communis) , L-PHA (leukoagglutinin from P. vulgaris), LCA (lentil agglutinin from L. culinaris) PSA (Pea lectin from P.
- AAL Aleuria aurantia Lectin
- ACL Amaranthus caudatus Lectin
- BPL Amaranthus caudatus Lectin
- DSL Datura stramonium Lectin
- DBA Dolichos biflorus Agglutinin
- EBL Elderberry Balk Lectin
- ECL Erythrina cristagalli Lectin
- EEL Euonymus europaeus Lectin
- GNL Galanthinus
- HHL Hippeastrura Hybrid Lectin
- Jacalin LTL Litus tetragonolobus Lectin
- LEL Licopersicon esculentum Lectin
- MAL MAL (Maackia amurensis
- a lectin that specifically recognizes a sugar chain structure in which fucose is bound to N-acetylethyl dalcosamine at the reducing end of N-dalcoside-linked complex type sugar chain.
- Specific examples thereof include lentil Lectin LCA (Lentil Agglutinin from Lens Culinaris) Endo bean lectin PSA (Pea Lectin from Pi sum sativum), Broad bean lectin VFA (Agglutinin from Vicia faba), and Lectin from Aleuria aurantia be able to. 8.
- the present invention provides a method for measuring an antibody composition, comprising reacting an antigen with a test antibody composition and then contacting the complex of the antigen and the antibody composition with FcyRIIIa.
- the present invention relates to detecting the ratio of sugar chains in which fucose is not bound to N-acetyltylcolasamine at the reducing end of sugar chains, and to detecting antibody-dependent cytotoxicity.
- the measurement method used in the present invention will be described in detail.
- the antigen is immobilized on the plate, and the test antibody composition is reacted.
- the complex that has undergone the antigen-antibody reaction is reacted with human FcyRIIIa.
- Human FcyRIIIa to be reacted can be labeled with an enzyme, radioisotope, fluorescence, or the like, and the binding activity with the antibody bound to the antigen can be measured by immunoassay.
- Immunoassays include the immunoassay method, the immunoblotting method, the reaction, the complement fixation reaction, the hemolysis reaction, the sedimentation reaction, the gold colloid method, and the chromatographic method.
- Any method using an antigen-antibody reaction such as an immunostaining method, may be included, and preferably, the Imnoassay method is used.
- a tagged human FcyRllla can be obtained.
- the tag include histidine.
- the detection method of the present invention can also be performed by directly contacting the test antibody composition with FcyRIIIa without reacting the antigen with the test antibody composition.
- an antibody against the tag can be immobilized, reacted with the tagged human FcT / RIIIa, reacted with the test antibody composition, and detected with a labeled antibody that recognizes the human Fc region.
- the following method is used to detect the ratio of sugar chains in which fucose is not bound to N-acetyltyl glucosamine at the reducing end of the sugar chain of the antibody composition.
- a glycan analysis is performed on a certain antibody composition, and antibody compositions differing in the proportion of glycans in which fucose is not bound to N-acetyldarcosamine at the reducing end of the bran chain by the number required to draw a calibration curve
- the concentration of the antibody composition used is fixed in advance.
- the above measurement of the prepared sample of the antibody composition The binding activity to FcyRIIIa was measured using the method, and the ratio of sugar chains and Fc
- the concentration of the antibody composition of the sample to be measured is kept constant, and the binding activity to FcyRIIIa is measured using the same measurement method as described above.
- the ratio of sugar chains in which fucose is not bound to N-acetyltylcosamine at the reducing end of the sugar chain can be determined.
- the ADCC activity of the standard used to prepare the calibration curve used to detect the percentage of sugar chains in which fucose is not bound to N-acetyltyl dalcosamine at the reducing end of the sugar chain of the antibody composition was determined. Measure. As a measuring method, an ADCC measuring method described later is used. The binding activity to FcyRIIIa is measured for each sample of the prepared antibody composition using the above-described measurement method, and a calibration curve between ADCC activity and binding activity to FcyRIIIa is prepared.
- the ADCC activity is determined by measuring the binding activity to FcyRIIIa using the same measurement method as above while keeping the concentration of the antibody and progeny in the sample to be measured constant. be able to.
- the present invention relates to a method for screening an antibody composition having a high binding activity to FcyRIIIa, which comprises reacting an antigen with a test antibody and then contacting it with FcyRIIIa.
- the antigen is immobilized on the plate, and the test antibody is reacted.
- the complex that has undergone antigen-antibody reaction is reacted with human FcyRIIIa.
- Human FcyRIIIa to be reacted can be labeled with an enzyme, radioisotope, fluorescence, or the like, and the binding activity with the antibody bound to the antigen can be measured by immunoassay.
- antigen-antibody reactions such as the immunoassay method, the immunoblotting method, the agglutination reaction, the complement fixation reaction, the hemolysis reaction, the sedimentation reaction, the colloidal gold method, the chromatography method, and the immunostaining method were used. Any method is included, but preferably the Imnoassy method.
- the immunoassay method antigen-antibody reactions such as the immunoassay method, the immunoblotting method, the agglutination reaction, the complement fixation reaction, the hemolysis reaction, the sedimentation reaction, the colloidal gold method, the chromatography method, and the immunostaining method were used. Any method is included, but preferably the Imnoassy method.
- human FeyRllla with a tag can be obtained. Examples of the tag include histidine.
- the antibody composition obtained by the screening method of the present invention has high ADCC activity.
- Antibodies having high ADCC activity are useful in the prevention and treatment of various diseases including cancer, inflammatory diseases, autoimmune diseases, immune diseases such as allergies, cardiovascular diseases, and viral or bacterial infections.
- Cancer or malignant tumor, is a growth of cancer cells.
- Ordinary anticancer drugs are characterized by inhibiting the growth of cancer cells.
- an antibody having a high ADCC activity can treat cancer by damaging cancer cells by a cell killing effect, and is therefore more effective as a therapeutic agent than ordinary anticancer agents.
- the antitumor effect of antibody drugs alone is insufficient, and combination therapy with chemotherapy is performed [Science, 280, 1197 (1998)], If a stronger antitumor effect of the antibody composition obtained by the method of the present invention alone is recognized, dependence on chemotherapy is reduced, and side effects are reduced.
- the in vivo reaction in those diseases is triggered by the release of mediator molecules by the immune cells, so the immune cells are eliminated using antibodies with high ADCC activity Thereby, the allergic reaction can be suppressed.
- Cardiovascular diseases include arteriosclerosis. Atherosclerosis is currently treated with a balloon catheter, but cardiovascular disease can be prevented and treated by suppressing the proliferation of arterial cells in post-treatment restenosis using antibodies with high ADCC activity. .
- Antibodies that recognize tumor-associated antigens include anti-GD2 antibody [Anticancer Res., 13, 331 (1993)] and anti-GD3 antibody [Cancer Immunol. Immunotherm. ), 36, 260 (1993)], anti-GM2 antibody [Cancer Res., 54, 1511 (1994)], anti-HER2 antibody [procedures 'op' the 'national. Academy' Natl. Acad. Sci. USA, 89, 4285 (1992)], anti-CD52 antibody [Procedures 'ob' The 'National' Academy 'op' Science (Proc. Natl. Acad. Sci. USA), 89, 4285 (1992)], anti-MAGE antibody [British J. Cancer (British J.
- Antibodies that recognize antigens related to allergy or inflammation include anti-interleukin-6 antibody [Immunological 'Reviews (Immunol. Rev.), 127, 5 (1992)], anti-interleukin-6 receptor antibody [Molecular Immunology. (Molecular Immunol.), 31, 371 (1994)], anti-interleukin 5 antibody [Immunol. Rev., 127, 5 (1992)], anti-interleukin 5 receptor antibody, anti-interleukin 5 antibody Leukin-4 antibody [Cytokine: 3,562 (1991)], anti-interleukin-4 receptor antibody [Journal of Obimnological 'Methods (J. Immunol.
- an antibody that recognizes an antigen associated with cardiovascular disease is an anti-GPIIb / IIIa antibody [Journal of Immunology (J. Immunol.), 152, 2968 (1994)], anti-platelet Derived growth factor antibody [Science, 253, 1129 (1991)], anti-platelet-derived growth factor receptor antibody Naru 'O Bed' Paiorojikaru 'Chemistry (J. Biol. Chem.), 272, 17400 (1997)], anti-blood coagulation factor antibody [Circulation (Circulation), 101, 1158 (2000)] and the like.
- Antibodies that recognize antigens associated with viral or bacterial infection include anti-gpl20 antibody [Structure, 8, 385 (2000)], anti-CD4 antibody [Journal of rheumatology], 25, 2065 (1998)], anti-CCR5 antibody, anti-verotoxin antibody [J. Clin. Microbiol. (J. Clin. Microbiol.), 37, 396 (1999)].
- the above antibodies can be obtained from public institutions such as ATCC (The American Type Culture Collection), RIKEN Cell Development Bank, National Institute of Advanced Industrial Science and Technology, Patent Organism Depositary, Dainippon Pharmaceutical Co., Ltd., and R & D SYSTEMS It can also be obtained from private reagent sales companies such as PharMingen, Cosmobay and Funakoshi.
- ATCC The American Type Culture Collection
- RIKEN Cell Development Bank National Institute of Advanced Industrial Science and Technology
- Patent Organism Depositary Dainippon Pharmaceutical Co., Ltd.
- R & D SYSTEMS It can also be obtained from private reagent sales companies such as PharMingen, Cosmobay and Funakoshi.
- the antibody composition obtained by the method of the present invention can be administered alone as a therapeutic agent for various diseases, it is usually used together with one or more pharmacologically acceptable carriers. It is desirable to mix and provide as a pharmaceutical preparation produced by any method well known in the pharmaceutical arts.
- intravenous administration can be preferably used.
- Dosage forms include sprays, capsules, tablets, granules, syrups, emulsions, suppositories, injections, ointments, tapes and the like.
- Formulations suitable for oral administration include emulsions, syrups, capsenoles, tablets, powders, granules and the like.
- Liquid preparations such as emulsions and syrups include water, sugars such as sucrose, sorbitol, fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil, soybean oil, P-hydroxy It can be produced using preservatives such as benzoic acid esters and flavors such as strawberry flavour and peppermint as additives.
- Capsules, tablets, powders, granules, etc. are excipients such as lactose, pudose, sucrose, mannitol, disintegrants such as starch and sodium alginate, lubricants such as magnesium stearate, talc, etc. It can be produced using a binder such as polybutyl alcohol, hydroxypropyl cellulose or gelatin, a surfactant such as a fatty acid ester, or a plasticizer such as glycerin as an additive.
- a binder such as polybutyl alcohol, hydroxypropyl cellulose or gelatin, a surfactant such as a fatty acid ester, or a plasticizer such as glycerin as an additive.
- Formulations suitable for parenteral administration include injections, suppositories, sprays and the like.
- An injection is prepared using a carrier comprising a salt solution, a glucose solution, or a mixture of both.
- a powder injection can be prepared by freeze-drying the antibody composition according to a conventional method and adding sodium chloride thereto.
- Suppositories are prepared using carriers such as cocoa butter, hydrogenated fats or carboxylic acids. Sprays are prepared using the antibody composition itself or a carrier that does not irritate the oral and respiratory tract mucosa of the recipient and disperses the antibody composition as fine particles to facilitate absorption.
- the carrier include lactose and glycerin.
- Formulations such as aerosols and dry powders are possible depending on the properties of the antibody composition and the carrier used. Also, in these parenteral preparations, the components exemplified as additives in the oral preparation can be added.
- the dose or frequency of administration varies depending on the desired therapeutic effect, administration method, treatment period, age, body weight, etc., but the amount of the active ingredient is usually 10 / 13 ⁇ 4 to 20 mg / kg per adult per day.
- Methods for examining the antitumor effect of the antibody composition on various tumor cells include CDC activity measurement and ADCC activity measurement in in vitro experiments, and in vivo experiments on mice and other experimental animals. Antitumor experiments using such tumor systems. CDC activity, ADCC activity, and antitumor experiments are described in the literature [Cancer 'Immology' Immunotherapy (Cancer Immunol. Immunother.), 36, 373 (1993); Cancer 'Research (Cancer Research), 54, 1511 (1994) )] Etc. can be used.
- FIG. 1 is a photograph showing the SDS-PAGE (using a 4 to 15% gradient gel) electrophoresis pattern of the five purified anti-GD3 chimeric antibodies.
- FIG. 1A is a photograph of electrophoresis under non-reducing conditions
- FIG. 1B is a photograph of electrophoresis under reducing conditions.
- Lane 1 is high molecular weight marker
- 2 YB2 / 0-GD3 chimeric antibody 3 S CH0 / DG44-GD3 chimeric antibody
- 4 is SP2 / 0-GD3 chimeric antibody
- 5 is NS0-GD3 chimeric antibody (302)
- 6 is NS0-GD3 chimeric antibody (GIT)
- 7 shows the migration pattern of the low molecular weight marker, respectively.
- FIG. 2 is a diagram showing the binding activity of five purified anti-GD3 chimeric antibodies to GD3, which was measured by changing the antibody concentration.
- the vertical axis indicates the binding activity to GD3, and the horizontal axis indicates the antibody concentration.
- ⁇ is YB2 / 0-GD3 chimeric antibody
- ⁇ is CH0 / DG44-GD3 chimeric antibody
- mouth is SP2 / 0-GD3 chimeric antibody
- garden is NS0-GD3 chimeric antibody (302)
- ⁇ is NSO-GD3 chimeric antibody ( GIT) activity.
- FIG. 3 shows ADCC activities of the purified five types of anti-GD3 chimeric antibodies against human melanoma cell line G-361.
- the vertical axis shows the cytotoxic activity, and the horizontal axis shows the antibody concentration.
- ⁇ is YB2 / 0-GD3 chimeric antibody
- ⁇ is CH0 / DG44-GD3 chimeric antibody
- mouth is SP2 / 0-GD3 chimeric antibody
- garden is NS0-GD3 chimeric antibody (302)
- ⁇ is NS0-GD3 chimeric antibody ( GIT) activity.
- FIG. 4 is a diagram showing an elution diagram obtained by analyzing a PA-linked sugar chain prepared from the anti-GD3 chimeric antibody of Lot 2 by reverse-phase HPLC.
- the vertical axis indicates relative fluorescence intensity, and the horizontal axis indicates elution time.
- FIG. 5 shows the binding activity of six types of anti-GD3 chimeric antibodies to GD3 with different proportions of sugar chains in which the 1-position of fucose is not a-linked to the 6-position of N-acetyltyldarcosamine at the reducing end.
- FIG. 6 is a diagram measured by changing the values of. The vertical axis shows the binding activity to GD3, and the horizontal axis shows the antibody concentration.
- FIG. 6 shows the results of ADCC activity using effector cells of each donor.
- Fig. 6A shows the effect of donor A
- Fig. 6B shows the effect of donor B.
- FIG. 2 shows ADCC activities of various anti-GD3 chimeric antibodies against human melanoma cell line G-361.
- the vertical axis shows the cytotoxic activity, and the horizontal axis shows the antibody concentration.
- Anti-GD3 chimeric antibody (50%), anti-GD3 chimeric antibody (45%) in mouth, anti-GD3 chimeric antibody (29%) in the mouth, ⁇ anti-GD3 chimeric antibody (24%), ⁇ anti-GD3 chimeric antibody (13%), indicating X is the activity of anti-GD 3 chimera antibody (7%), respectively.
- FIG. 7 is a diagram showing the content of a sugar chain in which position 1 of fucose is not ⁇ - linked to position 6 of N-acetyldarcosamine at the reducing end of donor ⁇ and donor B, and ADCC activity.
- FIG. 8 shows an elution diagram obtained by analyzing PA disaccharide chains prepared from six types of anti-CCR4 chimeric antibodies by reverse-phase HPLC. The vertical axis indicates relative fluorescence intensity, and the horizontal axis indicates elution time.
- Figure 9 shows the binding activity of six types of anti-CCR4 chimeric antibodies to CCR4 in which the proportion of sugar chains in which fucose at position 1 is not ⁇ -linked to position 6 of N-acetyltilcosamine at the reducing end is different. It is the figure which measured by changing the density.
- the vertical axis shows the binding activity to CCR4, and the horizontal axis shows the antibody concentration.
- ⁇ indicates anti-CCR4 chimeric antibody (46%)
- mouth indicates anti-CCR4 chimeric antibody (39%)
- A indicates anti-CCR4 chimeric antibody (27%)
- ⁇ indicates anti-CCR4 chimeric antibody (18%)
- • indicates anti-CCR4 chimera Antibody (9%) and ⁇ show the activity of anti-CCR4 chimeric antibody (8%), respectively.
- FIG. 10 shows that the effect of CCR4 / EL-anti-CCR4 chimeric antibody using donor A effector cells with a different ratio of sugar chains in which the fucose position 1 is not ⁇ -linked to position 6 of the reducing terminal N-acetyl-cosamine at the reducing end is different.
- FIG. 3 is a view showing ADCC activity on four cells. The effector cells used were donor A effector cells. The vertical axis shows cytotoxic activity, and the horizontal axis shows antibody concentration.
- FIG. 11 shows the effect of anti-CCR4 using donor B effector cells with different proportions of sugar chains in which position 1 of fucose is not ⁇ -linked to position 6 of N-acetyldanolecosamine at the reducing end.
- FIG. 2 is a view showing ADCC activity of a W chimeric antibody on CCR4 / EL-4 cells. The effector cells used were donor B effector cells.
- the vertical axis shows cytotoxic activity, and the horizontal axis shows antibody concentration.
- ⁇ indicates anti-CCR4 chimeric antibody (46%)
- mouth indicates anti-CCR4 chimeric antibody (39%)
- ⁇ indicates anti-CCR4 chimeric antibody (27%)
- mouse indicates anti-0: 1 chimeric antibody (18%)
- the CCR4 chimeric antibody (9%) shows the activity of the anti-CCR4 chimeric antibody (8%).
- FIG. 12 is a diagram showing the construction of plasmids CHFT8-pCR2.1 and YBFT8-pCR2.1.
- FIG. 13 is a diagram showing the construction of a plasmid CHAc_ P BS and YBAc- P BS.
- FIG. 14 is a diagram showing the construction of a plasmid CHFT8d- pCR2. 1 and YBFT8d_ P CR2. 1.
- FIG. 15 is a diagram showing the construction of a plasmid CHAcd- P BS and YBAcd- pBS.
- FIG. 16 shows the results of quantification of the amount of a 1,6-fucosinoretransferase (FUT8) transcript in each host cell strain using the competitive PCR method. Shown is the amount of FUT8 transcript in each host cell strain when the rat FUT8 sequence was used as a standard and internal control.
- the image shows the results using the CH0 cell line as the host cell, and the image shows the results using the YB2 / 0 cell line as the host cell.
- FIG. 17 shows the results of evaluating the ADCC activity of an anti-CCR4 chimeric antibody produced by a lectin-resistant strain.
- the vertical axis shows cytotoxicity '14, and the horizontal axis shows antibody concentration.
- the mouth indicates the activity of the 5-03 strain
- the garden indicates the activity of the CH0 / CCR4-LCA strain
- ⁇ indicates the activity of the antibody produced by the CH0 / CCR4-AAL strain
- ⁇ indicates the activity of the antibody produced by the CH0 / CCR4-PHA strain.
- FIG. 18 shows the results of evaluating the ADCC activity of the anti-CCR4 chimeric antibody produced by the lectin-resistant strain.
- the vertical axis shows cytotoxic activity, and the horizontal axis shows antibody concentration.
- the mouth indicates the activity of the antibody produced by the YB2 / 0 strain (KM2760 # 58-35-16), the triangle indicates the activity of the antibody produced by the 5-03 strain, and the triangle indicates the activity of the antibody produced by the CH0 / CCR4-LCA strain.
- FIG. 19 is a diagram showing an elution diagram obtained by analyzing a PA-linked sugar chain prepared from a purified anti-CCR4 chimeric antibody by reversed-phase HPLC.
- the vertical axis indicates relative fluorescence intensity, and the horizontal axis indicates elution time.
- Figure 27A shows antibodies produced by strain 5-03
- Figure 27B shows antibodies produced by strain CH0 / CCR4-LCA
- Figure 27C shows antibodies produced by strain CH0 / CCR4-AAL
- Figure 27D shows CH0 / CCR4-PHA
- Fig. 4 shows the results of analysis of antibodies produced by the strain.
- FIG. 20 is a diagram showing the first step of construction of an expression vector for GMD derived from CH0 cells (total of 6 steps).
- FIG. 21 is a view showing a second step of construction of an expression vector for GMD derived from CH0 cells (a total of 6 steps).
- FIG. 22 is a diagram showing a third step of constructing a CH0 cell-derived GMD expression vector (a total of 6 steps).
- FIG. 23 is a diagram showing a fourth step of the construction of the expression vector for GMD derived from CH0 cells (a total of six steps).
- FIG. 24 is a view showing a fifth step of the construction of the expression vector for GMD derived from CH0 cells (a total of 6 steps).
- FIG. 25 is a view showing a sixth step of constructing an expression vector for GMD derived from CH0 cells (six steps).
- FIG. 26 is a graph showing the degree of resistance to LCA lectin of the CH0 / CCR4-LCA strain expressing GMD.
- FIG. 2 is a diagram showing two measurements performed with the survival rate of a cell group cultured without addition of LCA lectin taken as 100%.
- 249 shows the survival rate of the CH0 / CCR4-LCA strain into which the expression vector pAGE249 was introduced, against LCA lectin.
- GMD indicates the flexibility of the CH0 / CCR4-LCA strain into which the GMD expression vector PAGE249GMD has been introduced, for LCA lectin.
- FIG. 2 is a diagram showing two measurements performed with the survival rate of a cell group cultured without addition of LCA lectin taken as 100%.
- 249 shows the survival rate of the CH0 / CCR4-LCA strain into which the expression vector pAGE249 was introduced, against LCA lectin.
- GMD indicates the flexibility of the CH0 / CCR4-LCA strain
- FIG. 27 is a view showing ADCC activity of an anti-CCR4 chimeric antibody produced by a cell group of the CH0 / CCR4-LCA strain expressing GMD.
- the vertical axis shows the cytotoxic activity, and the horizontal axis shows the antibody concentration.
- Figure 28 shows an elution diagram obtained by analyzing reversed-phase glycans prepared from anti-CCR4 chimeric antibodies purified from the CH0 / CCR4-LCA strain expressing the GMD gene by reversed-phase HPLC. is there.
- the vertical axis shows the relative fluorescence intensity, and the horizontal axis shows the elution time.
- FIG. 29 is a photograph showing an electrophoresis pattern of SDS-PAGE (using a 4-15% gradient gel) of purified shFcyRIIIa under reducing conditions. Lane 1 shows the migration pattern of shFc Y RIIIa, and lane M shows the migration pattern of the molecular weight marker.
- FIG. 30 shows the binding activities of various anti-GD3 chimeric antibodies to shFcyRllla.
- the vertical axis shows the binding activity, and the horizontal axis shows the antibody concentration.
- ⁇ indicates the activity of the anti-GD3 chimeric antibody (45%), and ⁇ indicates the activity of the anti-GD3 chimeric antibody (7%).
- FIG. 31 shows the binding activities of various anti-antifibroblast growth factor-8 (FGF-8) chimeric antibodies to shFcyRHIa.
- the vertical axis shows the binding activity, and the horizontal axis shows the antibody concentration.
- ⁇ indicates the activity of the anti-FGF-8 chimeric antibody (58%), and ⁇ indicates the activity of the anti-FGF-8 chimeric antibody (13%).
- FIG. 32 shows the binding activities of various anti-CCR4 chimeric antibodies to shFcyRllla.
- FIG. 32A shows the binding activity on the vertical axis and the antibody concentration on the horizontal axis.
- FIG. 32B shows the results in which the ordinate represents the binding activity, and the abscissa represents the proportion of sugar chains in which the 1-position of fucose is not bonded to the 6-position of N-acetyldarcosamine at the reducing end.
- FIG. 33 shows the binding activities of various anti-CCR chimeric antibodies to shFcyRIIIa.
- the vertical axis shows the binding activity, and the horizontal axis shows the antibody concentration.
- ⁇ indicates the activity of the anti-CCR4 chimeric antibody (87%), indicates the activity of the anti-CCR4 chimeric antibody (48%), and ⁇ indicates the activity of the anti-CCR4 chimeric antibody (8%).
- FIG. 34 shows ADCC activities of various anti-GD3 chimeric antibodies against human melanoma cell line G-361.
- the vertical axis shows cytotoxic activity, and the horizontal axis shows antibody concentration.
- ⁇ indicates anti-GD3 chimeric antibody (42%), and indicates anti-GD3 chimeric antibody (7%).
- FIG. 35 shows the results of measuring the binding activity of the FGF-8 / Fc fusion protein to KM1334.
- the vertical axis shows the binding activity, and the horizontal axis shows the antibody concentration.
- ⁇ shows the results of the activity of the FGF-8 / Fc fusion protein produced using the YB2 / 0 cell line and CH0 / DG44 cell line as the host cells, respectively.
- FIG. 36 shows the results of measuring the binding activities of various FGF-8 / Fc fusion proteins to shFco / RIIIa (V).
- the vertical axis shows the binding activity, and the horizontal axis shows the antibody concentration.
- Gardens show the results of the activity of the FGF-8 / Fc fusion protein produced using the YB2 / 0 cell line and CH0 / DG44 cell line as the host cells, respectively.
- FIG. 37 is a diagram showing a process for preparing a plasmid CH0-GMD in which the 5 ′ end of clone 34-2 was introduced into the 5 ′ end of GMD cDNA clone 22-8 derived from CH0 cells.
- FIG. 38 is a diagram showing a construction process of plasmid pKANTEX1334H and plasmid pKANTEX1334. BEST MODE FOR CARRYING OUT THE INVENTION
- L-chain expression vector pChi641LGM4 for anti-ganglioside GD3 human chimeric antibody (hereinafter referred to as anti-GD3 chimeric antibody) [J. Immunol. Methods, 167, 271 (1994)] Is digested with restriction enzymes Mlul (Takara Shuzo) and Sail (Takara Shuzo) to obtain an approximately 4.03 kb fragment containing the L chain cDNA and an animal cell expression vector PAGE107 [Cytotechnology, 3, 133 (1990)] with a restriction enzyme YU1 (Takara Shuzo) and a fragment of about 3.40 kb containing the G418 resistance gene and splicing signal obtained from (Takara Shuzo) and DNA Ligation Kit (Takara Shuzo) ) And transformed into Escherichia coli strain HB101 (Molecular 'Clone Jung, 2nd edition) to construct plasmid pChi641LGM40.
- the plasmid pChi641LGM40 constructed above is digested with a restriction enzyme (Takara Shuzo), blunt-ended using the DNA Blunting Kit (Takara Shuzo), and further cut with (Takara Shuzo) to obtain an L chain.
- a restriction enzyme Takara Shuzo
- blunt-ended using the DNA Blunting Kit Takara Shuzo
- Takara Shuzo the plasmid pChi641LGM40 constructed above is digested with a restriction enzyme (Takara Shuzo), blunt-ended using the DNA Blunting Kit (Takara Shuzo), and further cut with (Takara Shuzo) to obtain an L chain.
- Approximately 5.68 kb fragment including cDNA and anti-GD3 chimera antibody H chain expression vector pChi641HGM4 Journal of Immunological Methods (J. Immunol.
- the tandem expression vector P Chi641LHGM4 of the anti-GD3 chimeric antibody constructed in paragraph 1 of Example 1 above was introduced into various cell lines, and a stable cell line of the anti-GD3 chimeric antibody was obtained by selecting a superior strain as follows. Produced.
- G418 was added at 0.5 mg / mL and DHFR to increase antibody production using the dhfr gene amplification system.
- a suspension of methotrexet (hereinafter referred to as MTX; manufactured by SIGMA), which is an inhibitor of 50 mg / L, in RPMI1640-FBS (10) medium containing 1 to 2 ⁇ 10 5 cells / mL, was prepared. 2 mL was dispensed into a pellet plate (manufactured by Greiner). After culturing at 37 ° C.
- a transformant capable of growing on an RPMI1640-FBS (10) medium containing 0.5 mg / mL and MT at a concentration of 200 nmol / L and highly producing an anti-GD3 chimeric antibody was obtained.
- a superior strain was selected from the obtained transformants, and single cells were cloned (cloned) by the limiting dilution method twice.
- the thus-obtained transformed cell clone 7-9-51 that produces the anti-GD3 chimeric antibody was produced on April 5, 1999 by the Institute of Biotechnology and Industrial Technology, Institute of Advanced Industrial Science and Technology (Tsukuba East, Ibaraki, Japan 1 (Chome 1-3) (Currently, deposited at the National Institute of Advanced Industrial Science and Technology, Patent Organism Depositary, Tsukuba East, Ibaraki, Japan, 1-chome, Chuo No. 6) as FERM BP-6691.
- G418 was cultivated for 1 to 2 weeks by adding force to 0.5 mg / mL. A colony of a G418-resistant transformant appeared, and the culture supernatant was recovered from the wells in which proliferation was observed.
- the antigen-binding activity of the anti-GD3 chimeric antibody in the supernatant was determined by ELISA as described in Section 3 of Example 1. It was measured by the method.
- G418 was added at 0.5 mg / mL and MTX in order to increase the amount of antibody production using the dhfr gene amplification system.
- (10) medium IMDM medium containing 10% dialyzed fetal calf serum (hereinafter referred to as dFBS; manufactured by GIBC0 BRL)] containing 1-2 nmol / L so that the concentration becomes 1-2 ⁇ 10 5 cells / mL.
- dFBS dialyzed fetal calf serum
- transformants showing 10 nmol / L MTX resistance were induced.
- a transformant capable of growing in the IMDM-dFBS (10) medium and highly producing anti-GD3 chimeric antibodies was obtained. From the obtained transformants, superior strains were selected and cloned twice by the limiting dilution method.
- G418 was added to a concentration of 0.5 mg / mL and cultured for 1-2 weeks. A colony of a G418-resistant transformant appeared, and the culture supernatant was recovered from the wells in which proliferation was observed.
- the antigen binding activity of the anti-GD3 chimeric antibody in the supernatant was determined by the ELISA method described in Section 3 of Example 1. Was measured by For transformants of mice in which production of anti-GD3 chimeric antibody was observed in the culture supernatant, G418 was added at 0.5 mg / mL and MTX in order to increase antibody production using the dhfr gene amplification system.
- the 5 0nmol / L comprising EX- cELL 3 0 2 - dFBS ( 10) medium - to (10% dFBS, 2mmol / LL Gin EX- CELL302 medium containing) suspension to be 1 to 2 X 10 5 cells / mL It became turbid and 2 mL was dispensed into 24 l plates (Greiner). 5% C0 by 1 to 2 weeks of culture at 37 ° C for within 2 incubator to induce transformants showing 50 nmol / L MTX resistance.
- the antigen-binding activity of the anti-GD3 chimeric antibody in the culture supernatant of the wells in which the growth of the transformant was observed was measured by the ELISA method described in Example 1, section 3.
- the binding activity of the antibody to GD3 was measured as follows.
- GD3 product of Snow Brand Milk Products
- ethanol solution containing 10 g of dipalmitoyl phosphatidylcollin (product of SIGMA) and 5 zg of cholesterol (product of SIGMA).
- Twenty (40 pmol / ⁇ l) of this solution was dispensed into each well of a 96-well ELISA plate (manufactured by Greiner), air-dried, and 1% bovine serum albumin (hereinafter referred to as BSA; SIGMA).
- BSA bovine serum albumin
- the 1% BSA-PBS was discarded, and the culture supernatant of the transformant or various diluted solutions of the purified human chimeric antibody were washed with 50 ⁇ l of a 7-well plate and reacted at room temperature for 1 hour. After the reaction, each gel was washed with PBS containing 0.05% Tween20 (manufactured by Wako Pure Chemical Industries, Ltd.) (hereinafter referred to as Tween-PBS), and then diluted with 1% BSA-PBS to 3000 times peroxidase labeling. A goat anti-human IgG (H & L) antibody solution (American Qualex) was added as a secondary antibody solution at 50 IL / well, and reacted at room temperature for 1 hour.
- the transformed cell clone producing the anti-GD3 chimeric antibody obtained in the section 2 (1) of Example 1 was BSA at 0.2% and MTX at 200 nmol / retroodthyronine (hereinafter referred to as T3).
- SIGMA SIGMA
- Hybridoma-SFM medium 3 ⁇ 10 5 cells / raL
- spinner bottle Iwaki Glass
- the culture was stirred at a speed. After culturing for 10 days in a thermostat at 37 ° C, the culture supernatant was collected.
- the anti-GD3 chimeric antibody was purified from the culture supernatant using a Prosep-A (Bioprocessing) column according to the attached instructions.
- the purified anti-GD3 chimeric antibody was named YB2 / 0-GD3 chimeric antibody.
- the transformed cell clone producing the anti-GD3 chimeric antibody obtained in the above-mentioned Example 1, paragraph 2 (2) was cloned using L-Gin at 3 mmol / L and a fatty acid concentrate (hereinafter referred to as CDLC; manufactured by GIBCO BRL).
- CDLC a fatty acid concentrate
- PF68 Punorelonic F68
- the anti-GD3 chimeric antibody was purified from the culture supernatant using a Prosep-A (Bioprocessing) column according to the attached instructions.
- the purified anti-GD3 chimeric antibody was named CH0 / DG44-GD3 chimeric antibody.
- the transformed cell clone producing the anti-GD3 chimeric antibody obtained in the section 2 (3) of Example 1 was L_Gln at 2 mmol / L, G418 at 0.5 mg / mL, MTX at 200 nmol / L, and dFBS at 1 % concentration containing in suspension so that the 1 X 10 6 cells / mL in EX- cell 302 medium, aliquoted 200mL min to 175 Yuzuru 2 flasks (Greiner Co.). 5% C0 4 days after culturing at 37 ° C for within 2 incubator, the culture supernatant was recovered.
- the anti-GD3 chimeric antibody was purified from the culture supernatant using a Prosep-A (Bioprocessing) column according to the attached instructions.
- the purified anti-GD3 chimeric antibody was named NS0-GD3 chimeric antibody (302).
- the transformed cell clone was suspended in a 3 X 10 5 cells / mL in GIT medium containing 0. 5 mg / m Les MTX and G418 at a concentration of 200 nmol / L, 175 thigh 2 flasks (Greiner 200 mL). 5% C0 10 days after cultivation at 37 ° C for within 2 incubator, the culture supernatant was recovered.
- the anti-GD3 chimeric antibody was purified from the culture supernatant using a Prosep-A (Bioprocessing) column according to the attached instructions.
- the purified anti-GD3 chimeric antibody was named NS0-GD3 chimeric antibody (GIT).
- JP 5 - 3 04 98 9 transformation cells clones producing anti-GD3 chimeric antibody described (KM- 871 (FERM BP- 3512) ) and 0. 5 mg / mL of G418, the MTX 200 nmol /
- the cells were suspended in a GIT medium containing L at a concentration of 3 ⁇ 10 5 cells / mL and dispensed in 200-mL aliquots into two flasks of 175 orchids (Greiner). 5% C0 8 days after cultivation at 37 ° C for within 2 incubator, the culture supernatant was recovered.
- the anti-GD3 chimeric antibody was purified from the culture supernatant using a Prosep-A (Bioprocessing) column according to the attached instructions.
- the purified anti-GD3 chimeric antibody was named SP2 / 0-GD3 chimeric antibody.
- each of the purified anti-GD3 chimeric antibodies produced a single band with a molecular weight of about ⁇ kilodalton (hereinafter referred to as Kd) under non-reducing conditions. Then, two bands of about 50 Kd and about 25 Kd were observed.
- Kd ⁇ kilodalton
- the antibody has a molecular weight of about 150Kd under non-reducing conditions.
- FIG. 2 shows the results of examining the binding activity by changing the concentration of the added anti-GD3 chimeric antibody.
- the five kinds of anti-GD3 chimeric antibodies showed almost the same binding activity to GD3. This result indicates that the antigen-binding activity of the antibody is constant irrespective of the animal cell producing the antibody and the culture method.
- a comparison between the NS0-GD3 chimeric antibody (302) and the NS0-GD3 chimeric antibody (GIT) suggested that the antigen-binding activity was constant regardless of the culture medium used.
- the ADCC activities of the five purified anti-GD3 chimeric antibodies obtained in section 4 of Example 1 were measured as follows.
- RPMI1640 - FBS and 1 X 10 6 cells of human Tome Ranoma cell line G-361 were cultured in (IO) medium (ATCC CRL1424) were prepared and the Na 2 51 Cr0 4 is a radioactive substance 3. 7MBq eq addition 37 ° After reacting with C for 1 hour, the cells were radioactively labeled. After the reaction, the suspension was washed with RPMI1640-FBS (10) medium three times by centrifugation, resuspended in the medium, and left on ice at 4 ° C for 30 minutes to allow the radioactive substances to dissociate spontaneously. . After centrifugation, 5 mL of RPMI1640-FBS (IO) medium was added to adjust to 2 ⁇ 10 5 cells / mL, and used as a target cell solution.
- IO RPMI1640-FBS
- the amount of spontaneously dissociated 51 Cr was determined by performing the same operation as above using only the medium instead of the effector cell solution and the antibody solution, and measuring the amount of 51 Cr in the supernatant. All dissociated 51 Cr amount, only the medium instead of the antibody solution was added hydrochloric acid solution I mol / L instead of E Fuekuta single cell solution, and the same operation as above, the amount of 51 Cr in the supernatant It was determined by measurement. ADCC activity was determined by the following equation (1). 51 Cr content in sample supernatant-spontaneous dissociation 51 Cr content
- ADCC activity (%) X 100 (1)
- Example 3 Activity evaluation of anti-GD3 chimeric antibodies with different proportions of bran chains in which the 1-position of fucose is not ⁇ -linked to the 6-position of N-acetyltilcosamine at the reducing end
- Example 1 a plurality of ⁇ ⁇ ⁇ ⁇ 2/0 cell-derived transformed clones producing an anti-GD3 chimeric antibody were obtained. Purified antibodies were prepared from the transformed clones derived from each ⁇ 2 / 0 cell. And The sugar chain analysis of anti-GD3 chimeric antibody mouth 1, lot 2, and lot 3 was performed according to the following method.
- the pyridine solution was prepared by adding 760 ⁇ L of hydrochloric acid solution to 1-aminoviridine lg (1 ⁇ solution) and diluting the solution 10-fold with reverse osmosis purified water (10 ⁇ ⁇ dilution ⁇ solution).
- the sodium cyanoborohydride solution was prepared by adding 20 mg / zL of 1 XPA solution and 430 IL of reverse osmosis purified water to 10 mg of sodium cyanoborohydride.
- FIG. 4 shows an elution diagram of the purified PA-linked sugar chains of the anti-GD3 chimeric antibody of Lot 2.
- each PA-glycan was determined by post-source analysis (Post Source Decay) using matrix-assisted laser ionization time-of-flight mass spectrometry (MALD! -TOF-MS analysis) of the peaks of each of the collected PA-glycans.
- MALD! -TOF-MS analysis matrix-assisted laser ionization time-of-flight mass spectrometry
- the sugar chain content was calculated from the peak area of each PA-linked sugar chain in reverse phase HPLC analysis.
- PA-glycans having a reducing end other than N-acetyl-darcosamine were excluded from the peak area calculation because they were derived from impurities or were by-products during the preparation of PA-glycans.
- the peaks (i) to (ix) in the figure indicate the following sugar chain structures (1) to (9), respectively.
- GlcNAc ⁇ 1— 2Man 1 GlcNAc represents N-acetylacetylcosamine
- Gal represents galactose
- Man represents mannose
- Fuc represents fucose
- PA represents a pyridylamino group.
- the proportion of the group in which the 1-position of fucose is not ⁇ -linked to the 6-position of N-acetyltyldarcosamine at the reducing end is (i) to (iv) of (i) to (ix).
- the proportion of sugar chains in which the 1-position of fucose is not ⁇ -linked to the 6-position of N-acetyldarcosamine at the reducing end is 50%, 45%, and 29% for Lot 1, Lot 2, and Lot 3, respectively. %Met.
- anti-GD3 chimeric antibody 50%
- anti-GD3 chimeric antibody 45%
- anti-GD3 chimeric antibody 29%
- FIGS. 6 and 7 show the results of measuring the ADCC activity using effector cells of two healthy donors (A and B), respectively.
- the ADCC activity of the anti-GD3 chimeric antibody shows that no fucose at position 6 is ⁇ -linked to position 6 of N-acetyldarcosamine at the reducing end at any antibody concentration. It tended to increase in proportion to the sugar chain ratio. ADCC activity decreases when the antibody concentration is low.
- ADCC activity showed almost the same high activity.However, the antibody with less than 20% of sugar chains in which the 1-position of fucose is not ⁇ -linked to the 6-position of N-acetyltilcosamine at the reducing end. At% and 7%, ADCC activity was low. The results were similar for different effector cell donors.
- Example 4 Activity evaluation of anti-CCR4 chimeric antibodies with different proportions of sugar chains in which the 1-position of fucose is not ⁇ -linked to the 6-position of N-acetyltilcosamine at the reducing end
- the lO ⁇ tg of the anti-CCR4 chimeric antibody expression vector pKA TEX2160 was introduced into 4 ⁇ 10 6 rat myeloma YB2 / 0 cells (ATCC CRL1662) by the electroporation method [Cytotechnology, 3, 133 (1990)]. Then, the cells were suspended in 40 mL of Hybridoma-SFM-FBS (5) [Hybridoma-SFM medium (manufactured by Invitrogen) containing 5% of FBS (manufactured by PM Laboratories)], and a 96-well culture plate (manufactured by Sumitomo Bakelite) was used. Was dispensed at 200 psi / well.
- the MTX concentration was increased by the same method as above, and finally the hybridoma containing MTX at a concentration of 200 nmol / L was used.
- -A transformant capable of growing on SFM-FBS (5) medium and producing high anti-CCR4 chimeric antibody was obtained.
- the obtained transformant was cloned twice by the limiting dilution method, and the obtained transformant clone was named KM2760 # 58-35-16.
- the medium was exchanged I DM- dFBS (10) to (a dFBS IMDM medium containing 10%), and cultured for 1-2 weeks. A colony of the transformed strain showing HT-independent growth appeared, and the culture supernatant was recovered from the wells in which growth was observed.
- the expression level of the anti-CCR4 chimeric antibody in the supernatant was determined as described in item 2 of Example 4. It was measured by the ELISA method described.
- IMDM-dFBS containing 50 nmol / L of MTX for the purpose of increasing antibody production using the dhfr gene amplification system (10)
- the cells were suspended in a medium at a concentration of 1-2 ⁇ 10 5 cells / mL, and 0.5 mL was dispensed into a 24-well plate (manufactured by Iwaki Glass Co., Ltd.). 5% C0 2 incubator 37 in one.
- C . Cultured for 2 weeks to induce a transformant showing 50 nmol / L MTX resistance.
- Compound 1 (SEQ ID NO: 25) was selected as a human CCR4 extracellular domain peptide to which the anti-CCR4 chimeric antibody can react.
- a conjugate with BSA (manufactured by Nacalai Tesque) was prepared by the following method and used as an antigen to be used for activity measurement by ELISA. That is, in 900 mL of PBS solution containing 10 mg of BSA, 100 mL of 25 mg / mL SMCC [4- (N_maleimide methyl) cyclohexane-1-carboxylic acid N-hydroxysuccinimide ester] (Sigma -DMS0 solution was added dropwise with stirring and slowly stirred for 30 minutes.
- the conjugate prepared as described above was dispensed into a 96-well ELISA plate (manufactured by Glyna) at 0.05 ig / mL at 50 ⁇ l 7-well, and allowed to stand at 4 ° C for adsorption. I let you. After washing with PBS, 1% BSA-PBS was added at 100 ⁇ L / well and reacted at room temperature for 1 hour to block the remaining active groups. After washing each well with Tween-PBS, the culture supernatant of the transformant was added in 50 ⁇ L / well and allowed to react at room temperature for 1 hour.
- the transformed cell clone KM2760 # 58-35-16 expressing the anti-CCR4 chimeric antibody obtained in section 1 (1) of Example 4 was treated with 200 nmol / L MTX and Daigo's GF21 (manufactured by Wako Pure Chemical Industries) % concentration containing in Hybridoma- SFM (Inbitorojiwen Co.) were suspended media to 2 X 10 5 cells / mL and as ing, Fed in a thermostatic chamber at a temperature of 37 ° C using a spinner one bottle (manufactured by Iwaki Glass) -Batch stirred culture.
- the anti-CCR4 chimeric antibody was purified from the culture supernatant collected by culturing for 8 to 10 days, using a Prosep-A (Millipore) column and gel filtration.
- the purified anti-CCR4 chimeric antibody was named KM2760-1.
- the transformed cell line 5-03 producing the anti-CCR4 chimeric antibody obtained in section 1 (2) of Example 4 was cultured in IMDM-dFBS (10) medium in a 182 cm 2 flask (manufactured by Greiner). and cultured at 37 ° C in% C0 2 incubator. Several days later, when the cell density reached confluence, the culture supernatant was removed, the cells were washed with 25 mL of PBS buffer, and 35 mL of EXCELL301 medium (manufactured by JRH) was injected. 5% C0 7 days after culturing at 37 ° C in the incubator, the culture supernatant was recovered.
- the anti-CCR4 chimeric antibody was purified from the culture supernatant using a Prosep-A (Millipore) column according to the attached instructions.
- the purified anti-CCR4 chimeric antibody was named KM3060.
- the binding activity of KM2760-1 and KM3060 to CCR4 was measured by the ELISA method described in item 2 of Example 4, and as a result, the binding activity was equivalent.
- anti-CCR4 chimeric antibody 760-1 derived from YB2 / 0 cells and KM3060, an anti-CCR4 chimeric antibody derived from CH0 / DG44 cells, prepared in Section 3 of Example 4 was performed. Performed according to method. The percentage of sugar chains in which the 1-position of fucose was not ⁇ -linked to the 6-position of N-acetyltilcosamine at the reducing end was 87% for KM2760-1 and 8% for 3060. Hereinafter, these samples are referred to as anti-CCR4 chimeric antibody (87%) and anti-CCR4 chimeric antibody (8%).
- anti-CCR4 chimeric antibody 87%
- anti-CCR4 chimeric antibody 87%
- anti-CCR4 chimeric antibody 87%
- the proportions of sugar chains in which the 1st position of fucose was not bonded to the 6th position of ⁇ ⁇ -acetyldarcosamine at the reducing end were 9%, 18%, 27%, 39% and 46%, respectively.
- FIG. 8 shows the results of sugar chain analysis of each sample.
- the ratio of sugar chains in which the 1-position of fucose was not bonded to the 6-position of ⁇ -acetyldarcosamine at the reducing end was determined by averaging the results of two runs.
- the CCR4 portions of the six types of anti-CCR4 chimeric antibodies differing in the proportion of sugar chains in which the 1-position of fucose is not bonded to the 6-position of the reducing end prepared in Section 5, item 4 of Example 4
- the binding activity to the peptide was measured according to the method described in Example 4, paragraph 2.
- ADCC activity of the anti-CCR4 chimeric antibody on human CCR4 high-expressing cells was measured as follows.
- the amount of spontaneously dissociated 51 Cr was determined by performing the same operation as above using only the medium instead of the human effector cell solution and the antibody solution, and measuring the amount of 51 Cr in the supernatant.
- Total dissociation The amount of 51 Cr was determined by adding a lmol / L hydrochloric acid solution instead of the antibody solution and the human effector cell solution, performing the same operation as above, and measuring the amount of 51 Cr in the supernatant.
- ADCC activity (%) was determined by the above equation (1).
- Figures 10 and 11 show that the position of fucose at position 6 of N-acetyldarcosamine at the reducing end (3 ⁇ 4 various concentrations of anti-CCR4 chimeric antibodies with different proportions of unlinked sugar chains ( The results obtained by measuring the ADCC activity at 0.001 to 10 ig / mL) using the eflator cells of two healthy donors (A, B) are shown in Fig. 10 and Fig. 11, respectively.
- the ADCC activity of the anti-CCR4 chimeric antibody increases in all antibody concentrations in proportion to the proportion of sugar chains in which fucose 1 is not linked to position 6 of N-acetyltilcosamine at the reducing end. When the antibody concentration is low, ADCC activity is reduced.
- Single-stranded cDNA was prepared from CH0 / DG44 cells or rat myeloma YB2 / 0 cells lacking the dhfr gene by the following procedure.
- RNAeasy QIAGEN
- each of the obtained total RNA3 // g was used as a primer with oligo (dT) 20 / z according to the attached instructions.
- a single-stranded cDNA was synthesized by performing a reverse transcription reaction in the L system.
- For cloning of FUT8 and] 3-actin derived from each host cell use a 1-fold concentration of the reaction solution, and use a 50-fold diluted aqueous solution of the reaction solution for quantitative determination of the amount of each gene transcript by competitive PCR. Stored at -80 ° C until ready.
- PCR was performed at 94 ° C for 4 minutes, followed by 25 cycles of a reaction consisting of 98 ° C for 15 seconds, 65 ° C for 2 seconds, and 74 ° C for 30 seconds.
- the reaction solution was subjected to 0.8% agarose gel electrophoresis to purify 1128 bp of the specific amplified fragment.
- This DNA fragment was subjected to phosphorylation at the 5 'end using MEGALABEL (manufactured by Takara Shuzo) according to the attached instructions.
- MEGALABEL manufactured by Takara Shuzo
- the plasmid pBluescriptll KS (+) 3, ug (manufactured by Stratagene) is dissolved in NEBuffer 2 (manufactured by New England Biolabs) 35, and 16 units of the restriction enzyme EcoRV (manufactured by Takara Shuzo) are added thereto. For 3 hours.
- 35 iL of a lmol / L Tris-HCl buffer (pH 8.0) and 3.5 ⁇ l of Alkaline Phosphatase (manufactured by Takara Shuzo Co., Ltd.) derived from 5 strains of E. coli were added, and the mixture was reacted at 65 ° C for 30 minutes. As a result, dephosphorylation of the DNA ends was performed.
- This reaction solution was subjected to phenol / chloroform extraction, followed by ethanol precipitation, and the recovered DNA fragment was dissolved in 100 ⁇ L of sterilized water.
- the nucleotide sequence of the cDNA inserted into each plasmid was determined using the DNA Sequencer 377 (Parkin Elmer) and the BigDye Terminator Cycle Sequencing FS Ready Reaction Kit (Parkin Elmer) according to the attached manual. . All imported cDNAs sequenced by this method were confirmed to encode the 0RF full length sequence of each cDNA of Chinese hamster ⁇ -actin and rat] 3-actin. Among these, a plasmid DNA was selected which did not contain any base reading errors due to PCR in the sequence. Hereinafter referred to as the respective plasmid CHAc- P BS and YBAc-pBS.
- PCR was carried out at 94 ° C for 4 minutes, followed by 25 cycles of 1 cycle consisting of 98 ° C for 15 seconds, 65 ° C for 2 seconds, and 74 ° C for 30 seconds.
- the reaction solution was subjected to 0.8% agarose gel electrophoresis to purify a specific amplified fragment of about 4.7 Kb '.
- the DNA fragment was subjected to phosphorylation at the 5 'end using MEGALABEL (manufactured by Takara Shuzo Co., Ltd.) according to the attached instructions, and then the DNA fragment was recovered from the reaction solution using an ethanol precipitation method and sterilized. Dissolved in 50 L of water.
- the DNA fragment (approximately 4.7 Kb) (5 ⁇ M) and Ligation High (Toyobo Co., Ltd.) (5 ⁇ M) were mixed, and allowed to react at 16 ° C. for 30 minutes to perform a self-cyclization reaction.
- plasmid DNA was isolated from each of the obtained ampicillin-resistant cells according to a known method.
- DNA Sequencer 377 Parkin Elmer
- BigDye Sequence was determined using Terminator Cycle Sequencing FS Ready Reaction Kit (Parkin Elmer), and the internal nucleotide sequence of Chinese hamster FUT8 and rat FUT8 inserted into the plasmid was deleted 203 bp between Seal-Hinddlll It was confirmed.
- the resulting plasmids are referred to as CHFT8d-pCR2.1 and YBFT8d-pCR2.1. Then plasmid CHFT8d- pCR2.
- the internal control of 3-actin quantification was obtained by deleting 180 bp between Dralll-DralH of the internal nucleotide sequences of Chinese hamster-actin and rat ⁇ -actin in CHAc-pBS and YBAc-pBS.
- the obtained CHAcd-pBS and YBAcd-pBS were used, and the former was digested with restriction enzymes iidlll and £ 1, and the latter was digested with restriction enzymes ndlll and ⁇ I. The details are described below.
- the plasmid YBAc-pBS was dissolved in NEBuffer 2 (manufactured by New England Biolabs) in an amount of 40 tU, and 25 units of the restriction enzyme giiidlll (manufactured by Takara Shuzo) and 24 units of ⁇ (manufactured by Takara Shuzo) were added.
- the digestion reaction was performed at ° C for 3 hours.
- CHAc-pBS is dissolved in NEBuffer 3 (New England Biolabs) 100 / iL containing lOOng / LBSA (New England Biolabs), added with 10 units of restriction enzyme Drain (New England Biolabs), and added at 37 ° C.
- the digestion reaction was performed at C for 3 hours.
- DNA fragments were recovered from the reaction solution by the ethanol precipitation method, and after blunting the DNA ends using a DNA Blunting Kit (manufactured by Takara Shuzo) according to the attached instruction manual, the reaction solution was divided into two equal parts. .
- plasmid DNA was sequenced using DNA Sequencer 377 (Parkin Elmer) and BigDye Terminator Cycle Sequencing FS Ready Reaction Kit (Parkin Elmer), and the Chinese hamster ⁇ -actin inserted into the plasmid -It was confirmed that 180 bp was deleted between Dralll.
- This plasmid is referred to as CHAcd-pBS.
- a plasmid in which 180 bp was deleted between rat J3-actin Dralll-DralH was produced through the same steps as in CHAcd-pBS. This plasmid is called YBAcd-pBS.
- the quantification of the FUT8 transcript was performed according to the following procedure.
- a common sequence-specific primer set shown in SEQ ID NOs: 13 and 14
- SEQ ID NOs: 13 and 14 was designed for the internal sequence of the Chinese hamster FUT8 and rat FUT80 RF partial sequences obtained in section 2 of Example 5.
- the quantification of the transcript of ⁇ -actin was performed according to the following procedure. First, a primer set specific to each gene (for the Chinese hamster j3-actin and rat j8-actin 0RF full-length internal sequences obtained in section 3 of Example 5) (the former was set to SEQ ID NO: 15 and SEQ ID NO: 16, and the latter was set to SEQ ID NO: 17 and SEQ ID NO: 18) were designed respectively.
- a reaction solution having a total volume of 20 containing 5 Ai L of a 50-fold dilution of the cDNA solution derived from each host cell strain obtained in paragraph 1 of Example 5 and plasmid 5 / L (lpg) for internal control [1 Double-concentration ExTaq buffer (Takara Shuzo), 0.2 ⁇ l / L dNTPs, 0.5 ⁇ mol / L Gene-specific primer (SEQ ID NO: 15 and SEQ ID NO: 16, or SEQ ID NO: 17 and SEQ ID NO: 18) ), 5% DMS0] and DNA polymerase ExTaq (Takara Shuzo).
- PCR was performed under the conditions of heating at 94 ° C for 3 minutes, followed by 17 cycles of a reaction consisting of 94 ° C for 30 seconds, 65 ° C for 1 minute, and 72 ° C for 2 minutes. .
- PCR was performed in a system to which 5 L (10 pg, 5 pg, lpg, 500 fg, lOOfg) of J3-actin standard plasmid obtained in section 5 of Example 5 was added, and PCR was performed. It was used to create a calibration curve for the amount of 3-actin transcript.
- FUT8 F 5'-GTCCATGGTGATCCTGCAGTGTGG-3 > 638 431: 5'-CACCAATGATATCTCCAGGTTCC-3'3-actin F: 5'-GATATCGCTGCGCTC6TTGTCGAC-3 5 789 609
- the amount of amplification product generated by PCR using the standard plasmid as type I was measured, and the measured value and the amount of the standard plasmid were plotted to prepare a calibration spring.
- the amount of cDNA of the target gene in each strain was calculated from the amount of amplification product when the total cDNA derived from each expression strain was type II, and this was used as the mRNA transcription amount in each strain.
- FIG. 16 shows the amount of the FUT8 transcript in each host cell line when the rat FUT8 sequence was used as a standard and internal control.
- the CH0 / DG44 cell line showed a transcription level more than 10 times that of the YB2 / 0 cell line. This tendency was also observed when the Chinese nomster FUT8 sequence was used as a standard or internal control.
- Table 2 shows the FUT8 transcript amount as a relative value to the amount of actin transcript.
- the FUT8 transcript of the ⁇ 2/0 cell line was around 0.1% of i3-actin, while the CH0 / DG44 cell line was 0.5% to 2%.
- Example 6 Quantification of transcript of FUT8 gene in anti-GD3 chimeric antibody producing cell line 1. Preparation of single-stranded cDNA from various producing cell lines
- Single-stranded cDNA was prepared from the anti-GD3 chimera antibody-producing cell DCHI (U-20 strain 61-33 strain by the following procedure.
- the DCHI01-20 strain was prepared as described in Example 1, paragraph 2 (2)). It is a transformed clone derived from CH0 / DG44 cells, and strain 61-33 is a transformed cell clone 7-9-51 derived from YB2 / 0 (National Institute of Advanced Industrial Science and Technology, Patent Organism Depositary, FERM BP). This is a clone obtained by performing serum-free adaptation to -6691) and cloning twice by the limiting dilution method.
- DCHI01-20 strain was supplemented with 3ramol / L L-Gin (Life Technologies), 0.3% PLURONIC F-68 (Life Technologies) and 0.5% fatty acid concentrate (Life Technologies).
- the suspension was suspended in the prepared EXCELL302 medium (manufactured by JRH BIOSCIENCES), and seeded at a density of 210 5 cells / ⁇ into a T75 flask for suspension cell culture (manufactured by Greiner) at 15 mL.
- the 61-33 strain was suspended in Hybridoma-SFM medium (Life Technology) supplemented with 0.2% BSA and placed in a T75 flask (Greiner) for suspension cell culture at a density of 210 5 cells / 1111.
- RNAeasy QIAGE Total RNA was extracted according to the attached instructions. Dissolve the whole thigh in 45 Ai L of sterile water, and add 1 ⁇ l of RQ1 RNase-Free DNase (Promega), 5 ⁇ L of the attached lO XDNase buffer, 0.5 ⁇ l of RNasin Ribonuclease inhibitor (Promo), respectively. , And reacted at 37 ° C for 30 minutes to decompose genomic DNA contaminated in the sample. After the reaction, total RNA was repurified by RAeasy (QIAGEN) and dissolved in 50 ⁇ L of sterilized water.
- Reverse transcription of the obtained total RNA 3 ⁇ g was performed using the SUPERSCRIPT TM Preamplification System for First Strand cDNA Synthesis (manufactured by Life Technologies) in accordance with the attached instructions in a 20 L system with oligo (dT) as a primer. By performing the reaction, single-stranded cDNA was synthesized. The reaction was diluted 50-fold with water and stored at -80 ° C until use.
- the amount of each gene transcript was quantified by competitive PCR according to section 6 of Example 5.
- the quantification of the amount of mRNA transcribed from the FUT8 gene in each production cell line was performed by the following procedure.
- CHFT8- P a plasmid in which the cDNA partial fragments of Chinese hamster FUT8 and rat FUT8 obtained in Section 2 of Example 5 were incorporated into pCR2.1
- a linearized DNA obtained by cutting CR2.1 and YBFT8-pCR2.1 with restriction enzyme EcoRI was used.
- CHFT8d_pCR2.1 and YBFT8d-pCR2.1 prepared in Section 4 of Example 5, 203 bp between ⁇ 1 and Misdlll of the internal base sequence of Chinese hamster FUT8 and rat FUT8
- the] -actin gene is constantly transcribed in each cell, and the transcription amount is considered to be the same between cells. Therefore, as a measure of the efficiency of the cDNA synthesis reaction derived from each production cell line, ] The transcription amount of the 3-actin gene was quantified by the following procedure.
- CHAcd-pBS and YBAcd-pBS obtained by deleting 180 bp between DralHs were cut with the restriction enzymes Hindi II and 1, and linearized DNA was used.
- PCR was performed in a system supplemented with ⁇ -actin standard plasmids 10 pg, 5 pg, lpg, 500 fg, and 100 fg, respectively, to prepare a calibration curve for i3-actin transcription.
- ⁇ -actin standard plasmids 10 pg, 5 pg, lpg, 500 fg, and 100 fg, respectively.
- l-g / mL baker's yeast-derived t-RNA manufactured by SIGMA was used for dilution of the standard plasmid.
- the DNA fragment of the size shown in the above can be amplified. After 7 ⁇ l of the solution after PCR was subjected to 1.75% agarose gel electrophoresis, the gel was immersed in 1-fold SYBR Green I Nucleic Acid Gel Stain (Molecular Probes) for 30 minutes to stain. The amount of the amplified DNA fragment was measured by calculating the luminescence intensity of each amplified DNA fragment using a Fluorlmager SI (manufactured by Molecular Dynamics).
- the amount of amplification product generated by PCR using the standard plasmid as type I was measured, and the measured value and the amount of standard plasmid were plotted to prepare a calibration curve.
- the amount of cDNA of the target gene in each strain was calculated from the amount of amplification product when the total cDNA derived from each production cell line was type III, and this was used as the mRNA transcription amount in each strain.
- Table 3 shows the FUT8 transcript amount as a relative value to the amount of] 3-actin transcript.
- the YB2 / 0 cell-derived antibody-producing strain 61-33 has a FUT8 transcript of 0.3% or less of; 3-actin, while the CH0 cell-derived antibody-producing strain DCHI01-20 has 0.7-1.5%.
- the results showed that the amount of FUT8 transcript of the YB2 / 0 cell-derived antibody-producing strain was significantly smaller than that of the CH0 cell-derived antibody-producing strain.
- Example 7 Preparation of lectin-resistant CH0 / DG44 cells and production of antibodies using the cells
- CH0 / DG44 cells are cultured in an IMDM-FBS (10) -HT (1) medium [IMDM medium containing 10% FBS and HT supplement (GIBC0 BRL) at 1-fold concentration] in an adhesion culture flask 75 cm 2 (group). (Manufactured by Liner Co., Ltd.) and grown to just before confluence. After washing the cells with 5 mL of PBS (manufactured by Invitrogen), 0.05% trypsin (manufactured by Invitrogen) diluted with PBS was added to 1.5 raL-added cuvette and allowed to stand at 37 ° C for 5 minutes. Cells were detached from the bottom of the incubator.
- the were detached cells were recovered by centrifugation performed in conventional cell culture, 1 (10 5 so that the density of cells / mL IMDM- FBS (IO) - HT (1) medium was ⁇ Ka ⁇ suspension After turbidity, N_methyl-N, -nitro-N-nitrosoguanidin (hereinafter referred to as MNNG, manufactured by Sigma), which is an unadded or 0.1 l / ⁇ g / mL alkylating agent, was added.
- MNNG N_methyl-N, -nitro-N-nitrosoguanidin
- Each well contains lmg / mL of lentil agglutinin (Lens culinaris agglutinin; hereinafter referred to as LCA, manufactured by Vector) at a final concentration in the medium, or lmg / raL of Aleuria aurantia Lectin; AAL (indicated as Vector, manufactured by Vector) or lmg / mL kidney bean agglutinin (Phaseolus vulgaris Leucoagglutinin; hereinafter, referred to as L-PHA, manufactured by Vector) was added.
- the LCA-resistant strain was named CH0-LCA strain
- the AAL-resistant strain was named CHO-AAL strain
- the L-PHA-resistant strain was named CH0-PHA strain.
- the CH0-LCA strain was also resistant to AAL
- the CH0-AAL strain was also resistant to LCA.
- the CHO-LCA strain and the CH0-ML strain are lectins that recognize the same sugar chain structure as those recognized by LCA and AAL, that is, N-acetyldarco at the N-glycoside-linked sugar chain reducing terminal.
- CHO-LCA strains and CH0-ML strains survive even in a medium supplemented with Endum bean agglutinin (Pisum sativum Agglutinin; hereinafter, referred to as PSA, manufactured by Vector) at a final concentration of lmg / mL. I found out.
- PSA Endum bean agglutinin
- a lectin-resistant strain could be obtained by increasing the number of cells subjected to the above treatment. Thereafter, these strains were used for analysis.
- the anti-CCR4 chimeric antibody expression plasmid PKANTEX2160 was introduced into the three types of lectin-resistant strains obtained in paragraph 1 of Example 7 by the method described in Example 4, and the gene was amplified with the drug MTX to obtain the anti-CCR4 chimera.
- An antibody producing strain was produced.
- the antibody expression level was measured using the ELISA method described in Example 4, paragraph 2, and CHO-LCA strains, CHO-ML strains, and CH0-PHA strains were used to obtain transformed strains that expressed antibodies. .
- transformants derived from the CHO-LCA strain were used for the CH0 / CCR4-LCA strain
- the transformant derived from the AAL strain was named CH0 / CCR4-AAL strain
- the transformant derived from the CHO-PHA strain was named CH0 / CCR4-PHA strain.
- the CH0 / CCR4-LCA strain is the name of Nega-13, and the Patent Organism Depositary of the National Institute of Advanced Industrial Science and Technology (AIST) was established on September 26, 2001 (1-1-1, Higashi, Tsukuba, Ibaraki, Japan) 6) and deposited as FERM BP-7756.
- Purified antibodies were obtained using the three types of transformants obtained in section 2 of Example 7 by the method described in section 3 of Example 4.
- the antigen-binding activity of the purified anti-CCR4 chimeric antibody was evaluated using the ELISA method described in Example 4, paragraph 2.
- Antibodies produced by any of the transformants exhibited the same antigen-binding activity as the antibody produced by the production strain 5-03 using the normal CH0 / DG44 cells prepared in Example 4 as a host.
- the ADCC activity of each anti-CCR4 chimeric antibody was evaluated in accordance with the method described in Example 4, section 7. The results are shown in FIG.
- FIG. 19 shows elution diagrams of purified PA-linked sugar chains of various anti-CCR4 chimeric antibodies.
- Table 4 shows that the 1-position of fucose is not ⁇ -linked to the 6-position of N-acetyldarcosamine at the reducing end obtained as a result of sugar chain analysis of anti-CCR4 chimeric antibodies produced by various lectin-resistant strains. Indicates the sugar chain ratio (%).
- the antibody produced by the CH0 / CCR4-LCA strain has a sugar chain in which position 1 of fucose is not ⁇ -linked to position 6 of ⁇ ⁇ -acetyldarcosamine at the reducing end. Increased from 9% to 48%.
- the proportion of sugar chains without 1,6-fucose increased from 9% to 27%.
- the CH0 / CCR4-PHA strain showed almost no change in the sugar chain pattern and the ratio of sugar chains without ⁇ 1,6-fucose as compared to the strain 5-03.
- Example 8 Analysis of lectin-resistant CH0 cell line
- a 24-mer having the base sequence shown in SEQ ID NO: 32 was synthesized from the GMD cDNA sequence derived from the CH0 cell shown in Section 1 of Reference Example 2.
- a 26-mer synthetic DNA primer having a DNA primer and a base sequence represented by SEQ ID NO: 33 was prepared.
- a 28-mer synthetic DNA primer having the base sequence shown in SEQ ID NO: 36 and the SEQ ID NO: based on the cDNA sequence of FX derived from CH0 cells obtained in Section 1 of Reference Example 1 A 28-mer synthetic DNA primer having a base sequence represented by 37 was prepared.
- a 20 AiL reaction solution containing 0.5 iL of single-stranded cDNA from each cell line prepared as described in section 1 (1) of Example 8 as type III [1 fold concentration of EX Taq Buffer (Takara Shuzo Co., Ltd.), 0. 2 ramol / L of dNTPs, 0. 5 units of EX Taq polymerase (Takara Shuzo Co., Ltd.), the synthesis of SEQ ID NO: 13 and 14 of 0.
- DNA Primer 1 5 ⁇ mol / L DNA Primer 1
- DNA Thermal Cycler 480 manufactured by PerkinElmer
- the cycle was performed for 20 cycles.
- the DNA fragment was stained using Cybergreen (manufactured by BMA), and the expected amount of the DNA fragment of about 600 bp was analyzed using Fluor Imager SI (Molecular Dynamics, Inc.). Was used for the measurement.
- Anti-CCR4 antibody-producing cells 1.107 0.793 1.093 0.901
- the expression level of the GMD gene in the CH0 / CCR4-LCA strain was reduced to about 1/10 compared to other cell lines. This experiment was performed twice independently, and the average value was used.
- a 28-mer primer having the nucleotide sequence of SEQ ID NO: 38 and a 29-mer primer having the nucleotide sequence of SEQ ID NO: 39 based on the cDNA sequence of GMD derived from CH0 cells obtained in Section 1 of Reference Example 2 was prepared.
- the recovered DNA fragment was ligated to a pT7Blue (R) vector (Novagen) using a DNA Ligation kit (Takara Shuzo), and Escherichia coli DH5 strain (Toyobo) was obtained using the obtained recombinant plasmid DNA. ) was obtained to obtain a plasmid mt_C (FIG. 20).
- the plasmid CH0-GMD described in Paragraph 1 of Reference Example 2 was reacted with the restriction enzyme Sacl (manufactured by Takara Shuzo Co., Ltd.) at 37 ° C for 16 hours, followed by phenol / cloth form extraction and ethanol precipitation.
- the DNA was recovered by a reaction with a restriction enzyme i ⁇ RI (Takara Shuzo) at 37 ° C for 16 hours, followed by fractionation by agarose electrophoresis, and a DNA fragment of about 900 bp was recovered.
- the recovered DNA fragments were ligated using a DNA Ligation kit (Takara Shuzo), and the resulting recombinant plasmid DNA was used to transform Escherichia coli DH5o; strain to obtain plasmid WT-N (-) (Fig. 22).
- the plasmid WT-N (-) was reacted with the restriction enzyme BamHI (manufactured by Takara Shuzo) at 37 ° C for 16 hours, and DNA was recovered by phenol / cloth form extraction and ethanol precipitation to recover the DNA.
- the plasmid WT-N (-) in pBS was reacted with the restriction enzyme Hdni (Takara Shuzo) at 37 ° C for 16 hours, followed by phenol / cloth form extraction and ethanol precipitation to recover DNA.
- restriction enzyme ⁇ RI manufactured by Takara Shuzo
- the mixture was fractionated by agarose gel electrophoresis to recover a DNA fragment of about 4 kbp.
- the pAGE249 vector was introduced into the CH0 / CCR4-LCA strain in the same manner as above to obtain a group of transformants showing hygromycin resistance.
- the transformed cell group expressing the GMD obtained in Section 2 (2) of Example 8 was IMDM-dFBS (200 nmol / L, containing hygromycin at a concentration of 0.5 mg / mL) and MTX (manufactured by SUGMA). 10) Using the medium, the cells were cultured in a 182 cm 2 flask (manufactured by Greiner) in a 5% CO 2 incubator at 37 ° C. Several days later, when the cell density reached confluence, the culture supernatant was removed, the cells were washed with 25 mL of PBS (GIBCO BRL), and 35 mL of EXCELL301 medium (JRH) was injected.
- the culture supernatant was collected.
- the anti-CCR4 chimeric antibody was purified from the culture supernatant using a Prosep-A (Millipore) column according to the attached instructions.
- the transformed cells into which the pAGE249 vector was introduced were cultured in the same manner as described above, and the anti-CCR4 chimeric antibody was recovered from the culture supernatant and purified.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002481658A CA2481658A1 (en) | 2002-04-09 | 2003-04-09 | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
JP2003582297A JPWO2003085119A1 (ja) | 2002-04-09 | 2003-04-09 | 抗体組成物のFcγ受容体IIIaに対する結合活性を高める方法 |
EP03723098A EP1498491A4 (en) | 2002-04-09 | 2003-04-09 | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
AU2003236018A AU2003236018A1 (en) | 2002-04-09 | 2003-04-09 | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-106950 | 2002-04-09 | ||
JP2002106950 | 2002-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003085119A1 true WO2003085119A1 (fr) | 2003-10-16 |
Family
ID=28786448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/004504 WO2003085119A1 (fr) | 2002-04-09 | 2003-04-09 | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia |
Country Status (6)
Country | Link |
---|---|
US (2) | US20040259150A1 (ja) |
EP (1) | EP1498491A4 (ja) |
JP (1) | JPWO2003085119A1 (ja) |
AU (1) | AU2003236018A1 (ja) |
CA (1) | CA2481658A1 (ja) |
WO (1) | WO2003085119A1 (ja) |
Cited By (546)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005053742A1 (ja) * | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
WO2006041680A2 (en) | 2004-10-05 | 2006-04-20 | Genentech, Inc. | Method for treating vasculitis |
EP1500400A4 (en) * | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
EP1816140A1 (en) * | 2004-10-26 | 2007-08-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
WO2008011081A2 (en) | 2006-07-19 | 2008-01-24 | The Trustees Of The University Of Pennsylvania | Wsx-1/p28 as a target for anti-inflammatory responses |
WO2008032833A1 (fr) | 2006-09-14 | 2008-03-20 | Medical & Biological Laboratories Co., Ltd. | Anticorps présentant une activité adcc accrue et son procédé de production |
JP2009520503A (ja) * | 2005-12-20 | 2009-05-28 | ブリストル−マイヤーズ スクイブ カンパニー | 組成物および組成物の製造方法 |
US7541029B2 (en) | 2000-04-12 | 2009-06-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anti-rhesus D monoclonal antibodies |
US7662377B2 (en) | 2006-08-09 | 2010-02-16 | Glycart Biotechnology Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
US7722867B2 (en) | 2005-02-07 | 2010-05-25 | Glycart Biotechnology Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
WO2010075548A2 (en) | 2008-12-23 | 2010-07-01 | Genentech, Inc. | Immunoglobulin variants with altered binding to protein a |
WO2010108127A1 (en) | 2009-03-20 | 2010-09-23 | Genentech, Inc. | Bispecific anti-her antibodies |
US7803377B2 (en) | 2006-06-06 | 2010-09-28 | Genentech, Inc. | Anti-DLL4 antibodies and methods using same |
WO2010111254A1 (en) | 2009-03-25 | 2010-09-30 | Genentech, Inc. | Novel anti-alpha5beta1 antibodies and uses thereof |
WO2010111367A1 (en) | 2009-03-25 | 2010-09-30 | Genentech, Inc. | Anti-fgfr3 antibodies and methods using same |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
US7871613B2 (en) | 2004-08-24 | 2011-01-18 | Chugai Seiyaku Kabushiki Kaisha | Adjuvant therapy with the use of anti-glypican 3 antibody |
WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
WO2011014750A1 (en) | 2009-07-31 | 2011-02-03 | Genentech, Inc. | Inhibition of tumor metastasis using bv8- or g-csf-antagonists |
WO2011023787A1 (en) | 2009-08-31 | 2011-03-03 | Roche Glycart Ag | Affinity-matured humanized anti cea monoclonal antibodies |
WO2011028950A1 (en) | 2009-09-02 | 2011-03-10 | Genentech, Inc. | Mutant smoothened and methods of using the same |
US7919086B2 (en) | 2004-07-09 | 2011-04-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
WO2011050188A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Anti-hepsin antibodies and methods using same |
WO2011057120A1 (en) | 2009-11-05 | 2011-05-12 | Genentech, Inc. | Methods and composition for secretion of heterologous polypeptides |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056997A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011071577A1 (en) | 2009-12-11 | 2011-06-16 | Genentech, Inc. | Anti-vegf-c antibodies and methods using same |
WO2011079185A1 (en) | 2009-12-23 | 2011-06-30 | Genentech, Inc. | Anti-bv8 antibodies and uses thereof |
WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
WO2011103242A1 (en) | 2010-02-18 | 2011-08-25 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
WO2011101328A2 (en) | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
WO2011119661A1 (en) | 2010-03-24 | 2011-09-29 | Genentech, Inc. | Anti-lrp6 antibodies |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
WO2011153346A1 (en) | 2010-06-03 | 2011-12-08 | Genentech, Inc. | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
WO2011161189A1 (en) | 2010-06-24 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods of use |
EP2402373A2 (en) | 2006-01-05 | 2012-01-04 | Genentech, Inc. | Anti-EphB4 Antibodies and Methods Using Same |
WO2012006503A1 (en) | 2010-07-09 | 2012-01-12 | Genentech, Inc. | Anti-neuropilin antibodies and methods of use |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
WO2012017003A1 (en) | 2010-08-05 | 2012-02-09 | F. Hoffmann-La Roche Ag | Anti-mhc antibody anti-viral cytokine fusion protein |
WO2012018771A1 (en) | 2010-08-03 | 2012-02-09 | Genentech, Inc. | Chronic lymphocytic leukemia (cll) biomarkers |
WO2012020038A1 (en) | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-tenascin-c a2 antibodies and methods of use |
WO2012020006A2 (en) | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
WO2012025536A1 (en) | 2010-08-25 | 2012-03-01 | F. Hoffmann-La Roche Ag | Antibodies against il-18r1 and uses thereof |
WO2012031027A1 (en) | 2010-08-31 | 2012-03-08 | Genentech, Inc. | Biomarkers and methods of treatment |
WO2012047968A2 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
EP2446904A2 (en) | 2006-05-30 | 2012-05-02 | Genentech, Inc. | Anti-CD22 antibodies, their immunoconjugates and uses thereof |
WO2012064836A1 (en) | 2010-11-10 | 2012-05-18 | Genentech, Inc. | Methods and compositions for neural disease immunotherapy |
EP2468776A2 (en) | 2007-02-09 | 2012-06-27 | Genentech, Inc. | Anti-Robo4 antibodies and uses therefor |
EP2468772A2 (en) | 2006-03-16 | 2012-06-27 | Genentech, Inc. | Antibodies to EGFL7 and methods for their use |
WO2012088313A1 (en) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Anti-pcsk9 antibodies and methods of use |
WO2012087962A2 (en) | 2010-12-20 | 2012-06-28 | Genentech, Inc. | Anti-mesothelin antibodies and immunoconjugates |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
US8216807B2 (en) | 2006-10-12 | 2012-07-10 | Genentech, Inc. | Antibodies to lymphotoxin-α |
WO2012107416A2 (en) | 2011-02-10 | 2012-08-16 | Roche Glycart Ag | Improved immunotherapy |
WO2012138975A1 (en) | 2011-04-07 | 2012-10-11 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
WO2012146628A1 (en) | 2011-04-29 | 2012-11-01 | Roche Glycart Ag | Novel immunoconjugates |
WO2012146630A1 (en) | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | N-terminal acylated polypeptides, methods for their production and uses thereof |
WO2012155019A1 (en) | 2011-05-12 | 2012-11-15 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
WO2012158704A1 (en) | 2011-05-16 | 2012-11-22 | Genentech, Inc. | Fgfr1 agonists and methods of use |
WO2012171996A1 (en) | 2011-06-15 | 2012-12-20 | F. Hoffmann-La Roche Ag | Anti-human epo receptor antibodies and methods of use |
WO2012175508A1 (en) | 2011-06-22 | 2012-12-27 | F. Hoffmann-La Roche Ag | Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes |
WO2013003680A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
WO2013025944A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Inhibition of angiogenesis in refractory tumors |
WO2013025853A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
WO2013026831A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antigen binding molecules |
WO2013026832A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Anti-mcsp antibodies |
WO2013040433A1 (en) | 2011-09-15 | 2013-03-21 | Genentech, Inc. | Methods of promoting differentiation |
WO2013043715A1 (en) | 2011-09-19 | 2013-03-28 | Genentech, Inc. | Combination treatments comprising c-met antagonists and b-raf antagonists |
WO2013052155A1 (en) | 2011-10-05 | 2013-04-11 | Genentech, Inc. | Methods of treating liver conditions using notch2 antagonists |
WO2013056148A2 (en) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Methods of using scd1 antagonists |
WO2013055998A1 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE |
WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
WO2013063001A1 (en) | 2011-10-28 | 2013-05-02 | Genentech, Inc. | Therapeutic combinations and methods of treating melanoma |
WO2013078170A1 (en) | 2011-11-21 | 2013-05-30 | Genentech, Inc. | Purification of anti-c-met antibodies |
WO2013083497A1 (en) | 2011-12-06 | 2013-06-13 | F. Hoffmann-La Roche Ag | Antibody formulation |
WO2013096791A1 (en) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Process for making high concentration protein formulations |
WO2013092743A2 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
WO2013092720A1 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
WO2013092723A1 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
WO2013106489A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
WO2013106485A2 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
WO2013109819A1 (en) | 2012-01-18 | 2013-07-25 | Genentech, Inc. | Anti-lrp5 antibodies and methods of use |
WO2013109856A2 (en) | 2012-01-18 | 2013-07-25 | Genentech, Inc. | Methods of using fgf19 modulators |
EP2623516A2 (en) | 2005-12-02 | 2013-08-07 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R |
WO2013116287A1 (en) | 2012-01-31 | 2013-08-08 | Genentech, Inc. | Anti-ig-e m1' antibodies and methods using same |
WO2013120056A1 (en) | 2012-02-11 | 2013-08-15 | Genentech, Inc. | R-spondin translocations and methods using the same |
WO2013120929A1 (en) | 2012-02-15 | 2013-08-22 | F. Hoffmann-La Roche Ag | Fc-receptor based affinity chromatography |
WO2013149159A1 (en) | 2012-03-30 | 2013-10-03 | Genentech, Inc. | Anti-lgr5 antibodies and immunoconjugates |
WO2013148315A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
WO2013165940A1 (en) | 2012-05-01 | 2013-11-07 | Genentech, Inc. | Anti-pmel17 antibodies and immunoconjugates |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
WO2013177470A1 (en) | 2012-05-23 | 2013-11-28 | Genentech, Inc. | Selection method for therapeutic agents |
WO2014006123A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Anti-biotin antibodies and methods of use |
WO2014006118A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Anti-theophylline antibodies and methods of use |
WO2014006124A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
WO2014008391A1 (en) | 2012-07-05 | 2014-01-09 | Genentech, Inc. | Expression and secretion system |
WO2014011518A1 (en) | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
WO2014011519A1 (en) | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd79b antibodies |
WO2014011521A1 (en) | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti - cd79b antibodies |
WO2014011520A1 (en) | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
US8642742B2 (en) | 2011-03-02 | 2014-02-04 | Roche Glycart Ag | Anti-CEA antibodies |
WO2014023679A1 (en) | 2012-08-07 | 2014-02-13 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
WO2014072306A1 (en) | 2012-11-08 | 2014-05-15 | F. Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
WO2014078268A2 (en) | 2012-11-13 | 2014-05-22 | Genentech, Inc. | Anti-hemagglutinin antibodies and methods of use |
WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
WO2014128235A1 (en) | 2013-02-22 | 2014-08-28 | F. Hoffmann-La Roche Ag | Methods of treating cancer and preventing drug resistance |
WO2014131715A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Anti-mcsp antibodies |
WO2014138364A2 (en) | 2013-03-06 | 2014-09-12 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
WO2014144865A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Anti-crth2 antibodies and methods of use |
WO2014145016A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
WO2014144850A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
WO2014151866A1 (en) | 2013-03-15 | 2014-09-25 | Genentech, Inc. | Compositions and methods for diagnosis and treatment of hepatic cancers |
WO2014150877A2 (en) | 2013-03-15 | 2014-09-25 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
WO2014151006A2 (en) | 2013-03-15 | 2014-09-25 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
WO2014152358A2 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
WO2014153030A2 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
WO2014159835A1 (en) | 2013-03-14 | 2014-10-02 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
WO2014161845A1 (en) | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
WO2014177461A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases |
WO2014177460A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
WO2014194247A1 (en) | 2013-05-31 | 2014-12-04 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
WO2014193722A1 (en) | 2013-05-31 | 2014-12-04 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
WO2015010100A2 (en) | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Humanized antibodies with ultralong complementarity determining regions |
WO2015017146A2 (en) | 2013-07-18 | 2015-02-05 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
WO2015017600A1 (en) | 2013-08-01 | 2015-02-05 | Five Prime Therapeutics, Inc. | Afucosylated anti-fgfr2iiib antibodies |
WO2015023596A1 (en) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | Compositions and method for treating complement-associated conditions |
EP2845866A1 (en) | 2006-10-27 | 2015-03-11 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
EP2851372A1 (en) | 2007-11-30 | 2015-03-25 | Genentech, Inc. | Anti-VEGF antibodies |
WO2015042108A1 (en) | 2013-09-17 | 2015-03-26 | Genentech, Inc. | Methods of using anti-lgr5 antibodies |
WO2015052230A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
WO2015054670A1 (en) | 2013-10-11 | 2015-04-16 | Genentech, Inc. | Nsp4 inhibitors and methods of use |
WO2015058132A2 (en) | 2013-10-18 | 2015-04-23 | Genentech, Inc. | Anti-rspo antibodies and methods of use |
WO2015061441A1 (en) | 2013-10-23 | 2015-04-30 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
WO2015075011A1 (en) | 2013-11-21 | 2015-05-28 | F. Hoffmann-La Roche Ag | ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE |
WO2015089344A1 (en) | 2013-12-13 | 2015-06-18 | Genentech, Inc. | Anti-cd33 antibodies and immunoconjugates |
WO2015089117A1 (en) | 2013-12-09 | 2015-06-18 | Allakos Inc. | Anti-siglec-8 antibodies and methods of use thereof |
WO2015095418A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
WO2015095410A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
WO2015101588A1 (en) | 2014-01-06 | 2015-07-09 | F. Hoffmann-La Roche Ag | Monovalent blood brain barrier shuttle modules |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
WO2015101587A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
WO2015101589A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked polypeptide toxin-antibody conjugates |
WO2015107026A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
WO2015112909A1 (en) | 2014-01-24 | 2015-07-30 | Genentech, Inc. | Methods of using anti-steap1 antibodies and immunoconjugates |
US9102739B2 (en) | 2005-10-14 | 2015-08-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody |
WO2015120075A2 (en) | 2014-02-04 | 2015-08-13 | Genentech, Inc. | Mutant smoothened and methods of using the same |
WO2015120280A1 (en) | 2014-02-08 | 2015-08-13 | Genentech, Inc. | Methods of treating alzheimer's disease |
WO2015120233A1 (en) | 2014-02-08 | 2015-08-13 | Genentech, Inc. | Methods of treating alzheimer's disease |
WO2015127405A2 (en) | 2014-02-21 | 2015-08-27 | Genentech, Inc. | Anti-il-13/il-17 bispecific antibodies and uses thereof |
WO2015131155A1 (en) | 2014-02-28 | 2015-09-03 | Allakos Inc. | Methods and compositions for treating siglec-8 associated diseases |
WO2015139046A1 (en) | 2014-03-14 | 2015-09-17 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
WO2015140591A1 (en) | 2014-03-21 | 2015-09-24 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
WO2015148531A1 (en) | 2014-03-24 | 2015-10-01 | Genentech, Inc. | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
WO2015153514A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
WO2015153513A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Anti-ox40 antibodies and methods of use |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
WO2015179658A2 (en) | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
WO2015179835A2 (en) | 2014-05-23 | 2015-11-26 | Genentech, Inc. | Mit biomarkers and methods using the same |
WO2015191986A1 (en) | 2014-06-13 | 2015-12-17 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
WO2015191715A1 (en) | 2014-06-11 | 2015-12-17 | Genentech, Inc. | Anti-lgr5 antibodies and uses thereof |
WO2016007235A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
WO2016007775A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Notch pathway inhibition |
JP2016023152A (ja) * | 2014-07-17 | 2016-02-08 | 東ソー株式会社 | 抗体依存性細胞傷害活性の強さに基づき抗体を分離する方法 |
US9266961B2 (en) | 2012-06-15 | 2016-02-23 | Genentech, Inc. | Anti-PCSK9 antibodies, formulations, dosing, and methods of use |
WO2016033570A1 (en) | 2014-08-28 | 2016-03-03 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for cd19 |
WO2016040868A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
WO2016044396A1 (en) | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines |
WO2016061389A2 (en) | 2014-10-16 | 2016-04-21 | Genentech, Inc. | Anti-alpha-synuclein antibodies and methods of use |
WO2016073282A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
WO2016073378A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
WO2016077369A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Animal model for nephropathy and agents for treating the same |
WO2016077381A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2016081640A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
WO2016081639A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
WO2016081643A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
WO2016081384A1 (en) | 2014-11-17 | 2016-05-26 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
WO2016090040A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
WO2016090210A1 (en) | 2014-12-05 | 2016-06-09 | Genentech, Inc. | ANTI-CD79b ANTIBODIES AND METHODS OF USE |
WO2016090038A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
WO2016094566A2 (en) | 2014-12-10 | 2016-06-16 | Genentech, Inc. | Blood brain barrier receptor antibodies and methods of use |
WO2016098356A1 (en) | 2014-12-19 | 2016-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
WO2016115559A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
WO2016117346A1 (en) | 2015-01-22 | 2016-07-28 | Chugai Seiyaku Kabushiki Kaisha | A combination of two or more anti-c5 antibodies and methods of use |
WO2016126972A1 (en) | 2015-02-04 | 2016-08-11 | Genentech, Inc. | Mutant smoothened and methods of using the same |
WO2016138160A1 (en) | 2015-02-24 | 2016-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
WO2016149276A1 (en) | 2015-03-16 | 2016-09-22 | Genentech, Inc. | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
WO2016154177A2 (en) | 2015-03-23 | 2016-09-29 | Jounce Therapeutics, Inc. | Antibodies to icos |
WO2016154003A1 (en) | 2015-03-20 | 2016-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to gp120 and their use |
WO2016172551A2 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Methods of identifying bacteria comprising binding polypeptides |
WO2016179003A1 (en) | 2015-05-01 | 2016-11-10 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
WO2016179194A1 (en) | 2015-05-04 | 2016-11-10 | Jounce Therapeutics, Inc. | Lilra3 and method of using the same |
EP3095463A2 (en) | 2008-09-16 | 2016-11-23 | F. Hoffmann-La Roche AG | Methods for treating progressive multiple sclerosis |
EP3098240A2 (en) | 2010-06-18 | 2016-11-30 | F. Hoffmann-La Roche AG | Anti-axl antibodies and methods of use |
WO2016196975A1 (en) | 2015-06-03 | 2016-12-08 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2016196726A1 (en) | 2015-06-05 | 2016-12-08 | Genentech, Inc. | Anti-tau antibodies and methods of use |
WO2016196679A1 (en) | 2015-06-02 | 2016-12-08 | Genentech, Inc. | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
WO2016196343A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Humanized anti-ebola virus glycoprotein antibodies and methods of use |
WO2016196298A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Therapeutic and diagnolstic methods for cancer |
WO2016196381A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Pd-l1 promoter methylation in cancer |
WO2016200835A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
WO2016200836A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies |
WO2016205320A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
WO2016205531A2 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Anti-her2 antibodies and methods of use |
WO2016205200A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cll-1 antibodies and methods of use |
WO2016205520A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Humanized and affinity matured antibodies to fcrh5 and methods of use |
WO2016205176A1 (en) | 2015-06-15 | 2016-12-22 | Genentech, Inc. | Antibodies and immunoconjugates |
WO2017004091A1 (en) | 2015-06-29 | 2017-01-05 | Genentech, Inc. | Type ii anti-cd20 antibody for use in organ transplantation |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
EP3130349A1 (en) | 2004-06-04 | 2017-02-15 | Genentech, Inc. | Method for treating multiple sclerosis |
US9580506B2 (en) | 2005-07-21 | 2017-02-28 | Genmab A/S | Potency assays for antibody drug substance binding to an Fc receptor |
WO2017040342A1 (en) | 2015-08-28 | 2017-03-09 | Genentech, Inc. | Anti-hypusine antibodies and uses thereof |
WO2017050729A1 (en) | 2015-09-22 | 2017-03-30 | Spring Bioscience Corporation | Anti-ox40 antibodies and diagnostic uses thereof |
WO2017053807A2 (en) | 2015-09-23 | 2017-03-30 | Genentech, Inc. | Optimized variants of anti-vegf antibodies |
WO2017053906A1 (en) | 2015-09-24 | 2017-03-30 | Abvitro Llc | Hiv antibody compositions and methods of use |
EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
WO2017055540A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use |
WO2017059289A1 (en) | 2015-10-02 | 2017-04-06 | Genentech, Inc. | Pyrrolobenzodiazepine antibody drug conjugates and methods of use |
WO2017055542A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
WO2017062748A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
WO2017062682A2 (en) | 2015-10-06 | 2017-04-13 | Genentech, Inc. | Method for treating multiple sclerosis |
WO2017070423A1 (en) | 2015-10-22 | 2017-04-27 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
WO2017072210A1 (en) | 2015-10-29 | 2017-05-04 | F. Hoffmann-La Roche Ag | Anti-variant fc-region antibodies and methods of use |
WO2017075173A2 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
WO2017079768A1 (en) | 2015-11-08 | 2017-05-11 | Genentech, Inc. | Methods of screening for multispecific antibodies |
WO2017079479A1 (en) | 2015-11-03 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Neutralizing antibodies to hiv-1 gp41 and their use |
WO2017091580A1 (en) | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
US9684000B2 (en) | 2010-12-16 | 2017-06-20 | Genentech, Inc. | Diagnosis and treatments relating to TH2 inhibition |
WO2017104779A1 (en) | 2015-12-18 | 2017-06-22 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
WO2017127764A1 (en) | 2016-01-20 | 2017-07-27 | Genentech, Inc. | High dose treatments for alzheimer's disease |
WO2017136558A1 (en) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened and methods of using the same |
WO2017151502A1 (en) | 2016-02-29 | 2017-09-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
WO2017159699A1 (en) | 2016-03-15 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
WO2017165734A1 (en) | 2016-03-25 | 2017-09-28 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
WO2017180864A1 (en) | 2016-04-14 | 2017-10-19 | Genentech, Inc. | Anti-rspo3 antibodies and methods of use |
WO2017181111A2 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
WO2017181079A2 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
WO2017191101A1 (en) | 2016-05-02 | 2017-11-09 | F. Hoffmann-La Roche Ag | The contorsbody - a single chain target binder |
WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
WO2017197234A1 (en) | 2016-05-13 | 2017-11-16 | Bioatla, Llc | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
WO2017194441A1 (en) | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | Modified anti-tenascin antibodies and methods of use |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
WO2017223405A1 (en) | 2016-06-24 | 2017-12-28 | Genentech, Inc. | Anti-polyubiquitin multispecific antibodies |
WO2018023100A2 (en) | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies and related methods |
WO2018021450A1 (ja) | 2016-07-29 | 2018-02-01 | 中外製薬株式会社 | 増強されたfviii補因子機能代替活性を有する二重特異性抗体 |
WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
WO2018045379A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
WO2018049083A1 (en) | 2016-09-07 | 2018-03-15 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
WO2018050878A1 (en) | 2016-09-19 | 2018-03-22 | F. Hoffmann-La Roche Ag | Complement factor based affinity chromatography |
WO2018057849A1 (en) | 2016-09-23 | 2018-03-29 | Genentech, Inc. | Uses of il-13 antagonists for treating atopic dermatitis |
WO2018067618A1 (en) | 2016-10-03 | 2018-04-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
WO2018068028A1 (en) | 2016-10-06 | 2018-04-12 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
WO2018065501A1 (en) | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Methods for preparing antibody drug conjugates |
WO2018081648A2 (en) | 2016-10-29 | 2018-05-03 | Genentech, Inc. | Anti-mic antibidies and methods of use |
WO2018085358A1 (en) | 2016-11-02 | 2018-05-11 | Jounce Therapeutics, Inc. | Antibodies to pd-1 and uses thereof |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
WO2018091724A1 (en) | 2016-11-21 | 2018-05-24 | Cureab Gmbh | Anti-gp73 antibodies and immunoconjugates |
WO2018106776A2 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
WO2018106781A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc | Anti-tau antibodies and methods of use |
WO2018111890A1 (en) | 2016-12-12 | 2018-06-21 | Genentech, Inc. | Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens |
WO2018119171A1 (en) | 2016-12-23 | 2018-06-28 | Potenza Therapeutics, Inc. | Anti-neuropilin antigen-binding proteins and methods of use thereof |
US10011658B2 (en) | 2015-04-03 | 2018-07-03 | Eureka Therapeutics, Inc. | Constructs targeting AFP peptide/MHC complexes and uses thereof |
WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
EP3360567A1 (en) | 2007-11-07 | 2018-08-15 | Genentech, Inc. | Amp for use in treating microbial disorders |
WO2018148585A1 (en) | 2017-02-10 | 2018-08-16 | Genentech, Inc. | Anti-tryptase antibodies, compositions thereof, and uses thereof |
WO2018148660A1 (en) | 2017-02-10 | 2018-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
US10059768B2 (en) | 2014-09-12 | 2018-08-28 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
WO2018160841A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2018175752A1 (en) | 2017-03-22 | 2018-09-27 | Genentech, Inc. | Optimized antibody compositions for treatment of ocular disorders |
WO2018183889A1 (en) | 2017-03-30 | 2018-10-04 | Potenza Therapeutics, Inc. | Anti-tigit antigen-binding proteins and methods of use thereof |
WO2018183175A1 (en) | 2017-03-28 | 2018-10-04 | Genentech, Inc. | Methods of treating neurodegenerative diseases |
WO2018186063A1 (ja) * | 2017-04-04 | 2018-10-11 | 住友ベークライト株式会社 | 糖鎖を調製する方法 |
WO2018191660A1 (en) | 2017-04-14 | 2018-10-18 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2018195472A1 (en) | 2017-04-21 | 2018-10-25 | Genentech, Inc. | Use of klk5 antagonists for treatment of a disease |
WO2018201096A1 (en) | 2017-04-27 | 2018-11-01 | Tesaro, Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
WO2018213304A1 (en) | 2017-05-16 | 2018-11-22 | Five Prime Therapeutics, Inc. | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
WO2018220099A1 (en) | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
US10174124B2 (en) | 2013-12-17 | 2019-01-08 | Genentech, Inc. | Anti-CD3 antibodies and methods of use |
EP3428190A1 (en) | 2014-02-12 | 2019-01-16 | F. Hoffmann-La Roche AG | Anti-jagged1 antibodies and methods of use |
WO2019018757A1 (en) | 2017-07-21 | 2019-01-24 | Genentech, Inc. | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER |
WO2019023347A1 (en) | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS |
US10208120B2 (en) | 2014-11-05 | 2019-02-19 | Genentech, Inc. | Anti-FGFR2/3 antibodies and methods using same |
WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT |
WO2019070541A1 (en) | 2017-10-03 | 2019-04-11 | Juno Therapeutics, Inc. | HPV-SPECIFIC BINDING MOLECULES |
WO2019089969A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
WO2019090263A1 (en) | 2017-11-06 | 2019-05-09 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2019108639A1 (en) | 2017-12-01 | 2019-06-06 | Pfizer Inc. | Anti-cxcr5 antibodies and compositions and uses thereof |
WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
WO2019126472A1 (en) | 2017-12-22 | 2019-06-27 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
WO2019126514A2 (en) | 2017-12-22 | 2019-06-27 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
WO2019129211A1 (en) | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against pd-l1 |
WO2019136029A1 (en) | 2018-01-02 | 2019-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
WO2019134981A1 (en) | 2018-01-05 | 2019-07-11 | Ac Immune Sa | Misfolded tdp-43 binding molecules |
EP3514174A1 (en) | 2015-06-29 | 2019-07-24 | Ventana Medical Systems, Inc. | Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin |
WO2019143636A1 (en) | 2018-01-16 | 2019-07-25 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
WO2019148026A1 (en) | 2018-01-26 | 2019-08-01 | Genentech, Inc. | Il-22 fc fusion proteins and methods of use |
WO2019148020A1 (en) | 2018-01-26 | 2019-08-01 | Genentech, Inc. | Compositions and methods of use |
WO2019149269A1 (zh) | 2018-02-01 | 2019-08-08 | 信达生物制药(苏州)有限公司 | 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用 |
EP3524620A1 (en) | 2008-10-14 | 2019-08-14 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
WO2019157358A1 (en) | 2018-02-09 | 2019-08-15 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
WO2019157308A1 (en) | 2018-02-08 | 2019-08-15 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
WO2019158645A1 (en) | 2018-02-14 | 2019-08-22 | Abba Therapeutics Ag | Anti-human pd-l2 antibodies |
WO2019165434A1 (en) | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2019165140A1 (en) | 2018-02-21 | 2019-08-29 | Genentech, Inc. | DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS |
WO2019165122A1 (en) | 2018-02-21 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2019178316A1 (en) | 2018-03-14 | 2019-09-19 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
WO2019195514A1 (en) | 2018-04-04 | 2019-10-10 | Genentech, Inc. | Methods for detecting and quantifying fgf21 |
WO2019195486A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
US10450379B2 (en) | 2005-11-15 | 2019-10-22 | Genetech, Inc. | Method for treating joint damage |
US10472412B2 (en) | 2015-03-25 | 2019-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
WO2019235426A1 (ja) | 2018-06-04 | 2019-12-12 | 中外製薬株式会社 | 細胞質内での半減期が変化した抗原結合分子 |
WO2019234576A1 (en) | 2018-06-03 | 2019-12-12 | Lamkap Bio Beta Ltd. | Bispecific antibodies against ceacam5 and cd47 |
WO2019246557A1 (en) | 2018-06-23 | 2019-12-26 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
EP3594240A1 (en) | 2013-05-20 | 2020-01-15 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
WO2020018789A1 (en) | 2018-07-18 | 2020-01-23 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
WO2020027330A1 (ja) | 2018-08-03 | 2020-02-06 | 中外製薬株式会社 | 互いに連結された2つの抗原結合ドメインを含む抗原結合分子 |
EP3608674A1 (en) | 2018-08-09 | 2020-02-12 | Regeneron Pharmaceuticals, Inc. | Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor |
WO2020032230A1 (ja) | 2018-08-10 | 2020-02-13 | 中外製薬株式会社 | 抗cd137抗原結合分子およびその使用 |
EP3611188A1 (en) | 2014-11-06 | 2020-02-19 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn-binding and methods of use |
WO2020037154A1 (en) | 2018-08-17 | 2020-02-20 | 23Andme, Inc. | Anti-il1rap antibodies and methods of use thereof |
EP3620470A1 (en) | 2013-10-11 | 2020-03-11 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Tem8 antibodies and their use |
WO2020049286A1 (en) | 2018-09-03 | 2020-03-12 | Femtogenix Limited | Polycyclic amides as cytotoxic agents |
WO2020061349A1 (en) | 2018-09-21 | 2020-03-26 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
WO2020061060A1 (en) | 2018-09-19 | 2020-03-26 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
US10604561B2 (en) | 2016-09-16 | 2020-03-31 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
US10611825B2 (en) | 2011-02-28 | 2020-04-07 | Hoffmann La-Roche Inc. | Monovalent antigen binding proteins |
WO2020072896A1 (en) | 2018-10-05 | 2020-04-09 | Five Prime Therapeutics, Inc. | Anti-fgfr2 antibody formulations |
US10626176B2 (en) | 2014-10-31 | 2020-04-21 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind B7-H4 |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
WO2020081767A1 (en) | 2018-10-18 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
US10633457B2 (en) | 2014-12-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Multispecific antibodies |
US10640555B2 (en) | 2009-06-16 | 2020-05-05 | Hoffmann-La Roche Inc. | Bispecific antigen binding proteins |
WO2020102555A1 (en) | 2018-11-16 | 2020-05-22 | Memorial Sloan Kettering Cancer Center | Antibodies to mucin-16 and methods of use thereof |
WO2020117952A2 (en) | 2018-12-05 | 2020-06-11 | Genentech, Inc. | Diagnostic methods and compositions for cancer immunotherapy |
WO2020117257A1 (en) | 2018-12-06 | 2020-06-11 | Genentech, Inc. | Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
WO2020132230A2 (en) | 2018-12-20 | 2020-06-25 | Genentech, Inc. | Modified antibody fcs and methods of use |
WO2020132034A1 (en) | 2018-12-20 | 2020-06-25 | 23Andme, Inc. | Anti-cd96 antibodies and methods of use thereof |
WO2020132220A1 (en) | 2018-12-21 | 2020-06-25 | 23Andme, Inc. | Anti-il-36 antibodies and methods of use thereof |
WO2020132214A2 (en) | 2018-12-20 | 2020-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
WO2020139926A2 (en) | 2018-12-26 | 2020-07-02 | Akrevia Therapeutics Inc. | Anti-ctla4 antibodies and methods of use thereof |
WO2020141145A1 (en) | 2018-12-30 | 2020-07-09 | F. Hoffmann-La Roche Ag | Anti-rabbit cd19 antibodies and methods of use |
WO2020150152A1 (en) | 2019-01-14 | 2020-07-23 | Genentech, Inc. | Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine |
WO2020153467A1 (ja) | 2019-01-24 | 2020-07-30 | 中外製薬株式会社 | 新規がん抗原及びそれらの抗原に対する抗体 |
EP3689910A2 (en) | 2014-09-23 | 2020-08-05 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
WO2020157491A1 (en) | 2019-01-29 | 2020-08-06 | Femtogenix Limited | G-a crosslinking cytotoxic agents |
WO2020160050A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
WO2020176748A1 (en) | 2019-02-27 | 2020-09-03 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies |
US10767232B2 (en) | 2014-11-03 | 2020-09-08 | Genentech, Inc. | Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment |
US10774145B2 (en) | 2015-06-17 | 2020-09-15 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
WO2020185535A1 (en) | 2019-03-08 | 2020-09-17 | Genentech, Inc. | Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles |
WO2020186176A1 (en) | 2019-03-14 | 2020-09-17 | Genentech, Inc. | Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab |
US10793621B2 (en) | 2011-02-28 | 2020-10-06 | Hoffmann-La Roche Inc. | Nucleic acid encoding dual Fc antigen binding proteins |
WO2020214995A1 (en) | 2019-04-19 | 2020-10-22 | Genentech, Inc. | Anti-mertk antibodies and their methods of use |
WO2020213724A1 (ja) | 2019-04-19 | 2020-10-22 | 中外製薬株式会社 | 抗体改変部位認識キメラ受容体 |
WO2020227228A2 (en) | 2019-05-03 | 2020-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
WO2020226986A2 (en) | 2019-05-03 | 2020-11-12 | Genentech, Inc. | Methods of treating cancer with an anti-pd-l1 antibody |
WO2020232169A1 (en) | 2019-05-14 | 2020-11-19 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma |
WO2020236974A1 (en) | 2019-05-21 | 2020-11-26 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
WO2020234473A1 (en) | 2019-05-23 | 2020-11-26 | Ac Immune Sa | Anti-tdp-43 binding molecules and uses thereof |
US10851150B2 (en) | 2005-12-20 | 2020-12-01 | Bristol-Myers Squibb Company | Carbohydrate content of CTLA4 molecules |
WO2021003297A1 (en) | 2019-07-02 | 2021-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind egfrviii and their use |
WO2021010326A1 (ja) | 2019-07-12 | 2021-01-21 | 中外製薬株式会社 | 抗変異型fgfr3抗体およびその使用 |
WO2021024209A1 (en) | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Inc. | Antibodies that bind to pathological tau species and uses thereof |
EP3783029A1 (en) | 2015-05-12 | 2021-02-24 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
EP3782654A1 (en) | 2014-09-12 | 2021-02-24 | Genentech, Inc. | Anti-her2 antibodies and immunoconjugates |
EP3789402A1 (en) | 2014-11-20 | 2021-03-10 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
WO2021050645A1 (en) | 2019-09-12 | 2021-03-18 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
WO2021055694A1 (en) | 2019-09-20 | 2021-03-25 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
WO2021062085A1 (en) | 2019-09-27 | 2021-04-01 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021076196A1 (en) | 2019-10-18 | 2021-04-22 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
WO2021092171A1 (en) | 2019-11-06 | 2021-05-14 | Genentech, Inc. | Diagnostic and therapeutic methods for treatment of hematologic cancers |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
WO2021113776A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods |
WO2021113780A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods |
WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
EP3842453A1 (en) | 2014-11-06 | 2021-06-30 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and protein a-binding properties |
WO2021129872A1 (zh) | 2019-12-27 | 2021-07-01 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
WO2021131021A1 (ja) | 2019-12-27 | 2021-07-01 | 中外製薬株式会社 | 抗ctla-4抗体およびその使用 |
US11053294B2 (en) | 2018-09-27 | 2021-07-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
WO2021139777A1 (zh) | 2020-01-10 | 2021-07-15 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
WO2021155149A1 (en) | 2020-01-31 | 2021-08-05 | Genentech, Inc. | Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine |
WO2021155295A1 (en) | 2020-01-31 | 2021-08-05 | The Cleveland Clinic Foundation | Anti-müllerian hormone receptor 2 antibodies and methods of use |
EP3862365A1 (en) | 2016-01-08 | 2021-08-11 | F. Hoffmann-La Roche AG | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
WO2021162020A1 (ja) | 2020-02-12 | 2021-08-19 | 中外製薬株式会社 | 癌の治療に用いるための抗cd137抗原結合分子 |
WO2021168292A1 (en) | 2020-02-20 | 2021-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Epstein-barr virus monoclonal antibodies and uses thereof |
WO2021170067A1 (zh) | 2020-02-28 | 2021-09-02 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体及其用途 |
WO2021170071A1 (en) | 2020-02-28 | 2021-09-02 | Shanghai Henlius Biotech, Inc. | Anti-cd137 constructs, multispecific antibody and uses thereof |
EP3875481A1 (en) | 2014-11-14 | 2021-09-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
US11116835B2 (en) | 2017-05-10 | 2021-09-14 | Fred Hutchinson Cancer Research Center | Epstein Barr virus antibodies, vaccines, and uses of the same |
EP3878866A1 (en) | 2013-04-29 | 2021-09-15 | F. Hoffmann-La Roche AG | Fc-receptor binding modified asymmetric antibodies and methods of use |
WO2021183849A1 (en) | 2020-03-13 | 2021-09-16 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2021188749A1 (en) | 2020-03-19 | 2021-09-23 | Genentech, Inc. | Isoform-selective anti-tgf-beta antibodies and methods of use |
WO2021194913A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Tie2-binding agents and methods of use |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021202959A1 (en) | 2020-04-03 | 2021-10-07 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
US11149088B2 (en) | 2016-04-15 | 2021-10-19 | Bioatla, Inc. | Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
EP3896091A1 (en) | 2015-08-11 | 2021-10-20 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
WO2021217051A1 (en) | 2020-04-24 | 2021-10-28 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
WO2021222167A1 (en) | 2020-04-28 | 2021-11-04 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
WO2021222181A2 (en) | 2020-04-27 | 2021-11-04 | The Regents Of The University Of California | Isoform-independent antibodies to lipoprotein(a) |
WO2021225892A1 (en) | 2020-05-03 | 2021-11-11 | Levena (Suzhou) Biopharma Co., Ltd. | Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same |
US11180548B2 (en) | 2015-02-05 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Methods of neutralizing IL-8 biological activity |
WO2021238886A1 (en) | 2020-05-27 | 2021-12-02 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing nerve growth factor and uses thereof |
WO2021243204A1 (en) | 2020-05-29 | 2021-12-02 | 23Andme, Inc. | Anti-cd200r1 antibodies and methods of use thereof |
WO2021247769A1 (en) | 2020-06-02 | 2021-12-09 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
EP3922649A1 (en) | 2015-10-30 | 2021-12-15 | F. Hoffmann-La Roche AG | Anti-htra1 antibodies and methods of use thereof |
WO2021252977A1 (en) | 2020-06-12 | 2021-12-16 | Genentech, Inc. | Methods and compositions for cancer immunotherapy |
US11203638B2 (en) | 2017-05-05 | 2021-12-21 | Allakos Inc. | Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis |
WO2021257503A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
WO2021257124A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
WO2021259880A1 (en) | 2020-06-22 | 2021-12-30 | Almirall, S.A. | Anti-il-36 antibodies and methods of use thereof |
US11214619B2 (en) | 2018-07-20 | 2022-01-04 | Surface Oncology, Inc. | Anti-CD112R compositions and methods |
EP3936524A2 (en) | 2015-05-11 | 2022-01-12 | F. Hoffmann-La Roche AG | Compositions and methods of treating lupus nephritis |
WO2022023735A1 (en) | 2020-07-28 | 2022-02-03 | Femtogenix Limited | Cytotoxic agents |
WO2022026763A1 (en) | 2020-07-29 | 2022-02-03 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
WO2022031749A1 (en) | 2020-08-03 | 2022-02-10 | Genentech, Inc. | Diagnostic and therapeutic methods for lymphoma |
WO2022029660A1 (en) | 2020-08-05 | 2022-02-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods |
WO2022031876A1 (en) | 2020-08-07 | 2022-02-10 | Genentech, Inc. | Flt3 ligand fusion proteins and methods of use |
WO2022034228A1 (en) | 2020-08-14 | 2022-02-17 | Ac Immune Sa | Humanized anti-tdp-43 binding molecules and uses thereof |
WO2022043517A2 (en) | 2020-08-27 | 2022-03-03 | Cureab Gmbh | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2022053715A1 (en) | 2020-09-14 | 2022-03-17 | Ichnos Sciences SA | Antibodies that bind to il1rap and uses thereof |
WO2022067262A1 (en) | 2020-09-28 | 2022-03-31 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
WO2022076462A1 (en) | 2020-10-05 | 2022-04-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2022084400A1 (en) | 2020-10-20 | 2022-04-28 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof |
WO2022084210A1 (en) | 2020-10-20 | 2022-04-28 | F. Hoffmann-La Roche Ag | Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors |
WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
WO2022098648A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
WO2022098628A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
WO2022098638A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
US11332533B2 (en) | 2007-09-26 | 2022-05-17 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
US11352403B2 (en) | 2018-05-14 | 2022-06-07 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
WO2022123307A1 (en) | 2020-12-09 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
WO2022123316A1 (en) | 2020-12-09 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
WO2022140797A1 (en) | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines and uses thereof |
EP4026848A1 (en) | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
WO2022162201A1 (en) | 2021-01-28 | 2022-08-04 | Vaccinvent Gmbh | Method and means for modulating b-cell mediated immune responses |
WO2022162203A1 (en) | 2021-01-28 | 2022-08-04 | Vaccinvent Gmbh | Method and means for modulating b-cell mediated immune responses |
WO2022173689A1 (en) | 2021-02-09 | 2022-08-18 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
WO2022173670A1 (en) | 2021-02-09 | 2022-08-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies targeting the spike protein of coronaviruses |
WO2022172085A2 (en) | 2021-02-15 | 2022-08-18 | Takeda Pharmaceutical Company Limited | Cell therapy compositions and methods for modulating tgf-b signaling |
WO2022187272A1 (en) | 2021-03-01 | 2022-09-09 | Xilio Development, Inc. | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
WO2022184082A1 (en) | 2021-03-03 | 2022-09-09 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates comprising an anti-bcma antibody |
WO2022187863A1 (en) | 2021-03-05 | 2022-09-09 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
WO2022187270A1 (en) | 2021-03-01 | 2022-09-09 | Xilio Development, Inc. | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
WO2022192898A2 (en) | 2021-03-10 | 2022-09-15 | Immunowake Inc. | Immunomodulatory molecules and uses thereof |
US11447573B2 (en) | 2016-07-20 | 2022-09-20 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
US11447564B2 (en) | 2017-04-26 | 2022-09-20 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
WO2022198192A1 (en) | 2021-03-15 | 2022-09-22 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
US11453710B2 (en) | 2018-05-14 | 2022-09-27 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
WO2022204724A1 (en) | 2021-03-25 | 2022-09-29 | Dynamicure Biotechnology Llc | Anti-igfbp7 constructs and uses thereof |
US11472881B2 (en) | 2016-10-11 | 2022-10-18 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against CTLA-4 |
WO2022220275A1 (ja) | 2021-04-15 | 2022-10-20 | 中外製薬株式会社 | 抗C1s抗体 |
WO2022223651A1 (en) | 2021-04-23 | 2022-10-27 | F. Hoffmann-La Roche Ag | Prevention or mitigation of nk cell engaging agent-related adverse effects |
US11485782B2 (en) | 2018-03-14 | 2022-11-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
WO2022241082A1 (en) | 2021-05-14 | 2022-11-17 | Genentech, Inc. | Agonists of trem2 |
WO2022241446A1 (en) | 2021-05-12 | 2022-11-17 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
WO2022258600A1 (en) | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
WO2022266660A1 (en) | 2021-06-17 | 2022-12-22 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
WO2022270612A1 (ja) | 2021-06-25 | 2022-12-29 | 中外製薬株式会社 | 抗ctla-4抗体の使用 |
WO2022270611A1 (ja) | 2021-06-25 | 2022-12-29 | 中外製薬株式会社 | 抗ctla-4抗体 |
WO2023283611A1 (en) | 2021-07-08 | 2023-01-12 | Staidson Biopharma Inc. | Antibodies specifically recognizing tnfr2 and uses thereof |
WO2023284714A1 (zh) | 2021-07-14 | 2023-01-19 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
WO2023004386A1 (en) | 2021-07-22 | 2023-01-26 | Genentech, Inc. | Brain targeting compositions and methods of use thereof |
US11578372B2 (en) | 2012-11-05 | 2023-02-14 | Foundation Medicine, Inc. | NTRK1 fusion molecules and uses thereof |
WO2023016826A2 (en) | 2021-08-05 | 2023-02-16 | Vaccinvent Gmbh | Method and means for enhancing therapeutic antibodies |
WO2023019239A1 (en) | 2021-08-13 | 2023-02-16 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
WO2023019092A1 (en) | 2021-08-07 | 2023-02-16 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
US11584927B2 (en) | 2014-08-28 | 2023-02-21 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified T-cells |
US11584793B2 (en) | 2015-06-24 | 2023-02-21 | Hoffmann-La Roche Inc. | Anti-transferrin receptor antibodies with tailored affinity |
WO2023021055A1 (en) | 2021-08-19 | 2023-02-23 | F. Hoffmann-La Roche Ag | Multivalent anti-variant fc-region antibodies and methods of use |
WO2023028591A1 (en) | 2021-08-27 | 2023-03-02 | Genentech, Inc. | Methods of treating tau pathologies |
WO2023034750A1 (en) | 2021-08-30 | 2023-03-09 | Genentech, Inc. | Anti-polyubiquitin multispecific antibodies |
WO2023044272A1 (en) | 2021-09-17 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
EP4155321A1 (en) | 2021-06-04 | 2023-03-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-ddr2 antibodies and uses thereof |
WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2023091887A1 (en) | 2021-11-16 | 2023-05-25 | Genentech, Inc. | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
WO2023088959A1 (en) | 2021-11-16 | 2023-05-25 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
US11673968B2 (en) | 2014-06-26 | 2023-06-13 | Hoffmann-La Roche Inc. | Anti-BRDU antibodies and methods of use |
WO2023131901A1 (en) | 2022-01-07 | 2023-07-13 | Johnson & Johnson Enterprise Innovation Inc. | Materials and methods of il-1beta binding proteins |
US11713353B2 (en) | 2018-01-15 | 2023-08-01 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against PD-1 |
EP4219555A1 (en) | 2013-12-23 | 2023-08-02 | F. Hoffmann-La Roche AG | Antibodies and methods of use |
WO2023154824A1 (en) | 2022-02-10 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that broadly target coronaviruses |
WO2023156549A1 (en) | 2022-02-16 | 2023-08-24 | Ac Immune Sa | Humanized anti-tdp-43 binding molecules and uses thereof |
WO2023159182A1 (en) | 2022-02-18 | 2023-08-24 | Rakuten Medical, Inc. | Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use |
US11739132B2 (en) | 2019-05-14 | 2023-08-29 | Werewolf Therapeutics, Inc. | Separation moieties and methods of use thereof |
WO2023173026A1 (en) | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
WO2023180353A1 (en) | 2022-03-23 | 2023-09-28 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
US11774452B2 (en) | 2021-11-05 | 2023-10-03 | American Diagnostics & Therapy, LLC | Antibodies against carcinoembryonic antigens |
US11771698B2 (en) | 2013-01-18 | 2023-10-03 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023192881A1 (en) | 2022-03-28 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2023192827A1 (en) | 2022-03-26 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific antibodies to hiv-1 env and their use |
WO2023194565A1 (en) | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
WO2023201299A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
US11795228B2 (en) | 2020-09-30 | 2023-10-24 | Dren Bio, Inc. | Anti-CD94 antibodies and methods of use thereof |
WO2023203177A1 (en) | 2022-04-20 | 2023-10-26 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
EP4268831A2 (en) | 2018-09-12 | 2023-11-01 | Fred Hutchinson Cancer Center | Reducing cd33 expression to selectively protect therapeutic cells |
WO2023215737A1 (en) | 2022-05-03 | 2023-11-09 | Genentech, Inc. | Anti-ly6e antibodies, immunoconjugates, and uses thereof |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
WO2023237706A2 (en) | 2022-06-08 | 2023-12-14 | Institute For Research In Biomedicine (Irb) | Cross-specific antibodies, uses and methods for discovery thereof |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020407A1 (en) | 2022-07-19 | 2024-01-25 | Staidson Biopharma Inc. | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
US11891432B2 (en) | 2018-03-15 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use |
WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
WO2024028731A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Transferrin receptor binding proteins for treating brain tumors |
WO2024028732A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
US11905327B2 (en) | 2017-12-28 | 2024-02-20 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against TIGIT |
WO2024037633A2 (en) | 2022-08-19 | 2024-02-22 | Evive Biotechnology (Shanghai) Ltd | Formulations comprising g-csf and uses thereof |
US11912754B2 (en) | 2017-10-12 | 2024-02-27 | Immunowake Inc. | VEGFR-antibody light chain fusion protein |
WO2024044779A2 (en) | 2022-08-26 | 2024-02-29 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
WO2024054929A1 (en) | 2022-09-07 | 2024-03-14 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
US11958903B2 (en) | 2018-03-30 | 2024-04-16 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
US11970539B2 (en) | 2020-09-14 | 2024-04-30 | Ichnos Sciences SA | Antibodies that bind to IL1RAP and uses thereof |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
AU2005227326B2 (en) | 2004-03-24 | 2009-12-03 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
PA8635501A1 (es) * | 2004-06-04 | 2006-06-02 | Genentech Inc | Uso de un anticuerpo para el tratamiento del lupus |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
DK2325207T3 (en) | 2004-11-12 | 2017-06-06 | Xencor Inc | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CA2624189A1 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
JP4860703B2 (ja) | 2005-10-06 | 2012-01-25 | ゼンコー・インコーポレイテッド | 最適化された抗cd30抗体 |
US7884264B2 (en) | 2006-01-17 | 2011-02-08 | Biolex Therapeutics, Inc. | Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in duckweed plants |
US20090060921A1 (en) * | 2006-01-17 | 2009-03-05 | Biolex Therapeutics, Inc. | Glycan-optimized anti-cd20 antibodies |
TW200817435A (en) * | 2006-06-06 | 2008-04-16 | Genentech Inc | Compositions and methods for modulating vascular development |
JP5622390B2 (ja) | 2006-07-18 | 2014-11-12 | サノフイ | 癌治療用対epha2アンタゴニスト抗体 |
ES2457072T3 (es) | 2006-08-14 | 2014-04-24 | Xencor, Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
CA2660795C (en) | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
PE20081250A1 (es) * | 2006-11-28 | 2008-10-07 | Centelion | FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA |
CN101679934B (zh) * | 2007-03-07 | 2014-04-02 | 格利科菲公司 | 具有经修饰的岩藻糖基化的糖蛋白的生产 |
EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
WO2008143878A1 (en) | 2007-05-14 | 2008-11-27 | Medimmune, Llc | Methods of reducing eosinophil levels |
JP5545814B2 (ja) * | 2007-06-18 | 2014-07-09 | 中外製薬株式会社 | 抗体依存性細胞障害活性を模擬する抗体の結合活性測定法 |
EP4098661A1 (en) | 2007-12-26 | 2022-12-07 | Xencor, Inc. | Fc variants with altered binding to fcrn |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
AR078470A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
WO2011108502A1 (ja) | 2010-03-02 | 2011-09-09 | 協和発酵キリン株式会社 | 改変抗体組成物 |
MX354359B (es) | 2011-03-29 | 2018-02-28 | Roche Glycart Ag | Variantes de fragmento cristalizable (fc) de los anticuerpos. |
EP2852610B1 (en) | 2012-05-23 | 2018-07-11 | Glykos Finland Oy | Production of fucosylated glycoproteins |
WO2014009465A1 (en) | 2012-07-13 | 2014-01-16 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
JP6273205B2 (ja) | 2012-10-05 | 2018-01-31 | 協和発酵キリン株式会社 | ヘテロダイマータンパク質組成物 |
US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
WO2014096015A1 (en) | 2012-12-21 | 2014-06-26 | F. Hoffmann-La Roche Ag | Disulfide-linked multivalent mhc class i comprising multi-function proteins |
WO2014159831A1 (en) | 2013-03-13 | 2014-10-02 | Merck Sharp & Dohme Corp. | Adapted lepidopteran insect cells for the production of recombinant proteins |
EP3460054B1 (en) | 2013-03-15 | 2020-10-21 | aTyr Pharma, Inc. | Histidyl-trna synthetase-fc conjugates |
EP3162895B1 (en) * | 2014-06-27 | 2020-11-25 | Tosoh Corporation | Improved fc-binding protein, method for producing said protein, antibody adsorbent using said protein, and method for separating antibody using said adsorbent |
US10513724B2 (en) | 2014-07-21 | 2019-12-24 | Glykos Finland Oy | Production of glycoproteins with mammalian-like N-glycans in filamentous fungi |
SG11201704351WA (en) | 2014-12-01 | 2017-06-29 | Amgen Inc | Process for manipulating the level of glycan content of a glycoprotein |
WO2018132597A1 (en) | 2017-01-12 | 2018-07-19 | Eureka Therapeutics, Inc. | Constructs targeting histone h3 peptide/mhc complexes and uses thereof |
JP7247101B2 (ja) | 2017-04-03 | 2023-03-28 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Steap-1に結合する抗体 |
PL3606954T3 (pl) | 2017-04-05 | 2022-10-17 | F. Hoffmann-La Roche Ag | Przeciwciała anty-LAG3 |
WO2018195338A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
CN111527107A (zh) | 2017-12-21 | 2020-08-11 | 豪夫迈·罗氏有限公司 | 结合hla-a2/wt1的抗体 |
EP3731864A1 (en) | 2017-12-29 | 2020-11-04 | F. Hoffmann-La Roche SA | Anti-vegf antibodies and methods of use |
TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
CN111936625A (zh) | 2018-03-29 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 调节哺乳动物细胞中的生乳活性 |
WO2019207159A1 (en) | 2018-04-27 | 2019-10-31 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
TW202028467A (zh) | 2018-09-28 | 2020-08-01 | 日商協和麒麟股份有限公司 | 抗體組合物 |
US11130804B2 (en) | 2018-12-21 | 2021-09-28 | Hoffmann-La Roche Inc. | Antibody that binds to VEGF and IL-1beta and methods of use |
PE20211603A1 (es) | 2018-12-21 | 2021-08-18 | Hoffmann La Roche | Anticuerpos que se unen a cd3 |
AR119382A1 (es) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
CR20220019A (es) | 2019-07-31 | 2022-02-11 | Hoffmann La Roche | Anticuerpos que se fijan a gprc5d |
JP2022543551A (ja) | 2019-07-31 | 2022-10-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Gprc5dに結合する抗体 |
PE20221906A1 (es) | 2019-09-18 | 2022-12-23 | Genentech Inc | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso |
US20210230278A1 (en) | 2019-12-18 | 2021-07-29 | Hoffmann-La Roche Inc. | Antibodies binding to HLA-A2/MAGE-A4 |
EP4127153A2 (en) | 2020-03-26 | 2023-02-08 | Genentech, Inc. | Modified mammalian cells having reduced host cell proteins |
WO2021201236A1 (ja) | 2020-04-01 | 2021-10-07 | 協和キリン株式会社 | 抗体組成物 |
AR122569A1 (es) | 2020-06-08 | 2022-09-21 | Hoffmann La Roche | Anticuerpos anti-vhb y métodos de uso |
TW202216766A (zh) | 2020-06-19 | 2022-05-01 | 瑞士商赫孚孟拉羅股份公司 | 與cd3結合之抗體 |
WO2021255143A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and folr1 |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
AU2021291011A1 (en) | 2020-06-19 | 2023-01-05 | F. Hoffmann-La Roche Ag | Antibodies binding to CD3 and CD19 |
JP2023533217A (ja) | 2020-06-24 | 2023-08-02 | ジェネンテック, インコーポレイテッド | アポトーシス耐性細胞株 |
MX2023000339A (es) | 2020-07-10 | 2023-02-09 | Hoffmann La Roche | Anticuerpos que se unen a celulas cancerosas y dirigen radionucleotidos a dichas celulas. |
PE20231300A1 (es) | 2020-07-17 | 2023-08-24 | Genentech Inc | Anticuerpos anti-notch2 y metodos de uso |
WO2022040375A1 (en) * | 2020-08-19 | 2022-02-24 | Energesis Pharmaceuticals, Inc. | Analogs of human fibroblast growth factors |
CA3192344A1 (en) | 2020-08-28 | 2022-03-03 | Genentech, Inc. | Crispr/cas9 multiplex knockout of host cell proteins |
KR20230061458A (ko) | 2020-09-04 | 2023-05-08 | 에프. 호프만-라 로슈 아게 | Vegf-a 및 ang2에 결합하는 항체 및 사용 방법 |
AR123855A1 (es) | 2020-10-20 | 2023-01-18 | Genentech Inc | Anticuerpos anti-mertk conjugados con peg y métodos de uso |
EP4277705A1 (en) | 2021-01-12 | 2023-11-22 | F. Hoffmann-La Roche AG | Split antibodies which bind to cancer cells and target radionuclides to said cells |
CA3204291A1 (en) | 2021-01-13 | 2022-07-21 | F. Hoffmann-La Roche Ag | Combination therapy |
WO2022169872A1 (en) | 2021-02-03 | 2022-08-11 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
WO2022192647A1 (en) | 2021-03-12 | 2022-09-15 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
JP2024514222A (ja) | 2021-04-19 | 2024-03-28 | ジェネンテック, インコーポレイテッド | 改変された哺乳動物細胞 |
WO2022246259A1 (en) | 2021-05-21 | 2022-11-24 | Genentech, Inc. | Modified cells for the production of a recombinant product of interest |
WO2023288182A1 (en) | 2021-07-12 | 2023-01-19 | Genentech, Inc. | Structures for reducing antibody-lipase binding |
IL309856A (en) | 2021-07-14 | 2024-02-01 | Genentech Inc | Antibodies anti-C-C motif receptor 8 (CCR8) and methods of use |
WO2023001884A1 (en) | 2021-07-22 | 2023-01-26 | F. Hoffmann-La Roche Ag | Heterodimeric fc domain antibodies |
CN117794953A (zh) | 2021-08-03 | 2024-03-29 | 豪夫迈·罗氏有限公司 | 双特异性抗体及使用方法 |
WO2023094569A1 (en) | 2021-11-26 | 2023-06-01 | F. Hoffmann-La Roche Ag | Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies |
AR127887A1 (es) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y plap |
TW202340251A (zh) | 2022-01-19 | 2023-10-16 | 美商建南德克公司 | 抗notch2抗體及結合物及其使用方法 |
WO2023217933A1 (en) | 2022-05-11 | 2023-11-16 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf-a and il6 and methods of use |
WO2024077239A1 (en) | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997027303A1 (fr) * | 1996-01-24 | 1997-07-31 | Toyo Boseki Kabushiki Kaisha | Alpha-1-6 fucosyltransferases |
WO2000061739A1 (en) * | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2002031140A1 (fr) * | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2340112T3 (es) * | 1998-04-20 | 2010-05-28 | Glycart Biotechnology Ag | Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos. |
US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
DE102006035254A1 (de) * | 2006-07-26 | 2008-01-31 | Francotyp-Postalia Gmbh | Verfahren und Anordnung zum Erzeugen eines Abdrucks |
-
2003
- 2003-04-09 US US10/409,611 patent/US20040259150A1/en not_active Abandoned
- 2003-04-09 JP JP2003582297A patent/JPWO2003085119A1/ja active Pending
- 2003-04-09 EP EP03723098A patent/EP1498491A4/en not_active Withdrawn
- 2003-04-09 CA CA002481658A patent/CA2481658A1/en not_active Abandoned
- 2003-04-09 AU AU2003236018A patent/AU2003236018A1/en not_active Abandoned
- 2003-04-09 WO PCT/JP2003/004504 patent/WO2003085119A1/ja not_active Application Discontinuation
-
2009
- 2009-08-28 US US12/550,160 patent/US8313913B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997027303A1 (fr) * | 1996-01-24 | 1997-07-31 | Toyo Boseki Kabushiki Kaisha | Alpha-1-6 fucosyltransferases |
WO2000061739A1 (en) * | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2002031140A1 (fr) * | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
Non-Patent Citations (9)
Cited By (758)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124078B2 (en) | 2000-04-12 | 2012-02-28 | Lfb Biotechnologies | Method for treating idiopathic thrombocytopenic purpura using monoclonal antibodies |
US7931895B2 (en) | 2000-04-12 | 2011-04-26 | Lfb Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US8685725B2 (en) | 2000-04-12 | 2014-04-01 | Labortoire Francais du Fractionnement et des Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US9708409B2 (en) | 2000-04-12 | 2017-07-18 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US7541029B2 (en) | 2000-04-12 | 2009-06-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anti-rhesus D monoclonal antibodies |
US8153124B2 (en) | 2000-04-12 | 2012-04-10 | Lfb Biotechnologies | Method for treating cancer using monoclonal antibodies |
US8178093B2 (en) | 2000-04-12 | 2012-05-15 | Lfb Biotechnologies | Method for treating infectious disease using monoclonal antibodies |
US7579170B2 (en) | 2000-04-12 | 2009-08-25 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for preparing monoclonal antibodies capable of activating effector cells expressing FCγRIII |
US9718890B2 (en) | 2000-04-12 | 2017-08-01 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US10081683B2 (en) | 2000-04-12 | 2018-09-25 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US9718889B2 (en) | 2000-04-12 | 2017-08-01 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US8409572B2 (en) | 2000-04-12 | 2013-04-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Monoclonal antibodies with enhanced ADCC function |
US8357370B2 (en) | 2000-04-12 | 2013-01-22 | Lfb Biotechnologies | Anti-D monoclonal antibodies |
EP1500400A4 (en) * | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
WO2005053742A1 (ja) * | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
JPWO2005053742A1 (ja) * | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
EP3130349A1 (en) | 2004-06-04 | 2017-02-15 | Genentech, Inc. | Method for treating multiple sclerosis |
US7919086B2 (en) | 2004-07-09 | 2011-04-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
US7871613B2 (en) | 2004-08-24 | 2011-01-18 | Chugai Seiyaku Kabushiki Kaisha | Adjuvant therapy with the use of anti-glypican 3 antibody |
WO2006041680A2 (en) | 2004-10-05 | 2006-04-20 | Genentech, Inc. | Method for treating vasculitis |
EP1816140A4 (en) * | 2004-10-26 | 2009-09-02 | Chugai Pharmaceutical Co Ltd | ANTI-GLYPICAN ANTIBODY 3 MODIFIED SWEET CHAIN |
AU2005297772B2 (en) * | 2004-10-26 | 2011-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
JP4794457B2 (ja) * | 2004-10-26 | 2011-10-19 | 中外製薬株式会社 | 糖鎖改変抗グリピカン3抗体 |
EP1816140A1 (en) * | 2004-10-26 | 2007-08-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
JPWO2006046751A1 (ja) * | 2004-10-26 | 2008-05-22 | 中外製薬株式会社 | 糖鎖改変抗グリピカン3抗体 |
US7867734B2 (en) | 2004-10-26 | 2011-01-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
US9957326B2 (en) | 2005-02-07 | 2018-05-01 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
EP3660049A1 (en) | 2005-02-07 | 2020-06-03 | Roche Glycart AG | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof |
EP2404937A1 (en) | 2005-02-07 | 2012-01-11 | GlycArt Biotechnology AG | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
US9309317B2 (en) | 2005-02-07 | 2016-04-12 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
EP2402374A1 (en) | 2005-02-07 | 2012-01-04 | GlycArt Biotechnology AG | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
US7846432B2 (en) | 2005-02-07 | 2010-12-07 | Glycart Biotechnology Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
US7722867B2 (en) | 2005-02-07 | 2010-05-25 | Glycart Biotechnology Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
US8614065B2 (en) | 2005-02-07 | 2013-12-24 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
US9580506B2 (en) | 2005-07-21 | 2017-02-28 | Genmab A/S | Potency assays for antibody drug substance binding to an Fc receptor |
US9102739B2 (en) | 2005-10-14 | 2015-08-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody |
US10118959B2 (en) | 2005-10-14 | 2018-11-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody |
US10654940B2 (en) | 2005-11-15 | 2020-05-19 | Genentech, Inc. | Method for treating joint damage |
US10450379B2 (en) | 2005-11-15 | 2019-10-22 | Genetech, Inc. | Method for treating joint damage |
EP2623516A2 (en) | 2005-12-02 | 2013-08-07 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R |
EP3006466A2 (en) | 2005-12-02 | 2016-04-13 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
US10851150B2 (en) | 2005-12-20 | 2020-12-01 | Bristol-Myers Squibb Company | Carbohydrate content of CTLA4 molecules |
JP2010116402A (ja) * | 2005-12-20 | 2010-05-27 | Bristol Myers Squibb Co | 組成物および組成物の製造方法 |
US10808021B2 (en) | 2005-12-20 | 2020-10-20 | Bristol-Myers Squibb Company | Compositions and methods for producing a composition |
US10941189B2 (en) | 2005-12-20 | 2021-03-09 | Bristol-Myers Squibb Company | Carbohydrate content of CTLA4 molecules |
JP2009520503A (ja) * | 2005-12-20 | 2009-05-28 | ブリストル−マイヤーズ スクイブ カンパニー | 組成物および組成物の製造方法 |
US10508144B2 (en) | 2005-12-20 | 2019-12-17 | Bristol-Myers Squibb Company | Carbohydrate content of CTLA4 molecules |
EP3156418A1 (en) | 2006-01-05 | 2017-04-19 | Genentech, Inc. | Anti-ephb4 antibodies and methods using same |
EP2402373A2 (en) | 2006-01-05 | 2012-01-04 | Genentech, Inc. | Anti-EphB4 Antibodies and Methods Using Same |
EP2468772A2 (en) | 2006-03-16 | 2012-06-27 | Genentech, Inc. | Antibodies to EGFL7 and methods for their use |
EP2446904A2 (en) | 2006-05-30 | 2012-05-02 | Genentech, Inc. | Anti-CD22 antibodies, their immunoconjugates and uses thereof |
EP2447282A2 (en) | 2006-05-30 | 2012-05-02 | Genentech, Inc. | Anti-CD22 Antibodies, their Immunoconjugates and uses thereof |
US7803377B2 (en) | 2006-06-06 | 2010-09-28 | Genentech, Inc. | Anti-DLL4 antibodies and methods using same |
WO2008011081A2 (en) | 2006-07-19 | 2008-01-24 | The Trustees Of The University Of Pennsylvania | Wsx-1/p28 as a target for anti-inflammatory responses |
US9074008B2 (en) | 2006-08-09 | 2015-07-07 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
US7727741B2 (en) | 2006-08-09 | 2010-06-01 | Glycart Biotechnology Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
US7662377B2 (en) | 2006-08-09 | 2010-02-16 | Glycart Biotechnology Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
US8273328B2 (en) | 2006-08-09 | 2012-09-25 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
US8088380B2 (en) | 2006-08-09 | 2012-01-03 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
EP2444422A2 (en) | 2006-08-09 | 2012-04-25 | GlycArt Biotechnology AG | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
WO2008032833A1 (fr) | 2006-09-14 | 2008-03-20 | Medical & Biological Laboratories Co., Ltd. | Anticorps présentant une activité adcc accrue et son procédé de production |
US8216807B2 (en) | 2006-10-12 | 2012-07-10 | Genentech, Inc. | Antibodies to lymphotoxin-α |
US8642740B2 (en) | 2006-10-12 | 2014-02-04 | Genentech, Inc. | Antibodies to lymphotoxin-alpha |
US8541552B2 (en) | 2006-10-12 | 2013-09-24 | Genetech, Inc. | Antibodies to lymphotoxin-α |
EP2845866A1 (en) | 2006-10-27 | 2015-03-11 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
EP2468776A2 (en) | 2007-02-09 | 2012-06-27 | Genentech, Inc. | Anti-Robo4 antibodies and uses therefor |
US11332533B2 (en) | 2007-09-26 | 2022-05-17 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
EP3360567A1 (en) | 2007-11-07 | 2018-08-15 | Genentech, Inc. | Amp for use in treating microbial disorders |
EP2851372A1 (en) | 2007-11-30 | 2015-03-25 | Genentech, Inc. | Anti-VEGF antibodies |
EP3173425A1 (en) | 2007-11-30 | 2017-05-31 | Genentech, Inc. | Anti-vegf antibodies |
US9683047B2 (en) | 2008-09-16 | 2017-06-20 | Genentech, Inc. | Methods for treating progressive multiple sclerosis |
EP3747464A1 (en) | 2008-09-16 | 2020-12-09 | F. Hoffmann-La Roche AG | Methods for treating progessive multiple sclerosis using an anti-cd20 antibody |
US9994642B2 (en) | 2008-09-16 | 2018-06-12 | Genentech, Inc. | Methods for treating progressive multiple sclerosis |
EP3095463A2 (en) | 2008-09-16 | 2016-11-23 | F. Hoffmann-La Roche AG | Methods for treating progressive multiple sclerosis |
EP3524620A1 (en) | 2008-10-14 | 2019-08-14 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
EP3318573A1 (en) | 2008-12-23 | 2018-05-09 | F. Hoffmann-La Roche AG | Mmunoglobulin variants with altered binding to protein a |
WO2010075548A2 (en) | 2008-12-23 | 2010-07-01 | Genentech, Inc. | Immunoglobulin variants with altered binding to protein a |
WO2010108127A1 (en) | 2009-03-20 | 2010-09-23 | Genentech, Inc. | Bispecific anti-her antibodies |
EP3088420A1 (en) | 2009-03-20 | 2016-11-02 | F. Hoffmann-La Roche AG | Bispecific anti-her antibodies |
US11401333B2 (en) | 2009-03-25 | 2022-08-02 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
WO2010111254A1 (en) | 2009-03-25 | 2010-09-30 | Genentech, Inc. | Novel anti-alpha5beta1 antibodies and uses thereof |
WO2010111367A1 (en) | 2009-03-25 | 2010-09-30 | Genentech, Inc. | Anti-fgfr3 antibodies and methods using same |
EP2679600A1 (en) | 2009-03-25 | 2014-01-01 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
US9499623B2 (en) | 2009-03-25 | 2016-11-22 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
US10000571B2 (en) | 2009-03-25 | 2018-06-19 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
US8410250B2 (en) | 2009-03-25 | 2013-04-02 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
US9161977B2 (en) | 2009-03-25 | 2015-10-20 | F. Hoffmann-La Roche Ag | Anti-FGFR3 antibodies and methods using same |
US8710189B2 (en) | 2009-03-25 | 2014-04-29 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
US10287356B2 (en) | 2009-03-25 | 2019-05-14 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
US10640555B2 (en) | 2009-06-16 | 2020-05-05 | Hoffmann-La Roche Inc. | Bispecific antigen binding proteins |
US11673945B2 (en) | 2009-06-16 | 2023-06-13 | Hoffmann-La Roche Inc. | Bispecific antigen binding proteins |
WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
WO2011014750A1 (en) | 2009-07-31 | 2011-02-03 | Genentech, Inc. | Inhibition of tumor metastasis using bv8- or g-csf-antagonists |
WO2011023787A1 (en) | 2009-08-31 | 2011-03-03 | Roche Glycart Ag | Affinity-matured humanized anti cea monoclonal antibodies |
US9068008B2 (en) | 2009-08-31 | 2015-06-30 | Roche Glycart Ag | Antibodies to carcinoembryonic antigen (CEA), methods of making same, and uses thereof |
WO2011028950A1 (en) | 2009-09-02 | 2011-03-10 | Genentech, Inc. | Mutant smoothened and methods of using the same |
WO2011050188A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Anti-hepsin antibodies and methods using same |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056997A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
WO2011057120A1 (en) | 2009-11-05 | 2011-05-12 | Genentech, Inc. | Methods and composition for secretion of heterologous polypeptides |
WO2011071577A1 (en) | 2009-12-11 | 2011-06-16 | Genentech, Inc. | Anti-vegf-c antibodies and methods using same |
US9266948B2 (en) | 2009-12-23 | 2016-02-23 | Genentech, Inc. | Anti-Bv8 antibodies and uses thereof |
WO2011079185A1 (en) | 2009-12-23 | 2011-06-30 | Genentech, Inc. | Anti-bv8 antibodies and uses thereof |
WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
WO2011103242A1 (en) | 2010-02-18 | 2011-08-25 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
WO2011101328A2 (en) | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
WO2011119661A1 (en) | 2010-03-24 | 2011-09-29 | Genentech, Inc. | Anti-lrp6 antibodies |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
WO2011153346A1 (en) | 2010-06-03 | 2011-12-08 | Genentech, Inc. | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
US8771966B2 (en) | 2010-06-03 | 2014-07-08 | Genentech, Inc. | Immuno-PET imaging of antibodies and immunoconjugates and uses therefor |
EP3098240A2 (en) | 2010-06-18 | 2016-11-30 | F. Hoffmann-La Roche AG | Anti-axl antibodies and methods of use |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
WO2011161189A1 (en) | 2010-06-24 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods of use |
WO2012006503A1 (en) | 2010-07-09 | 2012-01-12 | Genentech, Inc. | Anti-neuropilin antibodies and methods of use |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
WO2012018771A1 (en) | 2010-08-03 | 2012-02-09 | Genentech, Inc. | Chronic lymphocytic leukemia (cll) biomarkers |
WO2012017003A1 (en) | 2010-08-05 | 2012-02-09 | F. Hoffmann-La Roche Ag | Anti-mhc antibody anti-viral cytokine fusion protein |
EP3333194A1 (en) | 2010-08-13 | 2018-06-13 | Roche Glycart AG | Anti-fap antibodies and methods of use |
WO2012020006A2 (en) | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
WO2012020038A1 (en) | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-tenascin-c a2 antibodies and methods of use |
WO2012025536A1 (en) | 2010-08-25 | 2012-03-01 | F. Hoffmann-La Roche Ag | Antibodies against il-18r1 and uses thereof |
US8883975B2 (en) | 2010-08-25 | 2014-11-11 | Hoffmann-La Roche, Inc. | Antibodies against IL-18R1 and uses thereof |
WO2012031027A1 (en) | 2010-08-31 | 2012-03-08 | Genentech, Inc. | Biomarkers and methods of treatment |
EP3264089A1 (en) | 2010-08-31 | 2018-01-03 | Genentech, Inc. | Biomarkers and methods of treatment |
WO2012047968A2 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
EP3176184A1 (en) | 2010-11-10 | 2017-06-07 | F. Hoffmann-La Roche AG | Methods and compositions for neural disease immunotherapy |
WO2012064836A1 (en) | 2010-11-10 | 2012-05-18 | Genentech, Inc. | Methods and compositions for neural disease immunotherapy |
US11226341B2 (en) | 2010-12-16 | 2022-01-18 | Genentech, Inc. | Method of treating asthma using an IL-13 antibody |
US9995755B2 (en) | 2010-12-16 | 2018-06-12 | Genentech, Inc. | Diagnosis and treatments relating to TH2 inhibition |
US9684000B2 (en) | 2010-12-16 | 2017-06-20 | Genentech, Inc. | Diagnosis and treatments relating to TH2 inhibition |
EP3447491A2 (en) | 2010-12-16 | 2019-02-27 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
WO2012087962A2 (en) | 2010-12-20 | 2012-06-28 | Genentech, Inc. | Anti-mesothelin antibodies and immunoconjugates |
EP3296321A1 (en) | 2010-12-20 | 2018-03-21 | F. Hoffmann-La Roche AG | Anti-mesothelin antibodies and immunoconjugates |
WO2012088313A1 (en) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Anti-pcsk9 antibodies and methods of use |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
WO2012107416A2 (en) | 2011-02-10 | 2012-08-16 | Roche Glycart Ag | Improved immunotherapy |
US10793621B2 (en) | 2011-02-28 | 2020-10-06 | Hoffmann-La Roche Inc. | Nucleic acid encoding dual Fc antigen binding proteins |
US10611825B2 (en) | 2011-02-28 | 2020-04-07 | Hoffmann La-Roche Inc. | Monovalent antigen binding proteins |
US8642742B2 (en) | 2011-03-02 | 2014-02-04 | Roche Glycart Ag | Anti-CEA antibodies |
US9206260B2 (en) | 2011-03-02 | 2015-12-08 | Roche Glycart Ag | Anti-CEA antibodies |
WO2012138975A1 (en) | 2011-04-07 | 2012-10-11 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
WO2012146628A1 (en) | 2011-04-29 | 2012-11-01 | Roche Glycart Ag | Novel immunoconjugates |
WO2012146630A1 (en) | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | N-terminal acylated polypeptides, methods for their production and uses thereof |
WO2012155019A1 (en) | 2011-05-12 | 2012-11-15 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
WO2012158704A1 (en) | 2011-05-16 | 2012-11-22 | Genentech, Inc. | Fgfr1 agonists and methods of use |
EP3219730A1 (en) | 2011-05-16 | 2017-09-20 | F. Hoffmann-La Roche AG | Fgfr1 agonists and methods of use |
WO2012171996A1 (en) | 2011-06-15 | 2012-12-20 | F. Hoffmann-La Roche Ag | Anti-human epo receptor antibodies and methods of use |
WO2012175508A1 (en) | 2011-06-22 | 2012-12-27 | F. Hoffmann-La Roche Ag | Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes |
WO2013003680A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
WO2013025944A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Inhibition of angiogenesis in refractory tumors |
WO2013025853A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
WO2013026831A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antigen binding molecules |
WO2013026832A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Anti-mcsp antibodies |
WO2013040433A1 (en) | 2011-09-15 | 2013-03-21 | Genentech, Inc. | Methods of promoting differentiation |
WO2013043715A1 (en) | 2011-09-19 | 2013-03-28 | Genentech, Inc. | Combination treatments comprising c-met antagonists and b-raf antagonists |
WO2013052155A1 (en) | 2011-10-05 | 2013-04-11 | Genentech, Inc. | Methods of treating liver conditions using notch2 antagonists |
WO2013055998A1 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE |
EP3461839A1 (en) | 2011-10-14 | 2019-04-03 | F. Hoffmann-La Roche AG | Anti-htra1 antibodies and methods of use |
WO2013056148A2 (en) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Methods of using scd1 antagonists |
WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
WO2013063001A1 (en) | 2011-10-28 | 2013-05-02 | Genentech, Inc. | Therapeutic combinations and methods of treating melanoma |
WO2013078170A1 (en) | 2011-11-21 | 2013-05-30 | Genentech, Inc. | Purification of anti-c-met antibodies |
WO2013083497A1 (en) | 2011-12-06 | 2013-06-13 | F. Hoffmann-La Roche Ag | Antibody formulation |
WO2013092743A2 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
WO2013092720A1 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
WO2013092723A1 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
WO2013096791A1 (en) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Process for making high concentration protein formulations |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
EP3663314A1 (en) | 2012-01-09 | 2020-06-10 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
WO2013106485A2 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
WO2013106489A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
WO2013109819A1 (en) | 2012-01-18 | 2013-07-25 | Genentech, Inc. | Anti-lrp5 antibodies and methods of use |
WO2013109856A2 (en) | 2012-01-18 | 2013-07-25 | Genentech, Inc. | Methods of using fgf19 modulators |
WO2013116287A1 (en) | 2012-01-31 | 2013-08-08 | Genentech, Inc. | Anti-ig-e m1' antibodies and methods using same |
WO2013120056A1 (en) | 2012-02-11 | 2013-08-15 | Genentech, Inc. | R-spondin translocations and methods using the same |
WO2013120929A1 (en) | 2012-02-15 | 2013-08-22 | F. Hoffmann-La Roche Ag | Fc-receptor based affinity chromatography |
WO2013148315A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
WO2013149159A1 (en) | 2012-03-30 | 2013-10-03 | Genentech, Inc. | Anti-lgr5 antibodies and immunoconjugates |
US9175089B2 (en) | 2012-03-30 | 2015-11-03 | Genentech, Inc. | Anti-LGR5 antibodies and immunoconjugates |
US9597411B2 (en) | 2012-05-01 | 2017-03-21 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
US9056910B2 (en) | 2012-05-01 | 2015-06-16 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
WO2013165940A1 (en) | 2012-05-01 | 2013-11-07 | Genentech, Inc. | Anti-pmel17 antibodies and immunoconjugates |
US10196454B2 (en) | 2012-05-01 | 2019-02-05 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
EP3605090A1 (en) | 2012-05-23 | 2020-02-05 | F. Hoffmann-La Roche AG | Selection method for therapeutic agents |
WO2013177470A1 (en) | 2012-05-23 | 2013-11-28 | Genentech, Inc. | Selection method for therapeutic agents |
US9266961B2 (en) | 2012-06-15 | 2016-02-23 | Genentech, Inc. | Anti-PCSK9 antibodies, formulations, dosing, and methods of use |
WO2014006123A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Anti-biotin antibodies and methods of use |
US9765153B2 (en) | 2012-07-04 | 2017-09-19 | Hoffmann-La Roche Inc. | Anti-biotin antibodies and methods of use |
US10517945B2 (en) | 2012-07-04 | 2019-12-31 | Hoffman-La Roche Inc. | Covalently linked antigen-antibody conjugates |
WO2014006118A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Anti-theophylline antibodies and methods of use |
WO2014006124A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
US9925272B2 (en) | 2012-07-04 | 2018-03-27 | Hoffmann-La Roche Inc. | Anti-theophylline antibodies and methods of use |
EP3578660A1 (en) | 2012-07-05 | 2019-12-11 | F. Hoffmann-La Roche AG | Expression and secretion system |
WO2014008391A1 (en) | 2012-07-05 | 2014-01-09 | Genentech, Inc. | Expression and secretion system |
WO2014011521A1 (en) | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti - cd79b antibodies |
WO2014011520A1 (en) | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
WO2014011518A1 (en) | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
WO2014011519A1 (en) | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd79b antibodies |
EP3434695A1 (en) | 2012-08-07 | 2019-01-30 | Roche Glycart AG | Improved immunotherapy |
WO2014023679A1 (en) | 2012-08-07 | 2014-02-13 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
US11578372B2 (en) | 2012-11-05 | 2023-02-14 | Foundation Medicine, Inc. | NTRK1 fusion molecules and uses thereof |
WO2014072306A1 (en) | 2012-11-08 | 2014-05-15 | F. Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
EP3461501A1 (en) | 2012-11-13 | 2019-04-03 | F. Hoffmann-La Roche AG | Anti-hemagglutinin antibodies and methods of use |
WO2014078268A2 (en) | 2012-11-13 | 2014-05-22 | Genentech, Inc. | Anti-hemagglutinin antibodies and methods of use |
US11771698B2 (en) | 2013-01-18 | 2023-10-03 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
WO2014128235A1 (en) | 2013-02-22 | 2014-08-28 | F. Hoffmann-La Roche Ag | Methods of treating cancer and preventing drug resistance |
WO2014131715A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Anti-mcsp antibodies |
WO2014138364A2 (en) | 2013-03-06 | 2014-09-12 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
WO2014152358A2 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
US11230600B2 (en) | 2013-03-14 | 2022-01-25 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
EP3299391A1 (en) | 2013-03-14 | 2018-03-28 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
US10150813B2 (en) | 2013-03-14 | 2018-12-11 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
WO2014159835A1 (en) | 2013-03-14 | 2014-10-02 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
WO2014153030A2 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
US9815880B2 (en) | 2013-03-15 | 2017-11-14 | Genentech, Inc. | IL-22 Fc fusion proteins |
US10584155B2 (en) | 2013-03-15 | 2020-03-10 | Genentech, Inc. | Pharmaceutical compositions of IL-22 Fc fusion proteins |
WO2014150877A2 (en) | 2013-03-15 | 2014-09-25 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
EP4356960A2 (en) | 2013-03-15 | 2024-04-24 | F. Hoffmann-La Roche AG | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
WO2014151866A1 (en) | 2013-03-15 | 2014-09-25 | Genentech, Inc. | Compositions and methods for diagnosis and treatment of hepatic cancers |
US11155591B2 (en) | 2013-03-15 | 2021-10-26 | Genentech, Inc. | Methods of treating acute pancreatitis using IL-22 fc fusion proteins |
WO2014144865A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Anti-crth2 antibodies and methods of use |
EP3385277A1 (en) | 2013-03-15 | 2018-10-10 | F. Hoffmann-La Roche AG | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
US10087227B2 (en) | 2013-03-15 | 2018-10-02 | Genentech, Inc. | Nucleic acids encoding IL-22 Fc fusion proteins |
WO2014144850A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
US10544198B2 (en) | 2013-03-15 | 2020-01-28 | Genentech, Inc. | Methods of accelerating or improving wound healing using IL-22 FC fusion proteins |
WO2014145016A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
WO2014151006A2 (en) | 2013-03-15 | 2014-09-25 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
US10160793B2 (en) | 2013-03-15 | 2018-12-25 | Genentech, Inc. | Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteins |
EP3633377A1 (en) | 2013-03-15 | 2020-04-08 | F. Hoffmann-La Roche AG | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
US11130791B2 (en) | 2013-03-15 | 2021-09-28 | Genentech, Inc. | Methods for treating metabolic syndrome using IL-22 Fc fusion proteins |
US11332507B2 (en) | 2013-03-15 | 2022-05-17 | Genentech, Inc. | IL-22 Fc fusion proteins |
US11136365B2 (en) | 2013-03-15 | 2021-10-05 | Genentech, Inc. | Methods for preventing or treating cardiovascular conditions using il-22 fc fusion proteins |
WO2014161845A1 (en) | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
EP3628685A1 (en) | 2013-04-29 | 2020-04-01 | F. Hoffmann-La Roche AG | Human fcrn-binding modified antibodies and methods of use |
EP3878866A1 (en) | 2013-04-29 | 2021-09-15 | F. Hoffmann-La Roche AG | Fc-receptor binding modified asymmetric antibodies and methods of use |
WO2014177460A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
WO2014177461A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases |
EP3594240A1 (en) | 2013-05-20 | 2020-01-15 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
EP4324480A2 (en) | 2013-05-20 | 2024-02-21 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
WO2014193722A1 (en) | 2013-05-31 | 2014-12-04 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
WO2014194247A1 (en) | 2013-05-31 | 2014-12-04 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
EP3381939A1 (en) | 2013-05-31 | 2018-10-03 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
WO2015017146A2 (en) | 2013-07-18 | 2015-02-05 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
WO2015010100A2 (en) | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Humanized antibodies with ultralong complementarity determining regions |
EP3708583A1 (en) | 2013-08-01 | 2020-09-16 | Five Prime Therapeutics, Inc. | Afucosylated anti-fgfr2iiib antibodies |
WO2015017600A1 (en) | 2013-08-01 | 2015-02-05 | Five Prime Therapeutics, Inc. | Afucosylated anti-fgfr2iiib antibodies |
EP4036118A1 (en) | 2013-08-01 | 2022-08-03 | Five Prime Therapeutics, Inc. | Afucosylated anti-fgfr2iiib antibodies |
WO2015023596A1 (en) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | Compositions and method for treating complement-associated conditions |
US10246515B2 (en) | 2013-09-17 | 2019-04-02 | Genentech, Inc. | Methods of treating hedgehog-related diseases with an anti-LGR5 antibody |
WO2015042108A1 (en) | 2013-09-17 | 2015-03-26 | Genentech, Inc. | Methods of using anti-lgr5 antibodies |
WO2015052230A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
EP4269421A2 (en) | 2013-10-11 | 2023-11-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Tem8 antibodies and their use |
WO2015054670A1 (en) | 2013-10-11 | 2015-04-16 | Genentech, Inc. | Nsp4 inhibitors and methods of use |
US10323099B2 (en) | 2013-10-11 | 2019-06-18 | Hoffmann-La Roche Inc. | Multispecific domain exchanged common variable light chain antibodies |
US10246519B2 (en) | 2013-10-11 | 2019-04-02 | Genentech, Inc. | NSP4 inhibitors and methods of use |
US9975963B2 (en) | 2013-10-11 | 2018-05-22 | Genentech, Inc. | NSP4 inhibitors and methods of use |
EP3620470A1 (en) | 2013-10-11 | 2020-03-11 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Tem8 antibodies and their use |
WO2015058132A2 (en) | 2013-10-18 | 2015-04-23 | Genentech, Inc. | Anti-rspo antibodies and methods of use |
WO2015061441A1 (en) | 2013-10-23 | 2015-04-30 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
WO2015075011A1 (en) | 2013-11-21 | 2015-05-28 | F. Hoffmann-La Roche Ag | ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE |
EP3611191A1 (en) | 2013-12-09 | 2020-02-19 | Allakos Inc. | Anti-siglec-8 antibodies and methods of use thereof |
US9546215B2 (en) | 2013-12-09 | 2017-01-17 | Allakos Inc. | Anti-Siglec-8 antibodies and methods of use thereof |
WO2015089117A1 (en) | 2013-12-09 | 2015-06-18 | Allakos Inc. | Anti-siglec-8 antibodies and methods of use thereof |
WO2015089344A1 (en) | 2013-12-13 | 2015-06-18 | Genentech, Inc. | Anti-cd33 antibodies and immunoconjugates |
EP3461845A1 (en) | 2013-12-13 | 2019-04-03 | Genentech, Inc. | Anti-cd33 antibodies and immunoconjugates |
US10174124B2 (en) | 2013-12-17 | 2019-01-08 | Genentech, Inc. | Anti-CD3 antibodies and methods of use |
EP3680254A1 (en) | 2013-12-17 | 2020-07-15 | F. Hoffmann-La Roche AG | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
US11732054B2 (en) | 2013-12-17 | 2023-08-22 | Genentech, Inc. | Anti-CD3 antibodies and methods of use |
EP3527587A1 (en) | 2013-12-17 | 2019-08-21 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists |
US11530275B2 (en) | 2013-12-17 | 2022-12-20 | Genentech, Inc. | Anti-CD3 antibodies and methods of use |
WO2015095418A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
WO2015095410A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
US11186650B2 (en) | 2013-12-17 | 2021-11-30 | Genentech, Inc. | Anti-CD3 antibodies and methods of use |
US10640572B2 (en) | 2013-12-17 | 2020-05-05 | Genentech, Inc. | Anti-CD3 antibodies and methods of use |
EP3647324A1 (en) | 2013-12-17 | 2020-05-06 | F. Hoffmann-La Roche AG | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
US10865251B2 (en) | 2013-12-17 | 2020-12-15 | Genentech, Inc. | Anti-CD3 antibodies and methods of use |
EP4219555A1 (en) | 2013-12-23 | 2023-08-02 | F. Hoffmann-La Roche AG | Antibodies and methods of use |
US10519249B2 (en) | 2014-01-03 | 2019-12-31 | Hoffmann-La Roche Inc. | Covalently linked polypeptide toxin-antibody conjugates |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
US10407511B2 (en) | 2014-01-03 | 2019-09-10 | Hoffmann-La Roche Inc. | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
WO2015101589A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked polypeptide toxin-antibody conjugates |
WO2015101587A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
WO2015101588A1 (en) | 2014-01-06 | 2015-07-09 | F. Hoffmann-La Roche Ag | Monovalent blood brain barrier shuttle modules |
EP3835318A1 (en) | 2014-01-15 | 2021-06-16 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
WO2015107026A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
WO2015112909A1 (en) | 2014-01-24 | 2015-07-30 | Genentech, Inc. | Methods of using anti-steap1 antibodies and immunoconjugates |
WO2015120075A2 (en) | 2014-02-04 | 2015-08-13 | Genentech, Inc. | Mutant smoothened and methods of using the same |
EP3900738A1 (en) | 2014-02-08 | 2021-10-27 | F. Hoffmann-La Roche AG | Methods of treating alzheimer's disease |
WO2015120233A1 (en) | 2014-02-08 | 2015-08-13 | Genentech, Inc. | Methods of treating alzheimer's disease |
WO2015120280A1 (en) | 2014-02-08 | 2015-08-13 | Genentech, Inc. | Methods of treating alzheimer's disease |
EP3718563A1 (en) | 2014-02-08 | 2020-10-07 | F. Hoffmann-La Roche AG | Methods of treating alzheimer's disease |
EP3825332A1 (en) | 2014-02-12 | 2021-05-26 | F. Hoffmann-La Roche AG | Anti-jagged1 antibodies and methods of use |
EP3428190A1 (en) | 2014-02-12 | 2019-01-16 | F. Hoffmann-La Roche AG | Anti-jagged1 antibodies and methods of use |
WO2015127405A2 (en) | 2014-02-21 | 2015-08-27 | Genentech, Inc. | Anti-il-13/il-17 bispecific antibodies and uses thereof |
WO2015131155A1 (en) | 2014-02-28 | 2015-09-03 | Allakos Inc. | Methods and compositions for treating siglec-8 associated diseases |
US10183996B2 (en) | 2014-02-28 | 2019-01-22 | Allakos Inc. | Methods and compositions for treating Siglec-8 associated diseases |
EP4014995A1 (en) | 2014-02-28 | 2022-06-22 | Allakos Inc. | Methods and compositions for treating siglec-8 associated diseases |
WO2015139046A1 (en) | 2014-03-14 | 2015-09-17 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
WO2015140591A1 (en) | 2014-03-21 | 2015-09-24 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
WO2015148531A1 (en) | 2014-03-24 | 2015-10-01 | Genentech, Inc. | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
US10240207B2 (en) | 2014-03-24 | 2019-03-26 | Genentech, Inc. | Cancer treatment with c-met antagonists and correlation of the latter with HGF expression |
EP3632934A1 (en) | 2014-03-31 | 2020-04-08 | F. Hoffmann-La Roche AG | Anti-ox40 antibodies and methods of use |
WO2015153514A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
WO2015153513A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Anti-ox40 antibodies and methods of use |
US10730951B2 (en) | 2014-03-31 | 2020-08-04 | Genentech, Inc. | Anti-OX40 antibodies and methods of use |
US9975957B2 (en) | 2014-03-31 | 2018-05-22 | Genentech, Inc. | Anti-OX40 antibodies and methods of use |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
WO2015179658A2 (en) | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
WO2015179835A2 (en) | 2014-05-23 | 2015-11-26 | Genentech, Inc. | Mit biomarkers and methods using the same |
WO2015191715A1 (en) | 2014-06-11 | 2015-12-17 | Genentech, Inc. | Anti-lgr5 antibodies and uses thereof |
WO2015191986A1 (en) | 2014-06-13 | 2015-12-17 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
US11673968B2 (en) | 2014-06-26 | 2023-06-13 | Hoffmann-La Roche Inc. | Anti-BRDU antibodies and methods of use |
EP3309174A1 (en) | 2014-07-11 | 2018-04-18 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
WO2016007235A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
WO2016007775A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Notch pathway inhibition |
JP2016023152A (ja) * | 2014-07-17 | 2016-02-08 | 東ソー株式会社 | 抗体依存性細胞傷害活性の強さに基づき抗体を分離する方法 |
US11827714B2 (en) | 2014-08-28 | 2023-11-28 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for CD19 |
EP3805267A1 (en) | 2014-08-28 | 2021-04-14 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for cd19 |
US11584927B2 (en) | 2014-08-28 | 2023-02-21 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified T-cells |
WO2016033570A1 (en) | 2014-08-28 | 2016-03-03 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for cd19 |
US10533055B2 (en) | 2014-08-28 | 2020-01-14 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for CD19 |
US11286302B2 (en) | 2014-09-12 | 2022-03-29 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
US10059768B2 (en) | 2014-09-12 | 2018-08-28 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
EP3782654A1 (en) | 2014-09-12 | 2021-02-24 | Genentech, Inc. | Anti-her2 antibodies and immunoconjugates |
US11084877B2 (en) | 2014-09-12 | 2021-08-10 | Genentech, Inc. | Anti-CLL-1 antibodies and immunoconjugates |
WO2016040868A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
EP3693391A1 (en) | 2014-09-12 | 2020-08-12 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
WO2016044396A1 (en) | 2014-09-17 | 2016-03-24 | Genentech, Inc. | Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines |
EP3689910A2 (en) | 2014-09-23 | 2020-08-05 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
US11001643B2 (en) | 2014-09-26 | 2021-05-11 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
WO2016061389A2 (en) | 2014-10-16 | 2016-04-21 | Genentech, Inc. | Anti-alpha-synuclein antibodies and methods of use |
US10626176B2 (en) | 2014-10-31 | 2020-04-21 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind B7-H4 |
WO2016073378A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
US10767232B2 (en) | 2014-11-03 | 2020-09-08 | Genentech, Inc. | Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment |
US10845364B2 (en) | 2014-11-03 | 2020-11-24 | Genentech, Inc. | Assays for detecting T cell immune subsets and methods of use thereof |
US10208120B2 (en) | 2014-11-05 | 2019-02-19 | Genentech, Inc. | Anti-FGFR2/3 antibodies and methods using same |
WO2016073282A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
EP3611188A1 (en) | 2014-11-06 | 2020-02-19 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn-binding and methods of use |
EP3842453A1 (en) | 2014-11-06 | 2021-06-30 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and protein a-binding properties |
EP3783023A1 (en) | 2014-11-10 | 2021-02-24 | H. Hoffnabb-La Roche Ag | Anti-interleukin-33 antibodies and uses thereof |
EP3552488A1 (en) | 2014-11-10 | 2019-10-16 | F. Hoffmann-La Roche AG | Animal model for nephropathy and agents for treating the same |
WO2016077381A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2016077369A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Animal model for nephropathy and agents for treating the same |
EP3875481A1 (en) | 2014-11-14 | 2021-09-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
WO2016081384A1 (en) | 2014-11-17 | 2016-05-26 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
EP3845565A2 (en) | 2014-11-19 | 2021-07-07 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
WO2016081640A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
WO2016081639A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
WO2016081643A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
EP4141032A1 (en) | 2014-11-20 | 2023-03-01 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
EP3789402A1 (en) | 2014-11-20 | 2021-03-10 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
WO2016090040A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
US10633457B2 (en) | 2014-12-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Multispecific antibodies |
WO2016090038A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
WO2016090210A1 (en) | 2014-12-05 | 2016-06-09 | Genentech, Inc. | ANTI-CD79b ANTIBODIES AND METHODS OF USE |
WO2016094566A2 (en) | 2014-12-10 | 2016-06-16 | Genentech, Inc. | Blood brain barrier receptor antibodies and methods of use |
WO2016098356A1 (en) | 2014-12-19 | 2016-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
EP3981794A1 (en) | 2014-12-19 | 2022-04-13 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
WO2016115559A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
EP3760644A1 (en) | 2015-01-16 | 2021-01-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
US10889652B2 (en) | 2015-01-16 | 2021-01-12 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ROR1 |
US11919970B2 (en) | 2015-01-16 | 2024-03-05 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ROR1 |
WO2016117346A1 (en) | 2015-01-22 | 2016-07-28 | Chugai Seiyaku Kabushiki Kaisha | A combination of two or more anti-c5 antibodies and methods of use |
WO2016126972A1 (en) | 2015-02-04 | 2016-08-11 | Genentech, Inc. | Mutant smoothened and methods of using the same |
US11180548B2 (en) | 2015-02-05 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Methods of neutralizing IL-8 biological activity |
WO2016138160A1 (en) | 2015-02-24 | 2016-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
WO2016149276A1 (en) | 2015-03-16 | 2016-09-22 | Genentech, Inc. | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
EP3683233A1 (en) | 2015-03-20 | 2020-07-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to gp120 and their use |
WO2016154003A1 (en) | 2015-03-20 | 2016-09-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to gp120 and their use |
EP3735986A1 (en) | 2015-03-23 | 2020-11-11 | Jounce Therapeutics, Inc. | Antibodies to icos |
WO2016154177A2 (en) | 2015-03-23 | 2016-09-29 | Jounce Therapeutics, Inc. | Antibodies to icos |
US10472412B2 (en) | 2015-03-25 | 2019-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
EP3590961A1 (en) | 2015-03-25 | 2020-01-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific multivalent fusion proteins |
US10011658B2 (en) | 2015-04-03 | 2018-07-03 | Eureka Therapeutics, Inc. | Constructs targeting AFP peptide/MHC complexes and uses thereof |
EP3913052A1 (en) | 2015-04-24 | 2021-11-24 | F. Hoffmann-La Roche AG | Methods of identifying bacteria comprising binding polypeptides |
WO2016172551A2 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Methods of identifying bacteria comprising binding polypeptides |
EP3778640A1 (en) | 2015-05-01 | 2021-02-17 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
WO2016179003A1 (en) | 2015-05-01 | 2016-11-10 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
WO2016179194A1 (en) | 2015-05-04 | 2016-11-10 | Jounce Therapeutics, Inc. | Lilra3 and method of using the same |
EP3936524A2 (en) | 2015-05-11 | 2022-01-12 | F. Hoffmann-La Roche AG | Compositions and methods of treating lupus nephritis |
EP4238994A2 (en) | 2015-05-11 | 2023-09-06 | F. Hoffmann-La Roche AG | Compositions and methods of treating lupus nephritis |
EP3783029A1 (en) | 2015-05-12 | 2021-02-24 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
EP3763827A1 (en) | 2015-05-29 | 2021-01-13 | F. Hoffmann-La Roche AG | Pd-l1 promoter methylation in cancer |
US11254987B2 (en) | 2015-05-29 | 2022-02-22 | Genentech, Inc. | PD-L1 promoter methylation in cancer |
WO2016196343A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Humanized anti-ebola virus glycoprotein antibodies and methods of use |
EP4335931A2 (en) | 2015-05-29 | 2024-03-13 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
EP3708681A1 (en) | 2015-05-29 | 2020-09-16 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
WO2016196298A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Therapeutic and diagnolstic methods for cancer |
WO2016196381A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Pd-l1 promoter methylation in cancer |
WO2016196679A1 (en) | 2015-06-02 | 2016-12-08 | Genentech, Inc. | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
WO2016196975A1 (en) | 2015-06-03 | 2016-12-08 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2016196726A1 (en) | 2015-06-05 | 2016-12-08 | Genentech, Inc. | Anti-tau antibodies and methods of use |
WO2016200835A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
WO2016200836A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies |
WO2016205176A1 (en) | 2015-06-15 | 2016-12-22 | Genentech, Inc. | Antibodies and immunoconjugates |
US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
EP4299073A2 (en) | 2015-06-16 | 2024-01-03 | F. Hoffmann-La Roche AG | Humanized and affinity matured antibodies to fcrh5 and methods of use |
US11466087B2 (en) | 2015-06-16 | 2022-10-11 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
US10323094B2 (en) | 2015-06-16 | 2019-06-18 | Genentech, Inc. | Humanized and affinity matured antibodies to FcRH5 and methods of use |
WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
US11192950B2 (en) | 2015-06-16 | 2021-12-07 | Genentech, Inc. | Humanized and affinity matured antibodies to FcRH5 and methods of use |
WO2016205520A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Humanized and affinity matured antibodies to fcrh5 and methods of use |
WO2016205200A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cll-1 antibodies and methods of use |
US10774145B2 (en) | 2015-06-17 | 2020-09-15 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
WO2016205531A2 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Anti-her2 antibodies and methods of use |
WO2016205320A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
US11584793B2 (en) | 2015-06-24 | 2023-02-21 | Hoffmann-La Roche Inc. | Anti-transferrin receptor antibodies with tailored affinity |
EP3978525A1 (en) | 2015-06-29 | 2022-04-06 | Ventana Medical Systems, Inc. | Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin |
WO2017004091A1 (en) | 2015-06-29 | 2017-01-05 | Genentech, Inc. | Type ii anti-cd20 antibody for use in organ transplantation |
EP3514174A1 (en) | 2015-06-29 | 2019-07-24 | Ventana Medical Systems, Inc. | Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin |
EP3896091A1 (en) | 2015-08-11 | 2021-10-20 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
EP4282877A2 (en) | 2015-08-11 | 2023-11-29 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
EP4063397A1 (en) | 2015-08-11 | 2022-09-28 | Legend Biotech Ireland Limited | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof |
EP4282878A2 (en) | 2015-08-11 | 2023-11-29 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
EP3932953A1 (en) | 2015-08-28 | 2022-01-05 | F. Hoffmann-La Roche AG | Anti-hypusine antibodies and uses thereof |
WO2017040342A1 (en) | 2015-08-28 | 2017-03-09 | Genentech, Inc. | Anti-hypusine antibodies and uses thereof |
WO2017050729A1 (en) | 2015-09-22 | 2017-03-30 | Spring Bioscience Corporation | Anti-ox40 antibodies and diagnostic uses thereof |
WO2017053807A2 (en) | 2015-09-23 | 2017-03-30 | Genentech, Inc. | Optimized variants of anti-vegf antibodies |
WO2017053906A1 (en) | 2015-09-24 | 2017-03-30 | Abvitro Llc | Hiv antibody compositions and methods of use |
EP3662930A1 (en) | 2015-09-24 | 2020-06-10 | AbVitro LLC | Hiv antibody compositions and methods of use |
EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
WO2017055540A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use |
US11603411B2 (en) | 2015-10-02 | 2023-03-14 | Hoffmann-La Roche Inc. | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
WO2017059289A1 (en) | 2015-10-02 | 2017-04-06 | Genentech, Inc. | Pyrrolobenzodiazepine antibody drug conjugates and methods of use |
US10941205B2 (en) | 2015-10-02 | 2021-03-09 | Hoffmann-La Roche Inc. | Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use |
WO2017055542A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
WO2017062682A2 (en) | 2015-10-06 | 2017-04-13 | Genentech, Inc. | Method for treating multiple sclerosis |
WO2017062748A1 (en) | 2015-10-07 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia |
WO2017070423A1 (en) | 2015-10-22 | 2017-04-27 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
WO2017072210A1 (en) | 2015-10-29 | 2017-05-04 | F. Hoffmann-La Roche Ag | Anti-variant fc-region antibodies and methods of use |
EP3922649A1 (en) | 2015-10-30 | 2021-12-15 | F. Hoffmann-La Roche AG | Anti-htra1 antibodies and methods of use thereof |
WO2017075173A2 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
EP4011911A1 (en) | 2015-11-03 | 2022-06-15 | The United States of America as represented by The Secretary Department of Health and Human Services | Neutralizing antibodies to hiv-1 gp41 and their use |
WO2017079479A1 (en) | 2015-11-03 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Neutralizing antibodies to hiv-1 gp41 and their use |
WO2017079768A1 (en) | 2015-11-08 | 2017-05-11 | Genentech, Inc. | Methods of screening for multispecific antibodies |
WO2017091580A1 (en) | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
WO2017091577A1 (en) | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
EP4026848A1 (en) | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
WO2017104779A1 (en) | 2015-12-18 | 2017-06-22 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
EP4342529A2 (en) | 2015-12-18 | 2024-03-27 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
EP3862365A1 (en) | 2016-01-08 | 2021-08-11 | F. Hoffmann-La Roche AG | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
WO2017127764A1 (en) | 2016-01-20 | 2017-07-27 | Genentech, Inc. | High dose treatments for alzheimer's disease |
WO2017136558A1 (en) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened and methods of using the same |
WO2017151502A1 (en) | 2016-02-29 | 2017-09-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
EP4155415A1 (en) | 2016-02-29 | 2023-03-29 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
EP4112641A1 (en) | 2016-03-15 | 2023-01-04 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
WO2017159699A1 (en) | 2016-03-15 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
EP4273551A2 (en) | 2016-03-25 | 2023-11-08 | F. Hoffmann-La Roche AG | Multiplexed total antibody and antibody-conjugated drug quantification assay |
WO2017165734A1 (en) | 2016-03-25 | 2017-09-28 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
EP3865511A1 (en) | 2016-04-14 | 2021-08-18 | F. Hoffmann-La Roche AG | Anti-rspo3 antibodies and methods of use |
WO2017180864A1 (en) | 2016-04-14 | 2017-10-19 | Genentech, Inc. | Anti-rspo3 antibodies and methods of use |
WO2017181079A2 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
WO2017181111A2 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
US11149088B2 (en) | 2016-04-15 | 2021-10-19 | Bioatla, Inc. | Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
US11897959B2 (en) | 2016-04-15 | 2024-02-13 | Bioatla, Inc. | Anti-AXL antibodies, antibody fragments and their immunoconjugates and uses thereof |
EP3889175A1 (en) | 2016-05-02 | 2021-10-06 | F. Hoffmann-La Roche AG | The contorsbody - a single chain target binder |
WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
WO2017191101A1 (en) | 2016-05-02 | 2017-11-09 | F. Hoffmann-La Roche Ag | The contorsbody - a single chain target binder |
WO2017194441A1 (en) | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | Modified anti-tenascin antibodies and methods of use |
WO2017197234A1 (en) | 2016-05-13 | 2017-11-16 | Bioatla, Llc | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
US11879011B2 (en) | 2016-05-13 | 2024-01-23 | Bioatla, Inc. | Anti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereof |
EP4122958A1 (en) | 2016-05-13 | 2023-01-25 | BioAtla, Inc. | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
US11254742B2 (en) | 2016-05-13 | 2022-02-22 | Bioatla, Inc. | Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
WO2017223405A1 (en) | 2016-06-24 | 2017-12-28 | Genentech, Inc. | Anti-polyubiquitin multispecific antibodies |
US11447573B2 (en) | 2016-07-20 | 2022-09-20 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
WO2018021450A1 (ja) | 2016-07-29 | 2018-02-01 | 中外製薬株式会社 | 増強されたfviii補因子機能代替活性を有する二重特異性抗体 |
WO2018023100A2 (en) | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies and related methods |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
US11780912B2 (en) | 2016-08-05 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of IL-8 related diseases |
WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
WO2018045379A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
US10870694B2 (en) | 2016-09-02 | 2020-12-22 | Dana Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
WO2018049083A1 (en) | 2016-09-07 | 2018-03-15 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
US10604561B2 (en) | 2016-09-16 | 2020-03-31 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use |
US10844113B2 (en) | 2016-09-16 | 2020-11-24 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use |
US11780908B2 (en) | 2016-09-16 | 2023-10-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use |
WO2018050878A1 (en) | 2016-09-19 | 2018-03-22 | F. Hoffmann-La Roche Ag | Complement factor based affinity chromatography |
WO2018057849A1 (en) | 2016-09-23 | 2018-03-29 | Genentech, Inc. | Uses of il-13 antagonists for treating atopic dermatitis |
EP4268845A2 (en) | 2016-09-23 | 2023-11-01 | F. Hoffmann-La Roche AG | Uses of il-13 antagonists for treating atopic dermatitis |
WO2018067618A1 (en) | 2016-10-03 | 2018-04-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
US11072660B2 (en) | 2016-10-03 | 2021-07-27 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
WO2018065501A1 (en) | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Methods for preparing antibody drug conjugates |
WO2018068028A1 (en) | 2016-10-06 | 2018-04-12 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
US11472881B2 (en) | 2016-10-11 | 2022-10-18 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against CTLA-4 |
WO2018081648A2 (en) | 2016-10-29 | 2018-05-03 | Genentech, Inc. | Anti-mic antibidies and methods of use |
EP3988569A1 (en) | 2016-11-02 | 2022-04-27 | Jounce Therapeutics, Inc. | Antibodies to pd-1 and uses thereof |
WO2018085358A1 (en) | 2016-11-02 | 2018-05-11 | Jounce Therapeutics, Inc. | Antibodies to pd-1 and uses thereof |
WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
US11466094B2 (en) | 2016-11-15 | 2022-10-11 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
WO2018091724A1 (en) | 2016-11-21 | 2018-05-24 | Cureab Gmbh | Anti-gp73 antibodies and immunoconjugates |
EP4015532A1 (en) | 2016-11-21 | 2022-06-22 | cureab GmbH | Anti-gp73 antibodies and immunoconjugates |
WO2018106781A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc | Anti-tau antibodies and methods of use |
WO2018106776A2 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
WO2018111890A1 (en) | 2016-12-12 | 2018-06-21 | Genentech, Inc. | Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens |
WO2018119171A1 (en) | 2016-12-23 | 2018-06-28 | Potenza Therapeutics, Inc. | Anti-neuropilin antigen-binding proteins and methods of use thereof |
WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
WO2018148585A1 (en) | 2017-02-10 | 2018-08-16 | Genentech, Inc. | Anti-tryptase antibodies, compositions thereof, and uses thereof |
WO2018148660A1 (en) | 2017-02-10 | 2018-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
WO2018160841A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2018175752A1 (en) | 2017-03-22 | 2018-09-27 | Genentech, Inc. | Optimized antibody compositions for treatment of ocular disorders |
WO2018183175A1 (en) | 2017-03-28 | 2018-10-04 | Genentech, Inc. | Methods of treating neurodegenerative diseases |
WO2018183889A1 (en) | 2017-03-30 | 2018-10-04 | Potenza Therapeutics, Inc. | Anti-tigit antigen-binding proteins and methods of use thereof |
US11293926B2 (en) | 2017-04-04 | 2022-04-05 | Sumitomo Bakelite Co., Ltd. | Method for preparing sugar chain |
WO2018186063A1 (ja) * | 2017-04-04 | 2018-10-11 | 住友ベークライト株式会社 | 糖鎖を調製する方法 |
WO2018191660A1 (en) | 2017-04-14 | 2018-10-18 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2018195472A1 (en) | 2017-04-21 | 2018-10-25 | Genentech, Inc. | Use of klk5 antagonists for treatment of a disease |
US11447564B2 (en) | 2017-04-26 | 2022-09-20 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
WO2018201096A1 (en) | 2017-04-27 | 2018-11-01 | Tesaro, Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
US11203638B2 (en) | 2017-05-05 | 2021-12-21 | Allakos Inc. | Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis |
US11116835B2 (en) | 2017-05-10 | 2021-09-14 | Fred Hutchinson Cancer Research Center | Epstein Barr virus antibodies, vaccines, and uses of the same |
WO2018213304A1 (en) | 2017-05-16 | 2018-11-22 | Five Prime Therapeutics, Inc. | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
WO2018220099A1 (en) | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
WO2019018757A1 (en) | 2017-07-21 | 2019-01-24 | Genentech, Inc. | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER |
WO2019023347A1 (en) | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS |
WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT |
WO2019070541A1 (en) | 2017-10-03 | 2019-04-11 | Juno Therapeutics, Inc. | HPV-SPECIFIC BINDING MOLECULES |
EP4215543A2 (en) | 2017-10-03 | 2023-07-26 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
US11912754B2 (en) | 2017-10-12 | 2024-02-27 | Immunowake Inc. | VEGFR-antibody light chain fusion protein |
US11623961B2 (en) | 2017-11-01 | 2023-04-11 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for B-cell maturation antigen |
WO2019089969A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
WO2019090263A1 (en) | 2017-11-06 | 2019-05-09 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2019108639A1 (en) | 2017-12-01 | 2019-06-06 | Pfizer Inc. | Anti-cxcr5 antibodies and compositions and uses thereof |
WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
EP4219559A2 (en) | 2017-12-22 | 2023-08-02 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
WO2019126514A2 (en) | 2017-12-22 | 2019-06-27 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
WO2019126472A1 (en) | 2017-12-22 | 2019-06-27 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
WO2019129211A1 (en) | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against pd-l1 |
US11905327B2 (en) | 2017-12-28 | 2024-02-20 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against TIGIT |
WO2019136029A1 (en) | 2018-01-02 | 2019-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
WO2019134981A1 (en) | 2018-01-05 | 2019-07-11 | Ac Immune Sa | Misfolded tdp-43 binding molecules |
US11713353B2 (en) | 2018-01-15 | 2023-08-01 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against PD-1 |
WO2019143636A1 (en) | 2018-01-16 | 2019-07-25 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
WO2019148026A1 (en) | 2018-01-26 | 2019-08-01 | Genentech, Inc. | Il-22 fc fusion proteins and methods of use |
WO2019148020A1 (en) | 2018-01-26 | 2019-08-01 | Genentech, Inc. | Compositions and methods of use |
WO2019149269A1 (zh) | 2018-02-01 | 2019-08-08 | 信达生物制药(苏州)有限公司 | 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用 |
US11807663B2 (en) | 2018-02-01 | 2023-11-07 | Innovent Biologics (Suzhou) Co., Ltd. | Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof |
WO2019157308A1 (en) | 2018-02-08 | 2019-08-15 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
US11866498B2 (en) | 2018-02-08 | 2024-01-09 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
WO2019157358A1 (en) | 2018-02-09 | 2019-08-15 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
WO2019158645A1 (en) | 2018-02-14 | 2019-08-22 | Abba Therapeutics Ag | Anti-human pd-l2 antibodies |
WO2019165122A1 (en) | 2018-02-21 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2019165140A1 (en) | 2018-02-21 | 2019-08-29 | Genentech, Inc. | DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS |
WO2019165434A1 (en) | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
US11485782B2 (en) | 2018-03-14 | 2022-11-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
WO2019178316A1 (en) | 2018-03-14 | 2019-09-19 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
US11891432B2 (en) | 2018-03-15 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use |
US11958903B2 (en) | 2018-03-30 | 2024-04-16 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
WO2019195514A1 (en) | 2018-04-04 | 2019-10-10 | Genentech, Inc. | Methods for detecting and quantifying fgf21 |
US11471489B2 (en) | 2018-04-05 | 2022-10-18 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
WO2019195486A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
US11535658B2 (en) | 2018-05-14 | 2022-12-27 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
US11352403B2 (en) | 2018-05-14 | 2022-06-07 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
US11453710B2 (en) | 2018-05-14 | 2022-09-27 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
WO2019234576A1 (en) | 2018-06-03 | 2019-12-12 | Lamkap Bio Beta Ltd. | Bispecific antibodies against ceacam5 and cd47 |
WO2019235426A1 (ja) | 2018-06-04 | 2019-12-12 | 中外製薬株式会社 | 細胞質内での半減期が変化した抗原結合分子 |
WO2019246557A1 (en) | 2018-06-23 | 2019-12-26 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
WO2020018789A1 (en) | 2018-07-18 | 2020-01-23 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
US11279758B2 (en) | 2018-07-20 | 2022-03-22 | Surface Oncology, Inc. | Anti-CD112R compositions and methods |
US11214619B2 (en) | 2018-07-20 | 2022-01-04 | Surface Oncology, Inc. | Anti-CD112R compositions and methods |
WO2020027330A1 (ja) | 2018-08-03 | 2020-02-06 | 中外製薬株式会社 | 互いに連結された2つの抗原結合ドメインを含む抗原結合分子 |
EP3608674A1 (en) | 2018-08-09 | 2020-02-12 | Regeneron Pharmaceuticals, Inc. | Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor |
WO2020032230A1 (ja) | 2018-08-10 | 2020-02-13 | 中外製薬株式会社 | 抗cd137抗原結合分子およびその使用 |
WO2020037154A1 (en) | 2018-08-17 | 2020-02-20 | 23Andme, Inc. | Anti-il1rap antibodies and methods of use thereof |
WO2020049286A1 (en) | 2018-09-03 | 2020-03-12 | Femtogenix Limited | Polycyclic amides as cytotoxic agents |
EP4268831A2 (en) | 2018-09-12 | 2023-11-01 | Fred Hutchinson Cancer Center | Reducing cd33 expression to selectively protect therapeutic cells |
WO2020061060A1 (en) | 2018-09-19 | 2020-03-26 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
WO2020061349A1 (en) | 2018-09-21 | 2020-03-26 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
EP4249917A2 (en) | 2018-09-21 | 2023-09-27 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
EP4321530A2 (en) | 2018-09-27 | 2024-02-14 | Xilio Development, Inc. | Masked cytokine polypeptides |
US11827685B2 (en) | 2018-09-27 | 2023-11-28 | Xilio Development, Inc. | Masked cytokine polypeptides |
US11827686B2 (en) | 2018-09-27 | 2023-11-28 | Xilio Development, Inc. | Masked cytokine polypeptides |
US11866476B2 (en) | 2018-09-27 | 2024-01-09 | Xilio Development, Inc. | Masked IL-2-Fc fusion polypeptides |
US11053294B2 (en) | 2018-09-27 | 2021-07-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
US11718655B2 (en) | 2018-09-27 | 2023-08-08 | Xilio Development, Inc. | Masked interleukin-12 polypeptides |
WO2020072896A1 (en) | 2018-10-05 | 2020-04-09 | Five Prime Therapeutics, Inc. | Anti-fgfr2 antibody formulations |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
WO2020081767A1 (en) | 2018-10-18 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
WO2020102555A1 (en) | 2018-11-16 | 2020-05-22 | Memorial Sloan Kettering Cancer Center | Antibodies to mucin-16 and methods of use thereof |
EP4198057A1 (en) | 2018-12-05 | 2023-06-21 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for cancer immunotherapy |
WO2020117952A2 (en) | 2018-12-05 | 2020-06-11 | Genentech, Inc. | Diagnostic methods and compositions for cancer immunotherapy |
WO2020117257A1 (en) | 2018-12-06 | 2020-06-11 | Genentech, Inc. | Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
WO2020132230A2 (en) | 2018-12-20 | 2020-06-25 | Genentech, Inc. | Modified antibody fcs and methods of use |
WO2020132034A1 (en) | 2018-12-20 | 2020-06-25 | 23Andme, Inc. | Anti-cd96 antibodies and methods of use thereof |
WO2020132214A2 (en) | 2018-12-20 | 2020-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
WO2020132220A1 (en) | 2018-12-21 | 2020-06-25 | 23Andme, Inc. | Anti-il-36 antibodies and methods of use thereof |
WO2020139926A2 (en) | 2018-12-26 | 2020-07-02 | Akrevia Therapeutics Inc. | Anti-ctla4 antibodies and methods of use thereof |
WO2020139920A2 (en) | 2018-12-26 | 2020-07-02 | City Of Hope | Activatable masked anti-ctla4 binding proteins |
WO2020141145A1 (en) | 2018-12-30 | 2020-07-09 | F. Hoffmann-La Roche Ag | Anti-rabbit cd19 antibodies and methods of use |
WO2020150152A1 (en) | 2019-01-14 | 2020-07-23 | Genentech, Inc. | Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine |
WO2020153467A1 (ja) | 2019-01-24 | 2020-07-30 | 中外製薬株式会社 | 新規がん抗原及びそれらの抗原に対する抗体 |
WO2020160050A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
WO2020157491A1 (en) | 2019-01-29 | 2020-08-06 | Femtogenix Limited | G-a crosslinking cytotoxic agents |
WO2020176748A1 (en) | 2019-02-27 | 2020-09-03 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies |
WO2020185535A1 (en) | 2019-03-08 | 2020-09-17 | Genentech, Inc. | Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles |
WO2020186176A1 (en) | 2019-03-14 | 2020-09-17 | Genentech, Inc. | Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab |
WO2020213724A1 (ja) | 2019-04-19 | 2020-10-22 | 中外製薬株式会社 | 抗体改変部位認識キメラ受容体 |
WO2020214995A1 (en) | 2019-04-19 | 2020-10-22 | Genentech, Inc. | Anti-mertk antibodies and their methods of use |
WO2020226986A2 (en) | 2019-05-03 | 2020-11-12 | Genentech, Inc. | Methods of treating cancer with an anti-pd-l1 antibody |
WO2020227228A2 (en) | 2019-05-03 | 2020-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
US11739132B2 (en) | 2019-05-14 | 2023-08-29 | Werewolf Therapeutics, Inc. | Separation moieties and methods of use thereof |
WO2020232169A1 (en) | 2019-05-14 | 2020-11-19 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma |
WO2020236974A1 (en) | 2019-05-21 | 2020-11-26 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
WO2020234473A1 (en) | 2019-05-23 | 2020-11-26 | Ac Immune Sa | Anti-tdp-43 binding molecules and uses thereof |
WO2021003297A1 (en) | 2019-07-02 | 2021-01-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind egfrviii and their use |
WO2021010326A1 (ja) | 2019-07-12 | 2021-01-21 | 中外製薬株式会社 | 抗変異型fgfr3抗体およびその使用 |
WO2021024209A1 (en) | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Inc. | Antibodies that bind to pathological tau species and uses thereof |
WO2021050645A1 (en) | 2019-09-12 | 2021-03-18 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
WO2021055694A1 (en) | 2019-09-20 | 2021-03-25 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
WO2021062085A1 (en) | 2019-09-27 | 2021-04-01 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021076196A1 (en) | 2019-10-18 | 2021-04-22 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
WO2021092171A1 (en) | 2019-11-06 | 2021-05-14 | Genentech, Inc. | Diagnostic and therapeutic methods for treatment of hematologic cancers |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
WO2021110647A1 (en) | 2019-12-02 | 2021-06-10 | Lamkap Bio Beta Ag | Bispecific antibodies against ceacam5 and cd47 |
WO2021113776A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods |
WO2021113780A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods |
WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
US11845799B2 (en) | 2019-12-13 | 2023-12-19 | Genentech, Inc. | Anti-Ly6G6D antibodies and methods of use |
WO2021129872A1 (zh) | 2019-12-27 | 2021-07-01 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
WO2021131021A1 (ja) | 2019-12-27 | 2021-07-01 | 中外製薬株式会社 | 抗ctla-4抗体およびその使用 |
WO2021139777A1 (zh) | 2020-01-10 | 2021-07-15 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
WO2021155295A1 (en) | 2020-01-31 | 2021-08-05 | The Cleveland Clinic Foundation | Anti-müllerian hormone receptor 2 antibodies and methods of use |
WO2021155149A1 (en) | 2020-01-31 | 2021-08-05 | Genentech, Inc. | Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine |
WO2021162020A1 (ja) | 2020-02-12 | 2021-08-19 | 中外製薬株式会社 | 癌の治療に用いるための抗cd137抗原結合分子 |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
WO2021168292A1 (en) | 2020-02-20 | 2021-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Epstein-barr virus monoclonal antibodies and uses thereof |
WO2021170067A1 (zh) | 2020-02-28 | 2021-09-02 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体及其用途 |
WO2021170071A1 (en) | 2020-02-28 | 2021-09-02 | Shanghai Henlius Biotech, Inc. | Anti-cd137 constructs, multispecific antibody and uses thereof |
WO2021183849A1 (en) | 2020-03-13 | 2021-09-16 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2021188749A1 (en) | 2020-03-19 | 2021-09-23 | Genentech, Inc. | Isoform-selective anti-tgf-beta antibodies and methods of use |
WO2021194913A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Tie2-binding agents and methods of use |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021202959A1 (en) | 2020-04-03 | 2021-10-07 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
WO2021217051A1 (en) | 2020-04-24 | 2021-10-28 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
WO2021222181A2 (en) | 2020-04-27 | 2021-11-04 | The Regents Of The University Of California | Isoform-independent antibodies to lipoprotein(a) |
WO2021222167A1 (en) | 2020-04-28 | 2021-11-04 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
WO2021225892A1 (en) | 2020-05-03 | 2021-11-11 | Levena (Suzhou) Biopharma Co., Ltd. | Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same |
WO2021238886A1 (en) | 2020-05-27 | 2021-12-02 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing nerve growth factor and uses thereof |
WO2021243204A1 (en) | 2020-05-29 | 2021-12-02 | 23Andme, Inc. | Anti-cd200r1 antibodies and methods of use thereof |
WO2021247769A1 (en) | 2020-06-02 | 2021-12-09 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
WO2021252977A1 (en) | 2020-06-12 | 2021-12-16 | Genentech, Inc. | Methods and compositions for cancer immunotherapy |
WO2021257503A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
WO2021257124A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
WO2021259880A1 (en) | 2020-06-22 | 2021-12-30 | Almirall, S.A. | Anti-il-36 antibodies and methods of use thereof |
WO2022023735A1 (en) | 2020-07-28 | 2022-02-03 | Femtogenix Limited | Cytotoxic agents |
WO2022026763A1 (en) | 2020-07-29 | 2022-02-03 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
WO2022031749A1 (en) | 2020-08-03 | 2022-02-10 | Genentech, Inc. | Diagnostic and therapeutic methods for lymphoma |
WO2022029660A1 (en) | 2020-08-05 | 2022-02-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods |
WO2022031876A1 (en) | 2020-08-07 | 2022-02-10 | Genentech, Inc. | Flt3 ligand fusion proteins and methods of use |
WO2022034228A1 (en) | 2020-08-14 | 2022-02-17 | Ac Immune Sa | Humanized anti-tdp-43 binding molecules and uses thereof |
WO2022043517A2 (en) | 2020-08-27 | 2022-03-03 | Cureab Gmbh | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
US11970539B2 (en) | 2020-09-14 | 2024-04-30 | Ichnos Sciences SA | Antibodies that bind to IL1RAP and uses thereof |
WO2022053715A1 (en) | 2020-09-14 | 2022-03-17 | Ichnos Sciences SA | Antibodies that bind to il1rap and uses thereof |
WO2022067262A1 (en) | 2020-09-28 | 2022-03-31 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
US11795228B2 (en) | 2020-09-30 | 2023-10-24 | Dren Bio, Inc. | Anti-CD94 antibodies and methods of use thereof |
WO2022076462A1 (en) | 2020-10-05 | 2022-04-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2022084400A1 (en) | 2020-10-20 | 2022-04-28 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof |
WO2022084210A1 (en) | 2020-10-20 | 2022-04-28 | F. Hoffmann-La Roche Ag | Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors |
WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
WO2022098638A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
WO2022098648A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
WO2022098628A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
WO2022123316A1 (en) | 2020-12-09 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
WO2022123307A1 (en) | 2020-12-09 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
WO2022140797A1 (en) | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines and uses thereof |
WO2022162203A1 (en) | 2021-01-28 | 2022-08-04 | Vaccinvent Gmbh | Method and means for modulating b-cell mediated immune responses |
WO2022162201A1 (en) | 2021-01-28 | 2022-08-04 | Vaccinvent Gmbh | Method and means for modulating b-cell mediated immune responses |
WO2022173670A1 (en) | 2021-02-09 | 2022-08-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies targeting the spike protein of coronaviruses |
WO2022173689A1 (en) | 2021-02-09 | 2022-08-18 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
WO2022172085A2 (en) | 2021-02-15 | 2022-08-18 | Takeda Pharmaceutical Company Limited | Cell therapy compositions and methods for modulating tgf-b signaling |
WO2022187270A1 (en) | 2021-03-01 | 2022-09-09 | Xilio Development, Inc. | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
WO2022187272A1 (en) | 2021-03-01 | 2022-09-09 | Xilio Development, Inc. | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
WO2022184082A1 (en) | 2021-03-03 | 2022-09-09 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates comprising an anti-bcma antibody |
WO2022187863A1 (en) | 2021-03-05 | 2022-09-09 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
WO2022192898A2 (en) | 2021-03-10 | 2022-09-15 | Immunowake Inc. | Immunomodulatory molecules and uses thereof |
WO2022198192A1 (en) | 2021-03-15 | 2022-09-22 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
WO2022204724A1 (en) | 2021-03-25 | 2022-09-29 | Dynamicure Biotechnology Llc | Anti-igfbp7 constructs and uses thereof |
WO2022220275A1 (ja) | 2021-04-15 | 2022-10-20 | 中外製薬株式会社 | 抗C1s抗体 |
WO2022223651A1 (en) | 2021-04-23 | 2022-10-27 | F. Hoffmann-La Roche Ag | Prevention or mitigation of nk cell engaging agent-related adverse effects |
WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
WO2022241446A1 (en) | 2021-05-12 | 2022-11-17 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
WO2022241082A1 (en) | 2021-05-14 | 2022-11-17 | Genentech, Inc. | Agonists of trem2 |
EP4155321A1 (en) | 2021-06-04 | 2023-03-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-ddr2 antibodies and uses thereof |
WO2022258600A1 (en) | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
WO2022266660A1 (en) | 2021-06-17 | 2022-12-22 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
WO2022270611A1 (ja) | 2021-06-25 | 2022-12-29 | 中外製薬株式会社 | 抗ctla-4抗体 |
WO2022270612A1 (ja) | 2021-06-25 | 2022-12-29 | 中外製薬株式会社 | 抗ctla-4抗体の使用 |
WO2023283611A1 (en) | 2021-07-08 | 2023-01-12 | Staidson Biopharma Inc. | Antibodies specifically recognizing tnfr2 and uses thereof |
WO2023284714A1 (zh) | 2021-07-14 | 2023-01-19 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
WO2023004386A1 (en) | 2021-07-22 | 2023-01-26 | Genentech, Inc. | Brain targeting compositions and methods of use thereof |
WO2023016826A2 (en) | 2021-08-05 | 2023-02-16 | Vaccinvent Gmbh | Method and means for enhancing therapeutic antibodies |
WO2023019092A1 (en) | 2021-08-07 | 2023-02-16 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
WO2023019239A1 (en) | 2021-08-13 | 2023-02-16 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
WO2023021055A1 (en) | 2021-08-19 | 2023-02-23 | F. Hoffmann-La Roche Ag | Multivalent anti-variant fc-region antibodies and methods of use |
WO2023028591A1 (en) | 2021-08-27 | 2023-03-02 | Genentech, Inc. | Methods of treating tau pathologies |
WO2023034750A1 (en) | 2021-08-30 | 2023-03-09 | Genentech, Inc. | Anti-polyubiquitin multispecific antibodies |
WO2023044272A1 (en) | 2021-09-17 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
US11774452B2 (en) | 2021-11-05 | 2023-10-03 | American Diagnostics & Therapy, LLC | Antibodies against carcinoembryonic antigens |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2023088959A1 (en) | 2021-11-16 | 2023-05-25 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
WO2023091887A1 (en) | 2021-11-16 | 2023-05-25 | Genentech, Inc. | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
WO2023131901A1 (en) | 2022-01-07 | 2023-07-13 | Johnson & Johnson Enterprise Innovation Inc. | Materials and methods of il-1beta binding proteins |
WO2023154824A1 (en) | 2022-02-10 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that broadly target coronaviruses |
WO2023156549A1 (en) | 2022-02-16 | 2023-08-24 | Ac Immune Sa | Humanized anti-tdp-43 binding molecules and uses thereof |
WO2023159182A1 (en) | 2022-02-18 | 2023-08-24 | Rakuten Medical, Inc. | Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use |
WO2023173026A1 (en) | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
WO2023180353A1 (en) | 2022-03-23 | 2023-09-28 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
WO2023192827A1 (en) | 2022-03-26 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bispecific antibodies to hiv-1 env and their use |
WO2023192881A1 (en) | 2022-03-28 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023194565A1 (en) | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
WO2023201299A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
WO2023203177A1 (en) | 2022-04-20 | 2023-10-26 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
WO2023215737A1 (en) | 2022-05-03 | 2023-11-09 | Genentech, Inc. | Anti-ly6e antibodies, immunoconjugates, and uses thereof |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023237706A2 (en) | 2022-06-08 | 2023-12-14 | Institute For Research In Biomedicine (Irb) | Cross-specific antibodies, uses and methods for discovery thereof |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020407A1 (en) | 2022-07-19 | 2024-01-25 | Staidson Biopharma Inc. | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
WO2024028731A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Transferrin receptor binding proteins for treating brain tumors |
WO2024028732A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
WO2024037633A2 (en) | 2022-08-19 | 2024-02-22 | Evive Biotechnology (Shanghai) Ltd | Formulations comprising g-csf and uses thereof |
WO2024044779A2 (en) | 2022-08-26 | 2024-02-29 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
WO2024054929A1 (en) | 2022-09-07 | 2024-03-14 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
Also Published As
Publication number | Publication date |
---|---|
US20100092997A1 (en) | 2010-04-15 |
CA2481658A1 (en) | 2003-10-16 |
AU2003236018A1 (en) | 2003-10-20 |
US8313913B2 (en) | 2012-11-20 |
EP1498491A4 (en) | 2006-12-13 |
JPWO2003085119A1 (ja) | 2005-08-11 |
US20040259150A1 (en) | 2004-12-23 |
EP1498491A1 (en) | 2005-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6270930B2 (ja) | 抗体組成物を生産する細胞 | |
WO2003085119A1 (fr) | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia | |
US20030115614A1 (en) | Antibody composition-producing cell | |
WO2003085107A1 (fr) | Cellules à génome modifié | |
US20060223147A1 (en) | Process for producing glycoprotein composition | |
WO2003085118A1 (fr) | Procede de production de composition anticorps | |
WO2003055993A1 (fr) | Composition d'un anticorps qui se lie spécifiquement à cd20 | |
WO2003085102A1 (fr) | Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose | |
WO2005035741A1 (ja) | ゲノムが改変された細胞 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003582297 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2481658 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003236018 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003723098 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003723098 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003723098 Country of ref document: EP |